0000721371-22-000133.txt : 20221104 0000721371-22-000133.hdr.sgml : 20221104 20221104091157 ACCESSION NUMBER: 0000721371-22-000133 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221104 DATE AS OF CHANGE: 20221104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 221360418 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 10-Q 1 cah-20220930.htm 10-Q cah-20220930
0000721371--06-302023Q1false00007213712022-07-012022-09-3000007213712022-10-31xbrli:sharesiso4217:USD00007213712021-07-012021-09-30iso4217:USDxbrli:shares00007213712022-09-3000007213712022-06-300000721371us-gaap:CommonStockMember2022-06-300000721371us-gaap:RetainedEarningsMember2022-06-300000721371us-gaap:TreasuryStockMember2022-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000721371us-gaap:NoncontrollingInterestMember2022-06-300000721371us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000721371us-gaap:CommonStockMember2022-07-012022-09-300000721371us-gaap:TreasuryStockMember2022-07-012022-09-300000721371us-gaap:RetainedEarningsMember2022-07-012022-09-300000721371us-gaap:CommonStockMember2022-09-300000721371us-gaap:RetainedEarningsMember2022-09-300000721371us-gaap:TreasuryStockMember2022-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000721371us-gaap:NoncontrollingInterestMember2022-09-300000721371us-gaap:CommonStockMember2021-06-300000721371us-gaap:RetainedEarningsMember2021-06-300000721371us-gaap:TreasuryStockMember2021-06-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000721371us-gaap:NoncontrollingInterestMember2021-06-3000007213712021-06-300000721371us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000721371us-gaap:CommonStockMember2021-07-012021-09-300000721371us-gaap:TreasuryStockMember2021-07-012021-09-300000721371us-gaap:RetainedEarningsMember2021-07-012021-09-300000721371us-gaap:CommonStockMember2021-09-300000721371us-gaap:RetainedEarningsMember2021-09-300000721371us-gaap:TreasuryStockMember2021-09-300000721371us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000721371us-gaap:NoncontrollingInterestMember2021-09-3000007213712021-09-300000721371cah:CordisDivestitureMember2021-07-012022-06-300000721371us-gaap:EmployeeSeveranceMember2022-06-300000721371us-gaap:FacilityClosingMember2022-06-300000721371us-gaap:EmployeeSeveranceMember2022-07-012022-09-300000721371us-gaap:FacilityClosingMember2022-07-012022-09-300000721371us-gaap:EmployeeSeveranceMember2022-09-300000721371us-gaap:FacilityClosingMember2022-09-300000721371cah:PharmaceuticalMember2022-06-300000721371cah:MedicalMember2022-06-300000721371cah:PharmaceuticalMember2022-07-012022-09-300000721371cah:MedicalMember2022-07-012022-09-300000721371cah:PharmaceuticalMember2022-09-300000721371cah:MedicalMember2022-09-300000721371cah:MedicalUnitMember2022-07-012022-09-30xbrli:pure0000721371cah:MedicalUnitMember2022-09-300000721371cah:IPRDTrademarksandOtherMember2022-09-300000721371us-gaap:CustomerRelationshipsMember2022-09-300000721371us-gaap:CustomerRelationshipsMember2022-07-012022-09-300000721371cah:TrademarksAndPatentsMember2022-09-300000721371cah:TrademarksAndPatentsMember2022-07-012022-09-300000721371us-gaap:DevelopedTechnologyRightsMember2022-09-300000721371us-gaap:DevelopedTechnologyRightsMember2022-07-012022-09-300000721371cah:IPRDTrademarksandOtherMember2022-06-300000721371us-gaap:CustomerRelationshipsMember2022-06-300000721371cah:TrademarksAndPatentsMember2022-06-300000721371us-gaap:DevelopedTechnologyRightsMember2022-06-300000721371cah:A2.616Notesdue2022Member2021-07-012021-09-300000721371us-gaap:CommercialPaperMember2022-09-300000721371us-gaap:RevolvingCreditFacilityMember2022-09-300000721371cah:ShortTermCreditFacilitiesMembercah:CommittedReceivablesSalesFacilityProgramMember2022-09-300000721371cah:ShortTermCreditFacilitiesMember2022-09-300000721371cah:CVSHealthMember2022-07-012022-09-300000721371cah:NewYorkOpioidStewardshipActMember2022-09-300000721371cah:NewYorkOpioidStewardshipActMember2021-07-012021-09-300000721371cah:NewYorkOpioidStewardshipActMember2021-10-012021-12-310000721371cah:PharmaceuticalMember2021-10-012021-12-310000721371us-gaap:SubsequentEventMembercah:TotalOpioidLitigationMember2022-11-03cah:statescah:numberOfUSTerritories0000721371cah:TotalOpioidLitigationMember2022-09-300000721371stpr:WVcah:OpioidLawsuitsMember2022-07-310000721371stpr:WAcah:OpioidLawsuitsMember2022-06-300000721371stpr:OKcah:OpioidLawsuitsMember2022-06-300000721371us-gaap:SubsequentEventMembercah:OpioidLawsuitsMember2022-10-310000721371cah:NativeAmericanTribesMemberus-gaap:SubsequentEventMembercah:OpioidLawsuitsMember2022-10-310000721371cah:OpioidLawsuitsMember2022-07-012022-09-300000721371us-gaap:AccruedLiabilitiesMembercah:TotalOpioidLitigationMember2022-09-300000721371us-gaap:SubsequentEventMembercah:PrivatePartiesMembercah:OpioidLawsuitsMember2022-10-31cah:lawsuit0000721371us-gaap:SubsequentEventMembercah:PrivatePartiesMembercah:ClassActionLawsuitsMembercah:OpioidLawsuitsMember2022-10-310000721371cah:PrivatePartiesMemberstpr:GAcah:OpioidLawsuitsMember2022-07-012022-07-31cah:plaintiff0000721371us-gaap:SubsequentEventMembercah:ProductLiabilityLawsuitsMember2022-11-030000721371us-gaap:SubsequentEventMembercah:ProductLiabilityLawsuitsMembercah:AlamedaCountyMember2022-11-032022-11-030000721371us-gaap:SubsequentEventMembercah:ProductLiabilityLawsuitsMember2022-11-030000721371us-gaap:SubsequentEventMembercah:OtherJurisdictionsMembercah:ProductLiabilityLawsuitsMember2022-11-032022-11-030000721371cah:ProductLiabilityLawsuitsMember2021-07-312021-07-310000721371srt:MinimumMembercah:ProductLiabilityLawsuitsMember2022-09-300000721371srt:MaximumMembercah:ProductLiabilityLawsuitsMember2022-09-300000721371us-gaap:SubsequentEventMember2022-10-012022-12-310000721371cah:MedicalMembersrt:ScenarioForecastMember2022-07-012023-06-300000721371srt:MaximumMemberus-gaap:InternalRevenueServiceIRSMember2022-07-012022-09-300000721371us-gaap:SubsequentEventMembercah:GoodwillImpairmentMedicalUnitMember2022-10-012023-06-300000721371srt:MinimumMember2022-09-300000721371srt:MaximumMember2022-09-300000721371us-gaap:InternalRevenueServiceIRSMembersrt:MinimumMember2022-07-012022-09-300000721371cah:CareFusionMember2022-09-300000721371cah:CareFusionMember2022-06-300000721371us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300000721371us-gaap:FairValueInputsLevel12And3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000721371us-gaap:FairValueMeasurementsRecurringMember2022-09-300000721371us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300000721371us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300000721371us-gaap:FairValueInputsLevel12And3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000721371us-gaap:FairValueMeasurementsRecurringMember2022-06-300000721371us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2022-09-300000721371us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMember2021-09-300000721371us-gaap:CashFlowHedgingMember2022-07-012022-09-300000721371us-gaap:ForeignExchangeContractMember2022-07-012022-09-300000721371us-gaap:ForeignExchangeContractMember2021-07-012021-09-300000721371us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300000721371us-gaap:FairValueInputsLevel2Member2022-09-300000721371us-gaap:FairValueInputsLevel2Member2022-06-300000721371cah:A1BillionShareRepurchaseProgramMember2022-07-012022-09-300000721371cah:A1BillionShareRepurchaseProgramMemberus-gaap:TreasuryStockMember2022-07-012022-09-300000721371cah:A500MillionShareRepurchaseProgramMember2021-07-012021-09-300000721371us-gaap:TreasuryStockMembercah:A500MillionShareRepurchaseProgramMember2021-07-012021-09-300000721371us-gaap:TreasuryStockMembercah:A500MillionShareRepurchaseProgramMember2021-10-042021-10-040000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300000721371us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300000721371us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300000721371us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-09-30cah:segment0000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalMembercah:PharmaceuticalDistributionandSpecialtyMember2022-07-012022-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalMembercah:PharmaceuticalDistributionandSpecialtyMember2021-07-012021-09-300000721371cah:NuclearPrecisionHealthServicesMemberus-gaap:OperatingSegmentsMembercah:PharmaceuticalMember2022-07-012022-09-300000721371cah:NuclearPrecisionHealthServicesMemberus-gaap:OperatingSegmentsMembercah:PharmaceuticalMember2021-07-012021-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalMember2022-07-012022-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalMember2021-07-012021-09-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMembercah:MedicaldistributionandproductsMember2022-07-012022-09-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMembercah:MedicaldistributionandproductsMember2021-07-012021-09-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMembercah:CardinalHealthAtHomeSolutionsMember2022-07-012022-09-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMembercah:CardinalHealthAtHomeSolutionsMember2021-07-012021-09-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2022-07-012022-09-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2021-07-012021-09-300000721371us-gaap:OperatingSegmentsMember2022-07-012022-09-300000721371us-gaap:OperatingSegmentsMember2021-07-012021-09-300000721371us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000721371us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000721371country:US2022-07-012022-09-300000721371country:US2021-07-012021-09-300000721371us-gaap:NonUsMember2022-07-012022-09-300000721371us-gaap:NonUsMember2021-07-012021-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalMember2022-09-300000721371us-gaap:OperatingSegmentsMembercah:PharmaceuticalMember2022-06-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2022-09-300000721371us-gaap:OperatingSegmentsMembercah:MedicalMember2022-06-300000721371us-gaap:CorporateNonSegmentMember2022-09-300000721371us-gaap:CorporateNonSegmentMember2022-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000721371us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000721371us-gaap:PerformanceSharesMember2022-07-012022-09-300000721371us-gaap:PerformanceSharesMember2021-07-012021-09-300000721371us-gaap:RestrictedStockUnitsRSUMember2022-06-300000721371us-gaap:RestrictedStockUnitsRSUMember2022-09-30cah:Reportable_Segments0000721371srt:MinimumMemberus-gaap:PerformanceSharesMember2020-07-012021-06-300000721371srt:MinimumMemberus-gaap:PerformanceSharesMember2019-07-012020-06-300000721371srt:MaximumMemberus-gaap:PerformanceSharesMember2020-07-012021-06-300000721371srt:MaximumMemberus-gaap:PerformanceSharesMember2019-07-012020-06-300000721371srt:MinimumMemberus-gaap:PerformanceSharesMember2021-07-012022-06-300000721371srt:MinimumMemberus-gaap:PerformanceSharesMember2022-07-012022-09-300000721371srt:MaximumMemberus-gaap:PerformanceSharesMember2021-07-012022-06-300000721371srt:MaximumMemberus-gaap:PerformanceSharesMember2022-07-012022-09-300000721371us-gaap:PerformanceSharesMember2022-06-300000721371us-gaap:PerformanceSharesMember2022-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
Ohio31-0958666
(State or other jurisdiction of
incorporation or organization)		(IRS Employer
Identification No.)
7000 Cardinal Place,Dublin,Ohio43017
(Address of principal executive offices)(Zip Code)
(614) 757-5000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares (without par value)CAHNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☑
The number of the registrant’s common shares, without par value, outstanding as of October 31, 2022, was the following: 262,134,053.


Cardinal Health
Q1 Fiscal 2023 Form 10-Q
Table of Contents

About Cardinal Health
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2023 and fiscal 2022 and to FY23 and FY22 are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.
Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our “2022 Form 10-K”). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.

 1
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

MD&AOverview
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at September 30, 2022 and June 30, 2022, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three months ended September 30, 2022 and 2021. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&A included in our 2022 Form 10-K.

 2
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

MD&AOverview
Overview of Consolidated Results
Revenue
Revenue for the three months ended September 30, 2022 increased 13 percent to $49.6 billion due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which primarily consisted of branded pharmaceutical sales to existing and net new customers.

GAAP and Non-GAAP Operating Earnings
Three Months Ended September 30,
(in millions)20222021Change
GAAP operating earnings$137 $415 (67)%
Shareholder cooperation agreement costs6 — 
Restructuring and employee severance29 18 
Amortization and other acquisition-related costs71 79 
Impairments and (gain)/loss on disposal of assets, net153 (2)
Litigation (recoveries)/charges, net27 18 
Non-GAAP operating earnings$423 $527 (20)%
The sum of the components and certain computations may reflect rounding adjustments.
GAAP operating earnings decreased 67 percent to $137 million during the three months ended September 30, 2022 primarily due to a $154 million pre-tax non-cash goodwill impairment charge related to the Medical Segment and a decline in Medical segment profit. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional information on the goodwill impairment charge. The decline in Medical segment profit was due to net inflationary impacts and an adverse impact from personal protective equipment, which included inventory charges as a result of our simplification strategy.
Non-GAAP operating earnings decreased 20 percent to $423 million, primarily due to the decline in Medical segment profit discussed above.


Cardinal Health | Q1 Fiscal 2023 Form 10-Q
3


MD&AOverview
GAAP and Non-GAAP Diluted EPS
Three Months Ended September 30,
($ per share)
2022 (2)
2021 (2)
Change
GAAP diluted EPS (1)
$0.40 $0.94 (57)%
Shareholder cooperation agreement costs
0.01 — 
Restructuring and employee severance0.08 0.04 
Amortization and other acquisition-related costs0.20 0.20 
Impairments and (gain)/loss on disposal of assets, net (3)
0.44 0.03 
Litigation (recoveries)/charges, net0.07 0.05 
Loss on early extinguishment of debt— 0.03 
Non-GAAP diluted EPS (1)
$1.20 $1.29 (7)%
The sum of the components and certain computations may reflect rounding adjustments.
(1) Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").
(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."
(3) Impairments and (gain)/loss on disposals of assets, net includes a pre-tax goodwill impairment charge of $154 million related to the Medical segment recorded during the three months ended September 30, 2022. For fiscal 2023, the net tax benefit related to this impairment charge is $12 million and is included in the annual effective tax rate. As a result, the amount of tax benefit for three months ended September 30, 2022 increased approximately by an incremental $22 million and is expected to increase the provision for income taxes during the remainder of the fiscal year.
During the three months ended September 30, 2022, GAAP diluted EPS decreased 57 percent to $0.40 and non-GAAP diluted EPS decreased 7 percent to $1.20 due to the factors impacting GAAP and non-GAAP operating earnings discussed above, partially offset by favorable changes in discrete tax items and a lower share count as a result of share repurchases. In addition, the goodwill impairment charge related to the Medical segment had a $(0.44) per share after-tax impact on GAAP diluted EPS. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 and Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional detail.

Cash and Equivalents
Our cash and equivalents balance was $3.5 billion at September 30, 2022 compared to $4.7 billion at June 30, 2022. During the three months ended September 30, 2022, net cash provided by operating activities was $23 million, which includes the impact of our second annual payment of $372 million related to the agreement to settle the vast majority of the opioid lawsuits filed by states and local governmental entities (the "Settlement Agreement"). See the Significant Developments in Fiscal 2023 and Trends section in this MD&A and Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to the Settlement Agreement. In addition, we deployed cash of $1.0 billion for share repurchases.





 4
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

MD&AOverview
Significant Developments in Fiscal 2023 and Trends
Inflationary Impacts
Medical segment profit was negatively affected by inflationary impacts, primarily related to transportation (including ocean and domestic freight), commodities and labor during the three months ended September 30, 2022 and on a year-over-year basis.
We expect these inflationary impacts to continue to adversely impact Medical segment profit in fiscal 2023 and beyond. In order to partially mitigate this impact, we have implemented certain price increases and we intend to implement additional price increases. We are also evolving our commercial contracting processes to provide us with greater pricing flexibility. These increased costs are difficult to predict and may be greater than we expect or continue longer than our current expectations. In the event these costs decrease, the benefit to Medical segment profit will be delayed until the higher-cost inventory has moved through our supply chain. Our plans to continue to increase prices and evolve our contracting strategies are subject to contingencies and uncertainties and it is possible that our results of operations will be adversely impacted to a greater extent than we currently anticipate or that we may not be able to mitigate the negative impact to the extent we anticipate.
To a lesser extent, inflationary impacts, primarily related to increased transportation and labor costs, also adversely affected Pharmaceutical segment profit during the three months ended September 30, 2022. We expect these inflationary supply chain costs to continue to adversely impact Pharmaceutical segment profit in fiscal 2023.

PPE Demand and Pricing
Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. Demand for PPE fluctuated during fiscal 2022 resulting in variability in sales volumes, inventory levels and costs to manufacture and source these products. We expect demand for PPE to continue to fluctuate during the remainder of fiscal 2023.
PPE adversely impacted Medical segment revenue during the three months ended September 30, 2022 and on a year-over-year basis, primarily due to declines in pricing and volumes.
Medical segment profit was adversely impacted during the three months ended September 30, 2022 and on a year-over-year basis due to $18 million of inventory charges related to our simplification strategy, which includes the impact from the sale of certain disposable gloves that are primarily utilized in non-healthcare industries.
The demand and pricing for PPE is subject to risks and uncertainties, which may continue to impact Medical segment revenue, Medical segment profit and consolidated operating earnings during the remainder of fiscal 2023.

Medical Goodwill
Due to the adverse impact on our financial results from and the risks and uncertainties related to inflationary impacts and PPE demand and pricing, as well as increases in the risk-free interest rate, we performed interim goodwill impairment testing for the Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (the “Medical Unit”) during the three months ended September 30, 2022. This testing resulted in a pre-tax charge of $154 million, which is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This charge was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements" for additional detail.
Adverse changes in key assumptions or a significant change in industry or economic trends during the remainder of fiscal 2023 could result in additional goodwill impairment.



Cardinal Health | Q1 Fiscal 2023 Form 10-Q
5


MD&AOverview
Shareholder Cooperation Agreement
In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors (the "Board"), among other things, (1) appointed four new independent directors, including a representative from Elliott, and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations.
The evaluation and implementation of any actions recommended by the Business Review Committee and the Board may impact our financial position and results of operations during the remainder of fiscal 2023. In addition, during the three months ended September 30, 2022, we incurred $6 million of expenses related to the negotiation and finalization of the Cooperation Agreement. We expect to incur additional legal, consulting and other expenses related to the Cooperation Agreement and the activities of the Business Review Committee during the remainder of fiscal 2023. See "Risk Factors" section for additional detail related to risks associated with the Cooperation Agreement.

 6
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

MD&AResults of Operations
Results of Operations
Revenue
cah-20220930_g1.jpgcah-20220930_g2.jpg
Three Months Ended September 30,
(in millions)20222021Change
Pharmaceutical$45,828 $39,822 15 %
Medical3,778 4,149 (9)%
Total segment revenue49,606 43,971 13 %
Corporate(3)(3)N.M.
Total revenue$49,603 $43,968 13 %

Pharmaceutical Segment
Pharmaceutical segment revenue increased during the three months ended September 30, 2022 due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which together increased revenue by $5.9 billion and primarily consisted of branded pharmaceutical sales to existing and net new customers.
Medical Segment
Medical segment revenue decreased during the three months ended September 30, 2022 primarily due to lower sales within products and distribution, largely due to the impact of PPE pricing and volumes. The adverse impact of the prior-year divestiture of the Cordis business was mostly offset by sales growth in at-Home Solutions.
Cost of Products Sold
Cost of products sold increased 13 percent to $48.0 billion due to the factors affecting the changes in revenue and gross margin.







Cardinal Health | Q1 Fiscal 2023 Form 10-Q
7


MD&AResults of Operations
Gross Margin
cah-20220930_g3.jpgcah-20220930_g4.jpg
Three Months Ended September 30,
(in millions)20222021Change
Gross margin$1,614 $1,642 (2)%
Gross margin during the three months ended September 30, 2022 decreased primarily due to net inflationary impacts in the Medical segment and the divestiture of the Cordis business, partially offset by the performance of our generics program in the Pharmaceutical segment.
Gross margin rate declined 48 basis points during the three months ended September 30, 2022 mainly due to changes in overall product mix, primarily driven by increased pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate. The performance of Medical segment products and distribution, which reflects increased costs due to net inflationary impacts, also had an adverse impact on gross margin rate.
Distribution, Selling, General, and Administrative ("SG&A") Expenses
Three Months Ended September 30,
(in millions)20222021Change
SG&A expenses$1,197 $1,114 7 %

During the three months ended September 30, 2022, SG&A expenses increased largely due to inflationary impacts, primarily related to increased transportation and labor costs, as well as other operating expenses.
During the three months ended September 30, 2022, we incurred $6 million of expenses related to the finalization of the Cooperation Agreement. See the Significant Developments in Fiscal 2023 and Trends section in this MD&A for additional detail related to the Cooperation Agreement.



 8
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

MD&AResults of Operations
Segment Profit
We evaluate segment performance based on segment profit, among other measures. See Note 12 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.

Three Months Ended September 30,
(in millions)20222021Change
Pharmaceutical$431 $406 6 %
Medical(8)123 N.M.
Total segment profit423 529 (20)%
Corporate(286)(114)N.M.
Total consolidated operating earnings$137 $415 (67)%
Pharmaceutical Segment Profit
Pharmaceutical segment profit increased during the three months ended September 30, 2022, primarily due to the performance of our generics program and increased contribution from branded pharmaceutical and specialty pharmaceutical products. These factors were partially offset by inflationary impacts, primarily related to increased transportation and labor costs.
Medical Segment Profit
Medical segment profit decreased during the three months ended September 30, 2022, largely due to net inflationary impacts, which primarily related to increased transportation and commodities costs, partially offset by price increases. Medical segment profit was also adversely affected by the impact of PPE, which included inventory charges related to the sale of certain disposable gloves in connection with our simplification strategy.
Corporate
The changes in Corporate during the three months ended September 30, 2022 are due to the factors discussed in the Other Components of Consolidated Operating Earnings section that follows.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
9


MD&AResults of Operations
Other Components of Consolidated Operating Earnings
In addition to revenue, gross margin, and SG&A expenses discussed previously, consolidated operating earnings were impacted by the following:
Three Months Ended September 30,
(in millions)20222021
Restructuring and employee severance$29 $18 
Amortization and other acquisition-related costs71 79 
Impairments and (gain)/loss on disposal of assets, net153 (2)
Litigation (recoveries)/charges, net27 18 
Restructuring and Employee Severance
During the three months ended September 30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September 30, 2021, restructuring also included costs related to the divestiture of the Cordis business.
Amortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets was $71 million and $78 million for the three months ended September 30, 2022 and 2021, respectively.
Impairments and (Gain)/Loss on Disposal of Assets, Net
During the three months ended September 30, 2022, we recognized a $154 million pre-tax non-cash goodwill impairment related to the Medical segment, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to Condensed Consolidated Financial Statements."
Litigation (Recoveries)/Charges, Net
During the three months ended September 30, 2022 and 2021, we recognized $21 million and $26 million, respectively, of estimated losses and legal defense costs associated with the inferior vena cava ("IVC") filter product liability claims. See Note 6 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
During the three months ended September 30, 2021, we recognized income of $17 million for recoveries in class action antitrust lawsuits in which we were a class member.
Earnings Before Income Taxes
In addition to the items discussed above, earnings before income taxes was impacted by the following:
Three Months Ended September 30,
(in millions)20222021Change
Other (income)/expense, net$2 $(4)N.M.
Interest expense, net25 40 (38)%
Loss on early extinguishment of debt— 10 N.M.

Interest Expense, Net
During the three months ended September 30, 2022, interest expense decreased by 38 percent primarily due to increased interest income from cash and equivalents.
Loss on Early Extinguishment of Debt
During three months ended September 30, 2021, we recognized a $10 million loss in connection with the debt redemption as described further in Note 5 of the “Notes to Condensed Consolidated Financial Statements.”


 10
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

MD&AResults of Operations
Provision for/(Benefit from) Income Taxes
During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The decrease in the effective tax rate for the three months ended September 30, 2022 compared to the prior-year period was primarily due to tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items. The effective tax rate for the three months ended September 30, 2022 also includes the tax effect of the goodwill impairment charge described below. See Note 7 of the “Notes to Condensed Consolidated Financial Statements” for additional information.
Tax Effects of Goodwill Impairment Charge
During the three months ended September 30, 2022, we recognized a $154 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12 million for fiscal 2023.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the three months ended September 30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September 30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September 30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September 30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.



Cardinal Health | Q1 Fiscal 2023 Form 10-Q
11


MD&ALiquidity and Capital Resources
Liquidity and Capital Resources
We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations and cash requirements; tax payments; current and projected debt service requirements, dividends and share repurchases; and known opioid litigation settlement payments. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.
Cash and Equivalents
Our cash and equivalents balance was $3.5 billion at September 30, 2022 compared to $4.7 billion at June 30, 2022. During the three months ended September 30, 2022, net cash provided by operating activities was $23 million, which includes the impact of our second annual payment of $372 million related to the Settlement Agreement. For additional information, see Opioid Litigation Settlement Agreement section below. In addition, we deployed cash of $1.0 billion for share repurchases.
At September 30, 2022, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.
Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.
The cash and equivalents balance at September 30, 2022 included $561 million of cash held by subsidiaries outside of the United States.
Other Financing Arrangements and Financial Instruments
Credit Facilities and Commercial Paper
In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2022 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility.
In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant.
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both September 30, 2022 and June 30, 2022.









 12
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

MD&ALiquidity and Capital Resources
Capital Deployment
Opioid Litigation Settlement Agreement
We had $6.03 billion accrued at September 30, 2022 related to certain opioid litigation, as further described within Note 6 of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the payment amounts to be spread over 18 years. The effective date of the Settlement Agreement was April 2, 2022. During the three months ended September 30, 2022, we made our second annual payment of $372 million under the Settlement Agreement. We expect to make subsequent annual payments under the Settlement Agreement every July for the term of the Settlement Agreement. The amounts of these future payments may differ from the payments that we have already made.
Capital Expenditures
Capital expenditures during the three months ended September 30, 2022 and 2021 were $70 million and $67 million, respectively.
Dividends
On each of May 10, 2022 and August 10, 2022, our Board of Directors approved a quarterly dividend of $0.4957 per share, or $1.98 per share on an annualized basis, which were paid on July 15, 2022 and October 17, 2022 to shareholders of record on July 1, 2022 and October 3, 2022, respectively.
Share Repurchases
During the three months ended September 30, 2022, we repurchased $1.0 billion of our common shares under an accelerated share repurchase ("ASR") program. We funded the ASR program with available cash. The ASR program is expected to conclude in the second quarter of fiscal 2023, which is expected to reduce the amount remaining under our existing share repurchase authorization to approximately $1.7 billion. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.



Cardinal Health | Q1 Fiscal 2023 Form 10-Q
13


MD&AOther Items

Other Items
The MD&A in our 2022 Form 10-K addresses our contractual obligations and cash requirements, as of and for the fiscal year ended June 30, 2022. There have been no subsequent material changes outside the ordinary course of business to those items.
Critical Accounting Policies and Sensitive Accounting Estimates
The discussion and analysis presented below are supplemental disclosures to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June 30, 2022. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2022 Form 10-K.
Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risk factors discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K and our other filings with the SEC since June 30, 2022.
Goodwill
Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).
Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.
Medical Unit Goodwill
During the three months ended September 30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the
risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.
Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September 30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September 30, 2022 after recognizing the impairment charge was $6.7 billion, of which $1.8 billion was goodwill. See Note 4 of the "Notes to Condensed Consolidated Financial Statements" for further discussion.
While we consider these assumptions to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2023 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, including the execution of key initiatives related to optimizing and growing sales of Cardinal Health branded medical products, increasing growth in certain strategic divisions within our Medical segment, and driving simplification efforts and cost optimization projects, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; the impact of the Cordis

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
14


MD&AOther Items

divestiture; estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates (including potential tax reform); or a significant change in industry or economic trends. Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could
adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.5 percent or decrease the terminal growth rate by a hypothetical 1.75 percent, the fair value for the Medical Unit would have further decreased by approximately $300 million.



Cardinal Health | Q1 Fiscal 2023 Form 10-Q
15


Explanation and Reconciliation of Non-GAAP Financial Measures
Explanation and Reconciliation of Non-GAAP Financial Measures
The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.
•Surgical gown recall costs or income includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•Shareholder cooperation agreement costs includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health, including costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the new Business Review Committee of the Board of Directors, which was formed under this Cooperation Agreement. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance.
•State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
•Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.
•Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts,

 16
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Explanation and Reconciliation of Non-GAAP Financial Measures
which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
•Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
•Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2022, we incurred a one-time contingent attorneys' fee of $18 million related to the finalization of the settlement agreement (the “Settlement Agreement”) resulting in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this fee was included in litigation recoveries or charges, net. Additionally, during fiscal 2022 our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits. This judgment was the result of an ordinary course intellectual property rights claim and, therefore, is not adjusted in calculating the litigation recoveries or charges, net adjustment. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges.
•Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
•(Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures.

The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.
Definitions
Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, and (8) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth.
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth, each net of tax.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
17


Explanation and Reconciliation of Non-GAAP Financial Measures
Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) shareholder cooperation agreement costs, (4) state opioid assessment related to prior fiscal years, (5) restructuring and employee severance, (6) amortization and other acquisition-related costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, (9) loss on early extinguishment of debt and (10) (gain)/loss on sale of equity interest in naviHealth divided by (earnings before income taxes adjusted for the ten items above).
Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

 18
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Explanation and Reconciliation of Non-GAAP Financial Measures
GAAP to Non-GAAP Reconciliations
(in millions, except per common share amounts)Operating EarningsOperating Earnings Growth RateEarnings Before Income TaxesProvision for/ (Benefit from) Income Taxes
Net Earnings1
Net Earnings1 Growth Rate
Diluted EPS1
Diluted EPS1
 Growth Rate
Three Months Ended September 30, 2022
GAAP$137 (67)%$110 $(1)$110 (59)%$0.40 (57)%
Shareholder cooperation agreement costs 6 6 2 4 0.01 
Restructuring and employee severance29 29 7 22 0.08 
Amortization and other acquisition-related costs71 71 18 53 0.20 
Impairments and (gain)/loss on disposal of assets, net2
153 153 34 119 0.44 
Litigation (recoveries)/charges, net 27 27 7 20 0.07 
Non-GAAP$423 (20)%$396 $67 $328 (12)%$1.20 (7)%
Three Months Ended September 30, 2021
GAAP$415 N.M.$369 $97 $271 N.M.$0.94 N.M.
Restructuring and employee severance18 18 4 14 0.04 
Amortization and other acquisition-related costs79 79 21 58 0.20 
Impairments and (gain)/loss on disposal of assets, net(2)(2)(10)8 0.03 
Litigation (recoveries)/charges, net18 18 4 14 0.05 
Loss on early extinguishment of debt— 10 3 7 0.03 
Non-GAAP$527 (15)%$491 $119 $372 (17)%$1.29 (15)%

1    Attributable to Cardinal Health, Inc.
2    For the three months ended September 30, 2022, impairments and (gain)/loss on disposals of assets, net includes a pre-tax goodwill impairment charge of $154 million related to the Medical segment. For fiscal 2023, the net tax benefit related to this impairment charge is $12 million and is included in the annual effective tax rate. As a result, the amount of tax benefit for the three months ended September 30, 2022 increased approximately by an incremental $22 million and is expected to increase the provision for income taxes during the remainder of the fiscal year.

The sum of the components and certain computations may reflect rounding adjustments.
We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.






Cardinal Health | Q1 Fiscal 2023 Form 10-Q
19


Other

Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2022 Form 10-K since the end of fiscal 2022 through September 30, 2022.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of September 30, 2022. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September 30, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


 20
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Other

Legal Proceedings
In addition to the proceeding described below, the legal proceedings described in Note 6 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In February 2021, the court granted in part and denied in part defendants' motion to dismiss. The court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.
In December 2021, the parties reached an agreement in principle to settle this matter and in October 2022, the court entered an order approving the settlement and dismissing the case. This settlement does not include any admission of liability. Under the settlement, Cardinal's director and officer's liability insurance carriers, on behalf of the defendants, will pay Cardinal $124 million, less approximately $31 million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel. Cardinal expects to receive this payment during fiscal year 2023.

 21
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Other
Risk Factors
You should carefully consider the information in this Form 10-Q, including the Risk Factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2022 Form 10-K and our filings with the SEC since June 30, 2022. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.
Our business could be affected by activist shareholders.
In September 2022, we entered into a Cooperation Agreement (the "Cooperation Agreement") with Elliott Associates, L.P. and Elliott International, L.P. (together, "Elliott") under which our Board of Directors, among other things, (1) appointed four new independent directors, including a representative from Elliott , and (2) formed an advisory Business Review Committee of the Board, which is tasked with undertaking a comprehensive review of our strategy, portfolio, capital-allocation framework and operations.
The Cooperation Agreement may create unintended consequences, such as creating uncertainty about our management or future strategic direction, which could result in the loss of future business opportunities or negatively impact our ability to attract and retain qualified talent. Additionally, implementing any actions recommended by the Business Review Committee and Board may be costly and time-consuming, may be disruptive to our ongoing business operations and may ultimately be unsuccessful.
It is possible that activist shareholders may, among other things, attempt to effect additional changes and exert influence over our Board of Directors and management or initiate a proxy contest, which may disrupt our operations by diverting the attention of management and the Board and be costly and time-consuming. Any such proxy contests, actions or requests, or the mere public presence of activist shareholders, may cause the market price for our shares to experience volatility.
We could be subject to adverse changes in the tax laws or challenges to our tax positions.
We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.
From time to time, proposals are made in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include possible increases in U.S. or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission’s investigation into illegal state aid. In August 2022, the U.S. federal government enacted the Inflation Reduction Act, which imposed a 15 percent corporate minimum tax on certain large corporations and a 1 percent tax on share repurchases after December 31, 2022. These
provisions may adversely impact our financial position and results of operations.
Additionally, in connection with the accruals taken in connection with opioid-related lawsuits in fiscal years 2021 and 2020, we recorded net tax benefits of $228 million and $488 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment, and it is possible that they could be subject to challenges by the U.S. Internal Revenue Service ("IRS").
The U.S. tax law governing deductibility was changed by the Tax Act and the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits, or tax law could change again. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters.
In fiscal year 2021, our provision for income taxes reflected a $424 million benefit from the tax benefits of a self-insurance pre-tax net operating loss carryback under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. Also, as a result of this net operating loss carryback, we received a U.S. federal income tax refund of $966 million. In connection with this net operating loss carryback, certain industry participants, including us, received a letter from the U.S. House of Representatives’ Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including our use of the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act. We responded to the letter. It is possible that the IRS could challenge our tax position with respect to this self-insurance loss. If these initiatives are successful, our effective tax rate could be adversely impacted. Additionally, laws governing insurance coverage vary by state and some state courts have interpreted laws and insurance policies in ways that may impact our self-insurance loss, which could negatively impact our financial position.
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. Tax laws are complex and subject to varying interpretations. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. Proposed adjustments

Cardinal Health | Q1 Fiscal 2022 Form 10-Q
22


Other
in ongoing audits may adversely affect our effective tax rate or tax payments.
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
PeriodTotal Number
of Shares
Purchased (1)		Average Price Paid per Share (2)Total Number of Shares
Purchased
as Part of Publicly Announced Programs (2,3)		Approximate
Dollar Value of
Shares That May
Yet be Purchased
Under the Program (3)
(in millions)
July 2022775 $54.32 — $2,743 
Aug 2022562 68.03 — 2,743 
Sept 202211,987,022 66.74 11,986,815 1,943 
Total11,988,359 $66.74 11,986,815 $1,943 
(1)Reflects 775, 562 and 207 common shares purchased in July, August and September 2022, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On September 14, 2022, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $1.0 billion and received an initial delivery of 12.0 million common shares using a reference price of $66.74. The ASR program is expected to conclude in the second quarter of fiscal 2023. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)On November 4, 2021, our Board of Directors approved a new $3.0 billion share repurchase program, which will expire on December 31, 2024. As of September 30, 2022, we have $1.9 billion authorized for share repurchases remaining under this program. The ASR program is expected to reduce the amount remaining under our existing share repurchase authorization to approximately $1.7 billion when concluded.


 23
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Financial Statements
Condensed Consolidated Statements of Earnings
(Unaudited)
Three Months Ended September 30,
(in millions, except per common share amounts)20222021
Revenue$49,603 $43,968 
Cost of products sold47,989 42,326 
Gross margin1,614 1,642 
Operating expenses:
Distribution, selling, general and administrative expenses1,197 1,114 
Restructuring and employee severance29 18 
Amortization and other acquisition-related costs71 79 
Impairments and (gain)/loss on disposal of assets, net153 (2)
Litigation (recoveries)/charges, net27 18 
Operating earnings137 415 
Other (income)/expense, net2 (4)
Interest expense, net25 40 
Loss on early extinguishment of debt— 10 
Earnings before income taxes110 369 
Provision for/(benefit from) income taxes(1)97 
Net earnings111 272 
   Less: Net earnings attributable to noncontrolling interests(1)(1)
Net earnings attributable to Cardinal Health, Inc. $110 $271 
Earnings per common share attributable to Cardinal Health, Inc.:
Basic$0.41 $0.94 
Diluted0.40 0.94 
Weighted-average number of common shares outstanding:
Basic271287
Diluted273289
Cash dividends declared per common share$0.4957 $0.4908 
See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
24


Financial Statements
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended September 30,
(in millions)20222021
Net earnings$111 $272 
Other comprehensive loss:
Foreign currency translation adjustments and other(58)(25)
Net unrealized gain/(loss) on derivative instruments, net of tax(4)(2)
Total other comprehensive loss, net of tax(62)(27)
Total comprehensive income49 245 
Less: comprehensive income attributable to noncontrolling interests(1)(1)
Total comprehensive income attributable to Cardinal Health, Inc. $48 $244 
See notes to condensed consolidated financial statements.


Cardinal Health | Q1 Fiscal 2023 Form 10-Q
25


Financial Statements
Condensed Consolidated Balance Sheets

(in millions)September 30, 2022June 30, 2022
Assets(Unaudited)
Current assets:
Cash and equivalents$3,492 $4,717 
Trade receivables, net11,039 10,561 
Inventories, net15,891 15,636 
Prepaid expenses and other2,274 2,021 
Total current assets32,696 32,935 
Property and equipment, net2,339 2,361 
Goodwill and other intangibles, net7,367 7,629 
Other assets985 953 
Total assets$43,387 $43,878 
Liabilities and Shareholders’ Deficit
Current liabilities:
Accounts payable$28,362 $27,128 
Current portion of long-term obligations and other short-term borrowings578 580 
Other accrued liabilities2,619 2,842 
Total current liabilities31,559 30,550 
Long-term obligations, less current portion4,689 4,735 
Deferred income taxes and other liabilities8,919 9,299 
Shareholders’ deficit:
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none
— — 
Common shares, without par value:
Authorized—755 million shares, Issued—327 million shares at September 30, 2022 and June 30,2022
2,576 2,813 
Accumulated deficit(301)(280)
Common shares in treasury, at cost: 65 million shares and 54 million shares at September 30, 2022 and June 30, 2022, respectively
(3,880)(3,128)
Accumulated other comprehensive loss(176)(114)
Total Cardinal Health, Inc. shareholders' deficit(1,781)(709)
Noncontrolling interests1 3 
Total shareholders’ deficit(1,780)(706)
Total liabilities and shareholders’ deficit$43,387 $43,878 
See notes to condensed consolidated financial statements.


Cardinal Health | Q1 Fiscal 2023 Form 10-Q
26


Financial Statements
Condensed Consolidated Statements of Shareholders' Equity/(Deficit)
(Unaudited)
Common SharesTreasury SharesAccumulated Other
Comprehensive
Loss		Noncontrolling InterestsTotal
Shareholders’
Equity/(Deficit)
(in millions)Shares IssuedAmountRetained
Earnings/(Accumulated Deficit)		SharesAmount
Three Months Ended September 30, 2022
Balance at June 30, 2022327 $2,813 $(280)(54)$(3,128)$(114)$3 $(706)
Net earnings110 1 111 
Other comprehensive loss, net of tax(62)(62)
Purchase of noncontrolling interests(2)(2)
Employee stock plans activity, net of shares withheld for employee taxes— (37)1 48 11 
Share repurchase program activity(200)(12)(800)(1,000)
Dividends declared(131)(131)
Other(1)(1)
Balance at September 30, 2022327 $2,576 $(301)(65)$(3,880)$(176)$1 $(1,780)
Three Months Ended September 30, 2021
Balance at June 30, 2021327 2,806 $1,205 (36)$(2,186)$(34)$3 $1,794 
Net earnings271 1 272 
Other comprehensive loss, net of tax(27)(27)
Employee stock plans activity, net of shares withheld for employee taxes— (40)1 39 (1)
Share repurchase program activity(100)(8)(400)(500)
Dividends declared(141)(141)
Other(1)(1)
Balance at September 30, 2021327 $2,666 $1,335 (43)$(2,547)$(61)$3 $1,396 
See notes to condensed consolidated financial statements.



Cardinal Health | Q1 Fiscal 2023 Form 10-Q
27


Financial Statements
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended September 30,
(in millions)20222021
Cash flows from operating activities:
Net earnings$111 $272 
Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:
Depreciation and amortization171 168 
Impairments and (gain)/loss on disposal of assets, net153 (2)
Loss on early extinguishment of debt— 10 
Share-based compensation23 24 
Provision for bad debts29 12 
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables(508)(214)
Increase in inventories(264)(129)
Increase/(decrease) in accounts payable1,234 (292)
Other accrued liabilities and operating items, net(926)(495)
Net cash provided by/(used in) operating activities23 (646)
Cash flows from investing activities:
Proceeds from divestitures, net of cash sold— 927 
Additions to property and equipment(70)(67)
Proceeds from disposal of property and equipment2 — 
Purchases of investments(3)(2)
Proceeds from investments1 4 
Net cash provided by/(used in) investing activities(70)862 
Cash flows from financing activities:
Reduction of long-term obligations(7)(587)
Net tax withholdings from share-based compensation(14)(28)
Dividends on common shares(142)(149)
Purchase of treasury shares(1,000)(500)
Net cash used in financing activities(1,163)(1,264)
Effect of exchange rate changes on cash and equivalents(15)(5)
Cash reclassified from assets held for sale— 109 
Net decrease in cash and equivalents(1,225)(944)
Cash and equivalents at beginning of period4,717 3,407 
Cash and equivalents at end of period$3,492 $2,463 
See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
28


Notes to Financial Statements
Notes to Condensed Consolidated Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").
Recently Issued Financial Accounting Standards Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as
material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the three months ended September 30, 2022.

2. Divestitures
In August 2021, we sold the Cordis business to Hellman & Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in Note 6. The Cordis business operated within our Medical segment.

3. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
Three Months Ended September 30,
(in millions)20222021
Employee-related costs$19 $8 
Facility exit and other costs10 10 
Total restructuring and employee severance$29 $18 

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
29


Notes to Financial Statements

During the three months ended September 30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September 30, 2021, restructuring also included costs related to the divestiture of the Cordis business.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2022$56 $10 $66 
Additions20 3 23 
Payments and other adjustments(11)(10)(21)
Balance at September 30, 2022$65 $3 $68 


4. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)PharmaceuticalMedical (1)Total
Balance at June 30, 2022$2,673 $3,182 $5,855 
Foreign currency translation adjustments and other— (26)(26)
Goodwill impairment— (154)(154)
Balance at September 30, 2022$2,673 $3,002 $5,675 
(1)At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion.
During the three months ended September 30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.
Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September 30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due
to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September 30, 2022 after recognizing the impairment charge was $6.7 billion, of which $1.8 billion was goodwill.
Other Intangible Assets
The following tables summarize other intangible assets by class at:
September 30, 2022
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 N/A
Total indefinite-life intangibles11 — 11 N/A
Definite-life intangibles:
Customer relationships3,206 2,157 1,049 10
Trademarks, trade names and patents546 361 185 8
Developed technology and other1,037 590 447 9
Total definite-life intangibles4,789 3,108 1,681 9
Total other intangible assets$4,800 $3,108 $1,692 N/A
June 30, 2022
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,272 2,165 1,107 
Trademarks, trade names and patents552 360 192 
Developed technology and other1,038 574 464 
Total definite-life intangibles4,862 3,099 1,763 
Total other intangible assets$4,873 $3,099 $1,774 
Total amortization of intangible assets was $71 million and $78 million for the three months ended September 30, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $212 million, $258 million, $233 million, $206 million, and $174 million.


Cardinal Health | Q1 Fiscal 2023 Form 10-Q
30


Notes to Financial Statements

5. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both September 30, 2022 and June 30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $28.4 billion and $27.1 billion at September 30, 2022 and June 30, 2022, respectively.
During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10 million loss on early extinguishment of debt. The early redemption was funded with available cash.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.
In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant.


6. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.
The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision.
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the fiscal year ended June 30, 2021 based on the probable estimated payment amount. In the second quarter of fiscal year 2022, we paid the State of New York $20 million, our portion of the assessment for calendar year 2017. As a result, at September 30, 2022, we had an accrual of $20 million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
31


Notes to Financial Statements
agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our
Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.
Opioid Lawsuits and Investigations
States & Political Subdivisions
National Settlement
As previously disclosed, in February 2022, we, along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and other political subdivisions. The Settlement Agreement became effective on April 2, 2022.
In addition to the Distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of November 3, 2022, over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation.
Under this Settlement Agreement, we will pay up to approximately $6.0 billion, the majority of which is expected to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors’ controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.
Other Settlements
West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.
In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160 million to the State of Washington and its participating subdivisions and approximately $95 million to the

 32
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Notes to Financial Statements
State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. The terms of these agreements are consistent with the terms of the Settlement Agreement.
As of October 2022, a sufficient number of subdivisions in each state had agreed to join their respective agreement, and the court in each state ordered the cases to be dismissed. We are in the process of finalizing the consent judgments in each state, and each agreement will become effective upon the entry of the relevant consent judgment. When each of these agreements is finalized, Washington and Oklahoma will become subject to the Settlement Agreement and 48 of 49 states will then be subject to the Settlement Agreement.
We are engaged in resolution discussions with the Attorney General for the State of Alabama.
In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.
During the three months ended September 30, 2022, we made our second annual payment of $372 million under the Settlement Agreement. In total, we have $6.03 billion accrued at September 30, 2022, of which $608 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.
Department of Justice Investigations
We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.
Private Plaintiffs
The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 454 lawsuits as of October, 2022. Of these, 151 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.
A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial date has been set for January 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September 30, 2022.
Cordis IVC Filter Matters
Product Liability Lawsuits
As of November 3, 2022, we are named as a defendant in 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,215 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 7 lawsuits involving similar claims by approximately 8 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.
These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.
At September 30, 2022, we had a total of $527 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07 billion, net of estimated insurance
Cardinal Health | Q1 Fiscal 2023 Form 10-Q
33


Notes to Financial Statements
recoveries. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. The court granted our motion to dismiss, and the indirect purchasers filed an amended complaint. We intend to vigorously defend ourselves.
Active Pharmaceutical Ingredient Impurity Litigation
Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. We have been named as a defendant in an MDL alleging API impurities in certain generic blood pressure medications; however we no longer believe that these matters are material to us and we will no longer report on them.
Antitrust Litigation Proceeds
In October 2022, we received net cash proceeds resulting from the settlements of a lawsuit in which we were a class member or plaintiff of approximately $66 million, which will be recognized in litigation (recoveries)/charges, net, during the three months ending December 31, 2022.
7. Income Taxes
Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Tax Effects of Goodwill Impairment Charge
During the three months ended September 30, 2022, we recognized a $154 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12 million for fiscal 2023.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the three months ended September 30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September 30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September 30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September 30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.
Effective Tax Rate
During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The effective tax rate for the three months ended September 30, 2022 reflects the impact of tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items.
Unrecognized Tax Benefits
We had $940 million and $943 million of unrecognized tax benefits at September 30, 2022 and June 30, 2022, respectively. Both the September 30, 2022 and June 30, 2022 balances include $858

 34
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Notes to Financial Statements
million of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.
At September 30, 2022 and June 30, 2022, we had $49 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $75 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2016 through the current fiscal year.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $77 million and $75 million at September 30, 2022 and June 30, 2022 respectively, and is included in other assets in the condensed consolidated balance sheets.

8. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
September 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,477 $— $— $1,477 
Other investments (1)88 — — 88 
Liabilities:
Forward contracts (2)— (5)— (5)
June 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$2,425 $— $— $2,425 
Other investments (1)97 — — 97 
Forward contracts (2)— 15 — 15 
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.

9. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Cardinal Health | Q1 Fiscal 2023 Form 10-Q
35


Notes to Financial Statements
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During three months ended September 30, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $100 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains recognized in other comprehensive loss were $4 million for the three months ended September 30, 2022. Pre-tax gains recognized in other comprehensive loss were immaterial for the three months ended September 30, 2021. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $22 million and a $5 million for the three months ended September 30, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million and $6 million during the three months ended September 30, 2022 and 2021, respectively.

 36
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Notes to Financial Statements
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $6 million loss and an immaterial gain during the three months ended September 30, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are the Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2022 and June 30, 2022 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)September 30, 2022June 30, 2022
Estimated fair value$4,838 $5,049 
Carrying amount5,267 5,315 
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
10. Shareholders' Equity/(Deficit)
During the three months ended September 30, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program is expected to conclude in the second quarter of fiscal 2023.
During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares.
We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive loss, before reclassifications(58)(2)(60)
Amounts reclassified to earnings— (2)(2)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million
(58)(4)(62)
Balance at September 30, 2022$(160)$(16)$(176)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2021$(46)$12 $(34)
Other comprehensive loss, before reclassifications(25)(1)(26)
Amounts reclassified to earnings— (1)(1)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax(25)(2)(27)
Balance at September 30, 2021$(71)$10 $(61)

11. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
Three Months Ended September 30,
(in millions)20222021
Weighted-average common shares–basic271 287 
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units2 2 
Weighted-average common shares–diluted273 289 
The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for both
Cardinal Health | Q1 Fiscal 2023 Form 10-Q
37


Notes to Financial Statements

the three months ended September 30, 2022 and 2021 were 4 million.
12. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
Three Months Ended September 30,
(in millions)20222021
Pharmaceutical Distribution and Specialty Solutions (1) (2)$45,547 $39,614 
Nuclear and Precision Health Solutions (3)281 208 
Pharmaceutical segment revenue
45,828 39,822 
Medical distribution and products (4)3,140 3,567 
Cardinal Health at-Home Solutions638 582 
Medical segment revenue
3,778 4,149 
  Total segment revenue49,606 43,971 
Corporate (5)(3)(3)
Total revenue$49,603 $43,968 
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.
(4)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
Three Months Ended September 30,
(in millions)20222021
United States$48,477 $42,841 
International1,129 1,130 
  Total segment revenue49,606 43,971 
Corporate (1)(3)(3)
Total revenue$49,603 $43,968 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Cardinal Health | Q1 Fiscal 2020 Form 10-Q
38


Notes to Financial Statements


Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•surgical gown recall costs/(income);
•shareholder cooperation agreement costs;
•state opioid assessment related to prior fiscal years;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets, net;
•litigation (recoveries)/charges, net;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt;
•(gain)/loss on sale of equity interest in naviHealth; or
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $7 million for the three months ended September 30, 2022 and 2021, respectively.
The following table presents segment profit by reportable segment and Corporate:
Three Months Ended September 30,
(in millions)20222021
Pharmaceutical$431 $406 
Medical(8)123 
Total segment profit423 529 
Corporate(286)(114)
Total operating earnings$137 $415 
The following table presents total assets for each reportable segment and Corporate at:
(in millions)September 30, 2022June 30, 2022
Pharmaceutical$27,253 $26,409 
Medical11,338 11,632 
Corporate4,796 5,837 
Total assets$43,387 $43,878 

13. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following table provides total share-based compensation expense by type of award:
Three Months Ended September 30,
(in millions)20222021
Restricted share unit expense$17 $18 
Performance share unit expense6 6 
Total share-based compensation
$23 $24 
The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended September 30, 2022 and 2021, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20222.7 $46.03 
Granted1.2 69.95 
Vested(1.2)49.62 
Canceled and forfeited(0.2)54.94 
Nonvested at September 30, 20222.5 $59.43 
At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $119 million, which is expected to be recognized over a weighted-average period of two years.
Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share

Cardinal Health | Q1 Fiscal 2023 Form 10-Q
39


Notes to Financial Statements

units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20221.2 $54.32 
Granted0.3 76.79 
Vested(0.4)59.04 
Canceled and forfeited(0.2)57.50 
Nonvested at September 30, 20220.9 $72.01 
At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.

 40
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Exhibits
Exhibits
Exhibit
Number		Exhibit Description
3.1
3.2
10.1
10.2
31.1
31.2
32.1
99.1
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings and certain other information on its website.


Cardinal Health | Q1 Fiscal 2023 Form 10-Q
41


Form 10-Q Cross Reference Index


Form 10-Q Cross Reference Index
Item NumberPage
Part I. Financial Information
Item 1
Item 2
Item 3
Item 4
Part II. Other Information
Item 1
Item 1A
Item 2
Item 3Defaults Upon Senior Securities N/A
Item 4Mine Safety Disclosures N/A
Item 5Other InformationN/A
Item 6
N/ANot applicable



 42
Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Additional Information
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cardinal Health, Inc.
Date:November 4, 2022/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ PATRICIA M. ENGLISH
Patricia M. English
Chief Financial Officer


Cardinal Health | Q1 Fiscal 2023 Form 10-Q
43

 EX-31.1 2 a23q1_10qx093022xex3113.htm EX-31.1 Document
Exhibit 31.1

I, Jason M. Hollar, certify that:
1.I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 4, 2022
/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer


 EX-31.2 3 a23q1_10qx093022xex3123.htm EX-31.2 Document
Exhibit 31.2

I, Patricia M. English, certify that:
1.I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 4, 2022
/s/ PATRICIA M. ENGLISH
Patricia M. English
Chief Financial Officer


 EX-32.1 4 a23q1_10qx093022xex3213.htm EX-32.1 Document
Exhibit 32.1

Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Jason M. Hollar, Chief Executive Officer of Cardinal Health, Inc. (the “Company”) and Patricia M. English, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that:
(1)the Periodic Report on Form 10-Q for the quarter ended September 30, 2022 containing the financial statements of the Company (the “Periodic Report”), which this statement accompanies, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2)the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 4, 2022
/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Executive Officer
/s/ PATRICIA M. ENGLISH
Patricia M. English
Chief Financial Officer


 EX-99.1 5 a23q1_10qx093022xex9911.htm EX-99.1 Document
Exhibit 99.1



Statement Regarding Forward-Looking Information
As used in this exhibit, “we,” “our,” “us” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the “2022 Form 10-K”), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include:
•competitive pressures in the markets in which we operate, including pricing pressures;
•uncertainties relating to the pricing of and demand for generic pharmaceuticals;
•significantly increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases;
•uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program;
•changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation;
•changes in the timing or frequency of the introduction of branded pharmaceuticals;
•continuing risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the investigations by the Department of Justice which we believe concern our anti-diversion program, our anti-diversion policies and procedures and our distribution of certain controlled substances;
•risks associated with the national settlement agreement to resolve the vast majority of opioid-related claims brought by states and other governmental entities, including the risk that the implementation and maintenance of the required changes to distributors' controlled substance anti-diversion programs may result in unforeseen costs or operational challenges and the risk that if we fail to or are alleged to have failed to comply with the terms of the settlement agreement, we could incur monetary or other penalties or result in additional lawsuits being filed against us;
•potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us;
•risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act;
•risks associated with our Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services, including the risk that failure to comply with the requirements set forth therein could result in monetary or other penalties;
•the possibility of additional adverse impacts to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications;
•our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx;
•our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;
•costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits;
•actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions;


•any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption;
•shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes;
•the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;
•uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance;
•risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment;
•uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel;
•difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities;
•manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities;
•risks associated with industry reliance on ethylene oxide ("EtO") to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread;
•the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;
•risks arising from possible violations of healthcare fraud and abuse laws;
•risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;
•risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;
•risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements;
•risks arising from pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact our customers;
•risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations;
•changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications;
•material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers;
•unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix;
•risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;
•uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All;
•reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services;
•changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;
•changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits;


•uncertainties arising as a result of the Supreme Court decision on Dobbs vs. Jackson, including uncertainties associated with states' proposed and adopted laws which may impact our ability to distribute or store certain pharmaceutical products and the risk that we could incur unforeseen costs to comply with these new laws in various jurisdictions;
•changes in hospital buying groups or hospital buying practices;
•changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution;
•changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;
•continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers;
•disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks;
•risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented;
•the risk that we may not effectively implement and maintain data governance structures across businesses to allow us to access and interpret our data, which could put us at a competitive disadvantage relative to our peers;
•the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings;
•the possibility that our business performance or internal control over financial reporting may be adversely impacted if we are not successful at attracting, retaining and developing talent;
•losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products;
•risks associated with the importation of products or source materials used in products that we manufacture or distribute, including risks associated with our country-of-origin determinations and the possibility that we could experience supply disruptions as a result of the Uyghur Forced Labor Prevention Act;
•our ability to maintain adequate intellectual property protections;
•the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions;
•risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected;
•our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives;
•bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;
•risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations;
•uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business;
•risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;
•our ability to introduce and market new products and our ability to keep pace with advances in technology;
•significant charges to earnings if goodwill or intangible assets become impaired;
•uncertainties relating to general political, business, industry, regulatory and market conditions;
•certain risks arising from the ongoing COVID-19 pandemic; and
•other factors described in the “Risk Factors” section of the 2022 Form 10-K.
The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions generally identify “forward-looking statements,” which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.

 EX-101.SCH 6 cah-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Restructuring and Employee Severance link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Commitments, Contingent Liabilities and Litigation link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Restructuring and Employee Severance (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Restructuring and Employee Severance Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Income Taxes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Fair Value Measurements Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Financial Instruments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Shareholders' Equity Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Segment Information Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Segment Information Revenue by Geographical Segments (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Share-Based Compensation Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cah-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 cah-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 cah-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amounts reclassified to earnings Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Short-term Borrowings Other Short-Term Borrowings Net earnings Net earnings/(loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Loss Contingency, Pending Claims, Number Loss Contingency, Pending Claims, Number Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pharmaceutical Pharmaceutical Member Pharmaceutical [Member] Other investments Investments, Fair Value Disclosure Debt Instrument [Axis] Debt Instrument [Axis] Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Dividends on common shares Payments of Ordinary Dividends, Common Stock Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Current portion of long-term obligations and other short-term borrowings Long-Term Debt and Lease Obligation, Current Estimated fair value Debt Instrument, Fair Value Disclosure Medical Segment [Axis] Medical Segment [Axis] Medical Segment [Axis] Beginning Balance Ending Balance Restructuring Reserve Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Vesting Period in years for Shares Vesting Period in years for Shares Vesting Period in years for Shares Number of plaintiffs Loss Contingency, Number of Plaintiffs Product Liability Lawsuits [Member] Product Liability Lawsuits [Member] Product Liability Lawsuits [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cordis Divestiture [Domain] Cordis Divestiture [Domain] Cordis Divestiture [Domain] Nuclear Precision Health Services [Member] Nuclear Precision Health Services [Member] Nuclear Precision Health Services [Member] Net earnings attributable to Cardinal Health, Inc. Net Earnings/(Loss) Net Income (Loss) Attributable to Parent Subsequent Event Type [Axis] Subsequent Event Type [Axis] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] WEST VIRGINIA WEST VIRGINIA Restructuring Plan [Axis] Restructuring Plan [Axis] Target performance goal (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Loss Contingency, Estimate of Possible Loss Loss Contingency, Estimate of Possible Loss Hedging Designation [Domain] Hedging Designation [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Committed Receivables Sales Facility Program [Member] Committed Receivables Sales Facility Program [Member] Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables. Goodwill [Line Items] Goodwill [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Project Costs On Investment And Other Spending Project Costs On Investment And Other Spending Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses. Medical Medical Member Medical [Member] Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share Schedule of Weighted Average Number of Shares [Table Text Block] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Indemnification receivable Indemnification Receivable Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes. Net cash provided by/(used in) operating activities Net Cash Provided by (Used in) Operating Activities Additions Restructuring Costs $1 billion share repurchase program $1 billion share repurchase program [Member] $1 billion share repurchase program Net tax withholdings from share-based compensation Net proceeds/(tax withholdings) from share-based compensation The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Proceeds from divestitures, net of cash sold Proceeds from Divestiture of Businesses Plaintiff Type [Domain] Plaintiff Type [Domain] [Domain] for Plaintiff Type [Axis] Statement of Stockholders' Equity Condensed Financial Statements, Captions [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Settling U.S Territories Settling U.S Territories Settling U.S Territories Revolving Credit Facility [Member] Revolving Credit Facility [Member] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Document Type Document Type Restricted Share Units Performance Share Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Assets: Assets, Fair Value Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Restructuring Type [Axis] Restructuring Type [Axis] Employee-related costs Severance Costs Severance Costs Nonvested at beginning of period (in usd per share) Nonvested at end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Segments [Axis] Operating and Reportable Segment Segments [Axis] Long-Term Obligations and Other Short-Term Borrowings Debt Disclosure [Text Block] Entity Shell Company Entity Shell Company Cordis Divestiture [Member] Cordis Divestiture [Member] Cordis Divestiture 2.616% Notes due 2022 2.616% Notes due 2022 [Member] 2.616% Notes due 2022 Proceeds from investments Proceeds from sale of available-for-sale securities and other investments The cash inflow from sales of available-for-sale securities and other investments. Developed technology and other Developed Technology Rights [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Financial Instruments Disclosure Financial Instruments Disclosure [Text Block] Subsequent Event Subsequent Event [Member] Consolidation Items [Domain] Consolidation Items [Domain] Document Period End Date Document Period End Date Schedule of Definite and Indefinite-Lived Intangible Assets Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block] Facility Exit and Other Costs Facility Exit and Other Costs Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs. Cardinal Health At Home Solutions [Member] Cardinal Health At Home Solutions [Member] Cardinal Health At Home Solutions [Member] Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Total assets Assets Segment Revenue by Geographic [Table] Segment Revenue by Geographic [Table] Segment Revenue by Geographic [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Performance Share Units Performance Share Unit Performance Shares [Member] Interest Rate Swap Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Cash Reclassified to Assets Held for Sale Cash Reclassified from Assets Held for Sale Cash Reclassified from Assets Held for Sale Shareholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Earnings before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segments [Domain] Segments [Domain] Goodwill [Table] Schedule of Goodwill [Table] Earnings Per Share Attributable to Cardinal Health, Inc. Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Amortization and other acquisition-related costs Amortization and other acquisition-related costs The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Goodwill Impairment [Axis] Goodwill Impairment [Axis] Goodwill Impairment Total comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Loss Contingency, Claims Settled, Number Loss Contingency, Claims Settled, Number Award Type [Domain] Award Type [Domain] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Loss on early extinguishment of debt Loss on Early Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Restructuring Plan [Domain] Restructuring Plan [Domain] Other comprehensive loss, before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Derivative, Name [Domain] Derivative Contract [Domain] Gross margin Gross Profit Entity Registrant Name Entity Registrant Name Income Taxes Tax Credit Carryforward [Line Items] Foreign currency translation adjustments and other Goodwill, Foreign Currency Translation Gain (Loss) Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Subsegments [Axis] Subsegments [Axis] Operating expenses: Operating Expenses [Abstract] Total shareholders' equity Balance at beginning of period Balance at end of period Balance at beginning of period Balance at end of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Terminal Growth Rate, Fair Value Input Terminal Growth Rate, Fair Value Input Terminal Growth Rate, Fair Value Input Minimum Minimum [Member] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] AOCI, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Trading Symbol Trading Symbol Entity File Number Entity File Number Treasury shares acquired, average price per share (in usd per share) Treasury Stock Acquired, Average Cost Per Share Short Term Credit Facilities Member Short Term Credit Facilities Member Other short-term credit facilities and an unsecured line of credit Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Asset, Expected Amortization, Year Four Medical Unit Goodwill Impairment [Member] Goodwill Impairment - Medical Unit [Member] Goodwill Impairment - Medical Unit Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Share Units Restricted Share Unit Restricted Stock Units (RSUs) [Member] Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Estimated Liability for New York Opioid Stewardship Act Estimated Liability for New York Opioid Stewardship Act Estimated Liability for New York Opioid Stewardship Act Judgment for lost profits Judgment for lost profits Judgment for lost profits Notional Amount Derivative Liability, Notional Amount Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Increase/(decrease) in accounts payable Increase (Decrease) in Accounts Payable Revenue Total revenue Revenues Net unrealized gain/(loss) on derivative instruments, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Income Tax Disclosure Income Tax Disclosure [Text Block] Credit Facility [Domain] Credit Facility [Domain] Trademarks, trade names and patents Trademarks And Patents Member The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law. Amortization of intangible assets Amortization of Intangible Assets Gross Intangible, Total other intangible assets Intangible Assets, Gross (Excluding Goodwill) Schedule of Goodwill by Reportable Segment Schedule of Goodwill [Table Text Block] Basic (in shares) Earnings Per Share, Basic Debt, Long-term and Short-term, Combined Amount Debt, Long-Term and Short-Term, Combined Amount Corporate Corporate Corporate, Non-Segment [Member] Treasury Shares Treasury Stock [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total Cardinal Health, Inc. shareholders' deficit Stockholders' Equity Attributable to Parent Canceled and forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Trademarks and patents IPR&D,TrademarksandOther [Member] Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. Change in operating assets and liabilities, net of effects from acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Asset, Expected Amortization, Year Three Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] GEORGIA GEORGIA Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) [Member] Litigation (recoveries)/charges, net Gain (Loss) Related to Litigation Settlement Gain (Loss) Related to Litigation Settlement Common Stock Common Stock [Member] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Medical Segment [Domain] Medical Segment [Domain] [Domain] for Medical Segment [Axis] Employee stock plans activity, net of shares withheld for employee taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Number of Reportable Segments Number of Reportable Segments Payments for Repurchase of Common Stock Purchase of treasury shares Payments for Repurchase of Common Stock Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Statement [Table] Statement [Table] Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Schedule of Transactions Related to Performance Share Units Under the Plans Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Trade receivables, net Receivables, Net, Current Document Quarterly Report Document Quarterly Report Medical distribution and products [Member] Medical distribution and products [Member] Medical distribution and products [Member] Tax Matter [Domain] Tax Matter [Domain] [Domain] for Tax Matter [Axis] Discontinued Operations and Disposal Groups [Abstract] Current assets: Assets, Current [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Treasury Stock, Shares, Acquired Treasury shares acquired (using cost method), shares Treasury Stock, Shares, Acquired Fair Value, Inputs, Level 1, 2 and 3 Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] Net Intangible Indefinite-Lived Intangible Assets (Excluding Goodwill) Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Settling States Settling States Settling States Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Recurring Fair Value, Recurring [Member] Litigation Case Type Litigation Case [Domain] Interest Income (Expense), Nonoperating, Net Interest Income (Expense), Nonoperating, Net Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Share repurchase program aggregate purchase price [Domain] Share repurchase program aggregate purchase price [Domain] Share repurchase program aggregate purchase price [Domain] Impairments and (gain)/loss on disposal of assets, net Gain (Loss) on Sale of Assets and Asset Impairment Charges Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Long Lived Assets Held-for-sale [Line Items] Long-Lived Assets Held-for-sale [Line Items] Variable Rate [Domain] Variable Rate [Domain] Schedule of Long Lived Assets Held-for-sale [Table] Schedule of Long-Lived Assets Held-for-sale [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Gross Intangible Finite-Lived Intangible Assets, Gross Distribution, selling, general and administrative expenses Selling, General and Administrative Expense Loss Contingencies Loss Contingencies [Table] Loss Contingency, Number of Eligible States Loss Contingency, Number of Eligible States Loss Contingency, Number of Eligible States AOCI Attributable to Parent AOCI Attributable to Parent [Member] Other Jurisdictions [Member] Other Jurisdictions [Member] Other Jurisdictions [Member] Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Carrying Amount of Long-Term and other Short-Term Borrowings Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Opioid Litigation [Domain] Opioid Litigation [Domain] Opioid Litigation [Domain] Operating earnings Total operating earnings Operating Income (Loss) Increase in inventories Increase (Decrease) in Inventories $500 million share repurchase program $500 million share repurchase program [Member] $500 million share repurchase program [Domain] Recent Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] CareFusion [Member] CareFusion [Member] CareFusion [Member] Effect of dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Goodwill Impairment [Domain] Goodwill Impairment [Domain] Goodwill Impairment Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Litigation Type [Domain] Litigation Type [Domain] [Domain] for Litigation Type [Axis] Beginning balance Ending balance Goodwill Goodwill Treasury Stock, Shares Treasury, balance at beginning of period (in shares) Treasury, balance at end of period (in shares) Treasury Stock, Shares Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Provision for/(benefit from) income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Earnings per common share attributable to Cardinal Health, Inc.: Earnings Per Share, Basic [Abstract] Cost of Goods and Services Sold Cost of Goods and Services Sold Derivative [Line Items] Derivative [Line Items] Diluted (in shares) Weighted-average common shares–diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Forward Contract Derivative Assets (Liabilities), at Fair Value, Net Medical Unit [Member] Medical Unit [Member] Medical Unit Loss Contingencies [Line Items] Loss Contingencies [Line Items] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Common Stock, Value, Issued Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Operating Segments Operating Segments [Member] Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Estimated range of decrease in unrecognized tax benefits within the next 12 months Decrease in Unrecognized Tax Benefits is Reasonably Possible Cash and equivalents at beginning of period Cash and equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustments and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Less: Net earnings attributable to noncontrolling interests Less: comprehensive income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Commitments, Contingent Liabilities and Litigation Commitments and Contingencies Disclosure [Text Block] Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Current liabilities: Liabilities, Current [Abstract] Common Stock, Shares, Issued Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Issued Income Statement Location [Domain] Income Statement Location [Domain] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Facility Exit and Other Costs Facility Closing [Member] Amendment Flag Amendment Flag Net cash provided by/(used in) investing activities Net Cash Provided by (Used in) Investing Activities Fair Value Hedging Fair Value Hedging [Member] Federal Internal Revenue Service (IRS) [Member] Weighted- Average Remaining Amortization Period (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Total other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Total comprehensive income attributable to Cardinal Health, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pharmaceutical Segment [Axis] Pharmaceutical Segment [Axis] Pharmaceutical Segment [Axis] Litigation Case Litigation Case [Axis] Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Other Assets Other Assets, Noncurrent Payments and other adjustments Payments for Restructuring Depreciation and amortization Depreciation, Depletion and Amortization Share repurchase program aggregate purchase price [Axis] Share repurchase program aggregate purchase price [Axis] Share repurchase program aggregate purchase price Repayments of Notes Payable Repayments of Notes Payable Employee- Related Costs Employee Severance [Member] Total Opioid Litigation [Member] Total Opioid Litigation [Member] Total Opioid Litigation Derivative [Table] Derivative [Table] Reclassification out of Accumulated Other Comprehensive Loss [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Goodwill and other intangibles, net Intangible Assets, Net (Including Goodwill) Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Stockholders' Equity, Other Stockholders' Equity, Other Lawsuit Type [Axis] Lawsuit Type [Axis] Lawsuit Type [Axis] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Reduction of long-term obligations Repayments of Long-Term Debt Treasury Stock, Value Treasury, balance at beginning of period Treasury, balance at end of period Treasury Stock, Value Segment Revenue by Geographic [Line Items] Segment Revenue by Geographic [Line Items] [Line Items] for Segment Revenue by Geographic [Table] Preferred shares, without par value: Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Dividends Dividends Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other (income)/expense, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Open Tax Year Open Tax Year Restructuring and Employee Severance Restructuring and Related Activities Disclosure [Text Block] Common Stock, Shares Authorized Common Stock, Shares Authorized Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Cash and equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Designated as Hedging Instrument Designated as Hedging Instrument [Member] Payments for Legal Settlements Payments for Legal Settlements Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Cash dividends declared per common share Common Stock, Dividends, Per Share, Declared Net Intangible Finite-Lived Intangible Assets, Net Assets by Reportable Segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Cordis Divestiture [Axis] Cordis Divestiture [Axis] Cordis Divestiture Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Tax benefit related to share-based compensation Share-Based Payment Arrangement, Expense, Tax Benefit Restructuring Charges [Abstract] Restructuring Charges [Abstract] Title of 12(b) Security Title of 12(b) Security Condensed Consolidated Statement of Shareholders' Equity Condensed Financial Statements [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Reporting Unit [Axis] Reporting Unit [Axis] Common shares, without par value: Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] CVS Health CVS Health [Member] CVS Health [Member] Class of Stock [Line Items] Class of Stock [Line Items] New York Opioid Stewardship Act [Member] New York Opioid Stewardship Act [Member] New York Opioid Stewardship Act Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Segment Information Segment Reporting Disclosure [Text Block] Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Asset, Expected Amortization, Year Two Liabilities and Shareholders’ Deficit Liabilities and Equity [Abstract] Subsegments [Domain] Subsegments [Domain] Fair Value Measurements, Recurring and Nonrecurring Fair Value, Recurring and Nonrecurring [Table] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Inventories, net Inventory, Net Accounts Payable, Current Accounts Payable, Current Restructuring and employee severance Total restructuring and employee severance Restructuring Charges Income Tax Authority Income Tax Authority [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Entity Filer Category Entity Filer Category Basic (in shares) Weighted-average common shares–basic (in shares) Weighted Average Number of Shares Outstanding, Basic UNITED STATES UNITED STATES Loss Contingency Accrual Loss Contingency Accrual Liabilities: Liabilities, Fair Value Disclosure [Abstract] Total share-based compensation Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Net Assets Net Assets Preferred Stock, Value, Issued Preferred Stock, Value, Issued Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Goodwill impairment Goodwill, Impairment Loss Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Schedule of Total Share-based Compensation Expense by Type of Award Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Plaintiff Type [Axis] Plaintiff Type [Axis] Plaintiff Type [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Noncontrolling Interest Noncontrolling Interest [Member] Forecast [Member] Forecast [Member] Total liabilities and shareholders’ deficit Liabilities and Equity Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Increase in trade receivables Increase (Decrease) in Receivables Non-US [Member] Non-US [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Native American tribes [Member] Native American tribes [Member] Native American tribes Level 2 Fair Value, Inputs, Level 2 [Member] Segment Profit by Reportable Segment Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Purchases of investments Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Tax Matter [Axis] Tax Matter [Axis] Tax Matter [Axis] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Opioid Lawsuits [Member] OKLAHOMA OKLAHOMA Alameda County [Member] Alameda County [Member] Alameda County [Member] Net Intangible, Total other intangible assets Intangible Assets, Net (Excluding Goodwill) Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted (in shares) Earnings Per Share, Diluted Private Parties [Member] Private Parties [Member] Private Parties [Member] Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Consolidation Items [Axis] Consolidation Items [Axis] Reconciliation of Revenue from Segments to Consolidated [Table] Schedule of Segment Reporting Information, by Segment [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Total current liabilities Liabilities, Current Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Reporting Unit [Domain] Reporting Unit [Domain] Prepaid expenses and other Other Assets, Current Long-term Purchase Commitment, Period Long-Term Purchase Commitment, Period Unrecognized tax benefits Unrecognized Tax Benefits Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Schedule of Transactions Related to Restricted Share Units Under the Plans Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Accounts Payable Accounts Payable Disposal Groups, Including Discontinued Operations, Disclosure Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Opioid Litigation Opioid Litigation [Axis] Opioid Litigation Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Entity Address, Address Line One Entity Address, Address Line One Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Income Tax Authority Income Tax Authority [Domain] Aggregate Annual Assessment Aggregate Annual Assessment Aggregate Annual Assessment Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Weighted Average Number Diluted Shares Outstanding Adjustment Number of shares excluded from calculation of diluted shares Number of shares excluded from calculation of diluted shares Interest expense, net Interest Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Credit Facility [Axis] Credit Facility [Axis] Income Taxes Tax Credit Carryforward [Table] Long-term obligations, less current portion Long-Term Debt and Lease Obligation Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Equity [Abstract] Equity [Abstract] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Deferred income taxes and other liabilities Deferred Tax and Other Liabilities, Noncurrent Schedule of Segment Reporting Information, by Segment [Table Text Block] Disaggregation of Revenue [Table Text Block] WASHINGTON WASHINGTON Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Net decrease in cash and equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued Liabilities Accrued Liabilities [Member] Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number of Shares Outstanding, Diluted, Adjustment Summary of Restructuring and Employee Severance Restructuring and Related Costs [Table Text Block] Pharmaceutical Segment [Domain] Pharmaceutical Segment [Domain] [Domain] for Pharmaceutical Segment [Axis] Commercial Paper [Member] Commercial Paper [Member] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted-Average Grant Date Fair Value per Share Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Other accrued liabilities Other Accrued Liabilities, Current litigation settlement liability recorded Estimated Litigation Liability Estimated Litigation Liability Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] City Area Code City Area Code Assets Assets [Abstract] Other accrued liabilities and operating items, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Loss Contingency Accrual, Payments Loss Contingency Accrual, Payments Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Finite-Lived Intangible Asset, Expected Amortization, Year One Finite-Lived Intangible Asset, Expected Amortization, Year One Customer [Domain] Customer [Domain] EX-101.PRE 10 cah-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 cah-20220930_g1.jpg begin 644 cah-20220930_g1.jpg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end GRAPHIC 12 cah-20220930_g2.jpg begin 644 cah-20220930_g2.jpg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end GRAPHIC 13 cah-20220930_g3.jpg begin 644 cah-20220930_g3.jpg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end GRAPHIC 14 cah-20220930_g4.jpg begin 644 cah-20220930_g4.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 3 Months Ended
Sep. 30, 2022
Oct. 31, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 1-11373  
Entity Registrant Name Cardinal Health, Inc.  
Entity Central Index Key 0000721371  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Incorporation, State or Country Code OH  
Entity Tax Identification Number 31-0958666  
Entity Address, Address Line One 7000 Cardinal Place  
Entity Address, City or Town Dublin  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43017  
City Area Code 614  
Local Phone Number 757-5000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common shares (without par value)  
Trading Symbol CAH  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   262,134,053
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue $ 49,603 $ 43,968
Cost of Goods and Services Sold 47,989 42,326
Gross margin 1,614 1,642
Operating expenses:    
Distribution, selling, general and administrative expenses 1,197 1,114
Restructuring and employee severance 29 18
Amortization and other acquisition-related costs 71 79
Impairments and (gain)/loss on disposal of assets, net 153 (2)
Litigation (recoveries)/charges, net 27 18
Operating earnings 137 415
Other (income)/expense, net 2 (4)
Interest expense, net 25 40
Loss on early extinguishment of debt 0 10
Earnings before income taxes 110 369
Provision for/(benefit from) income taxes (1) 97
Net earnings 111 272
Less: Net earnings attributable to noncontrolling interests (1) (1)
Net earnings attributable to Cardinal Health, Inc. $ 110 $ 271
Earnings per common share attributable to Cardinal Health, Inc.:    
Basic (in shares) $ 0.41 $ 0.94
Diluted (in shares) $ 0.40 $ 0.94
Weighted-average number of common shares outstanding:    
Basic (in shares) 271 287
Diluted (in shares) 273 289
Cash dividends declared per common share $ 0.4957 $ 0.4908
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]    
Net earnings/(loss) $ 111 $ 272
Other comprehensive loss:    
Foreign currency translation adjustments and other (58) (25)
Net unrealized gain/(loss) on derivative instruments, net of tax (4) (2)
Total other comprehensive loss, net of tax (62) (27)
Total comprehensive income 49 245
Less: comprehensive income attributable to noncontrolling interests (1) (1)
Total comprehensive income attributable to Cardinal Health, Inc. $ 48 $ 244
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
shares in Thousands, $ in Millions
Sep. 30, 2022
Jun. 30, 2022
Current assets:    
Cash and equivalents $ 3,492 $ 4,717
Trade receivables, net 11,039 10,561
Inventories, net 15,891 15,636
Prepaid expenses and other 2,274 2,021
Total current assets 32,696 32,935
Property and equipment, net 2,339 2,361
Goodwill and other intangibles, net 7,367 7,629
Other Assets 985 953
Total assets 43,387 43,878
Current liabilities:    
Accounts Payable, Current 28,362 27,128
Current portion of long-term obligations and other short-term borrowings 578 580
Other accrued liabilities 2,619 2,842
Total current liabilities 31,559 30,550
Long-term obligations, less current portion 4,689 4,735
Deferred income taxes and other liabilities $ 8,919 $ 9,299
Preferred shares, without par value:    
Preferred Stock, Shares Authorized 500 500
Preferred Stock, Shares Issued 0 0
Preferred Stock, Value, Issued $ 0 $ 0
Common shares, without par value:    
Common Stock, Shares Authorized 755,000 755,000
Common Stock, Shares, Issued 327,000 327,000
Common Stock, Value, Issued $ 2,576 $ 2,813
Accumulated deficit (301) (280)
Treasury Stock, Value $ (3,880) $ (3,128)
Treasury Stock, Shares 65,000 54,000
Accumulated other comprehensive loss $ (176) $ (114)
Total Cardinal Health, Inc. shareholders' deficit (1,781) (709)
Noncontrolling interests 1 3
Total shareholders' equity (1,780) (706)
Total liabilities and shareholders’ deficit $ 43,387 $ 43,878
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Shareholders' Equity - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Retained Earnings
Treasury Shares
AOCI Attributable to Parent
Noncontrolling Interest
Balance at beginning of period (in shares) at Jun. 30, 2021   327,000        
Balance at beginning of period at Jun. 30, 2021 $ (1,794) $ (2,806) $ (1,205)   $ 34 $ (3)
Treasury, balance at beginning of period (in shares) at Jun. 30, 2021       (36,000)    
Treasury, balance at beginning of period at Jun. 30, 2021       $ (2,186)    
Statement of Stockholders' Equity            
Net Earnings/(Loss) 271          
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 272         1
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (27)       (27)  
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   1,000    
Employee stock plans activity, net of shares withheld for employee taxes 1 $ (40)   $ (39)    
Treasury Stock, Shares, Acquired       (8,000)    
Payments for Repurchase of Common Stock 500 $ 100   $ 400    
Dividends 141   141      
Stockholders' Equity, Other (1)         (1)
Balance at end of period (in shares) at Sep. 30, 2021   327,000        
Balance at end of period at Sep. 30, 2021 $ (1,396) $ (2,666) (1,335)   61 (3)
Treasury, balance at end of period (in shares) at Sep. 30, 2021       (43,000)    
Treasury, balance at end of period at Sep. 30, 2021       $ (2,547)    
Balance at beginning of period (in shares) at Jun. 30, 2022 327,000 327,000        
Balance at beginning of period at Jun. 30, 2022 $ 706 $ (2,813) 280   114 (3)
Treasury, balance at beginning of period (in shares) at Jun. 30, 2022 (54,000)     (54,000)    
Treasury, balance at beginning of period at Jun. 30, 2022 $ (3,128)     $ (3,128)    
Statement of Stockholders' Equity            
Net Earnings/(Loss) 110          
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 111         1
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (62)       (62)  
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests (2)         (2)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture   0   1,000    
Employee stock plans activity, net of shares withheld for employee taxes (11) $ (37)   $ (48)    
Treasury Stock, Shares, Acquired       (12,000)    
Payments for Repurchase of Common Stock 1,000 $ 200   $ 800    
Dividends 131   131      
Stockholders' Equity, Other $ (1)         (1)
Balance at end of period (in shares) at Sep. 30, 2022 327,000 327,000        
Balance at end of period at Sep. 30, 2022 $ 1,780 $ (2,576) $ 301   $ 176 $ (1)
Treasury, balance at end of period (in shares) at Sep. 30, 2022 (65,000)     (65,000)    
Treasury, balance at end of period at Sep. 30, 2022 $ (3,880)     $ (3,880)    
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Cash flows from operating activities:      
Net earnings/(loss) $ 111 $ 272  
Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:      
Depreciation and amortization 171 168  
Impairments and (gain)/loss on disposal of assets, net 153 (2)  
Loss on early extinguishment of debt 0 10  
Share-based compensation 23 24  
Provision for bad debts 29 12  
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:      
Increase in trade receivables (508) (214)  
Increase in inventories (264) (129)  
Increase/(decrease) in accounts payable 1,234 (292)  
Other accrued liabilities and operating items, net (926) (495)  
Net cash provided by/(used in) operating activities 23 (646)  
Cash flows from investing activities:      
Proceeds from divestitures, net of cash sold 0 927  
Additions to property and equipment (70) (67)  
Proceeds from disposal of property and equipment 2 0  
Purchases of investments 3 2  
Proceeds from investments 1 4  
Net cash provided by/(used in) investing activities (70) 862  
Cash flows from financing activities:      
Reduction of long-term obligations (7) (587)  
Net tax withholdings from share-based compensation (14) (28)  
Dividends on common shares (142) (149)  
Purchase of treasury shares (1,000) (500)  
Net cash used in financing activities (1,163) (1,264)  
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations (15) (5)  
Cash Reclassified to Assets Held for Sale 0 109  
Net decrease in cash and equivalents (1,225) (944)  
Cash and equivalents at beginning of period 4,717 3,407 $ 3,407
Cash and equivalents at end of period $ 3,492 $ 2,463 $ 4,717
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies
 3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").
Recently Issued Financial Accounting Standards Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as
material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the three months ended September 30, 2022.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Divestitures
 3 Months Ended
Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations, Disclosure
2. Divestitures
In August 2021, we sold the Cordis business to Hellman & Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in Note 6. The Cordis business operated within our Medical segment.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring and Employee Severance
 3 Months Ended
Sep. 30, 2022
Restructuring Charges [Abstract]  
Restructuring and Employee Severance
3. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
Three Months Ended September 30,
(in millions)20222021
Employee-related costs$19 $8 
Facility exit and other costs10 10 
Total restructuring and employee severance$29 $18 

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.
During the three months ended September 30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September 30, 2021, restructuring also included costs related to the divestiture of the Cordis business.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2022$56 $10 $66 
Additions20 3 23 
Payments and other adjustments(11)(10)(21)
Balance at September 30, 2022$65 $3 $68 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets
 3 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure
4. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)PharmaceuticalMedical (1)Total
Balance at June 30, 2022$2,673 $3,182 $5,855 
Foreign currency translation adjustments and other— (26)(26)
Goodwill impairment— (154)(154)
Balance at September 30, 2022$2,673 $3,002 $5,675 
(1)At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion.
During the three months ended September 30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.
Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September 30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due
to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September 30, 2022 after recognizing the impairment charge was $6.7 billion, of which $1.8 billion was goodwill.
Other Intangible Assets
The following tables summarize other intangible assets by class at:
September 30, 2022
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 N/A
Total indefinite-life intangibles11 — 11 N/A
Definite-life intangibles:
Customer relationships3,206 2,157 1,049 10
Trademarks, trade names and patents546 361 185 8
Developed technology and other1,037 590 447 9
Total definite-life intangibles4,789 3,108 1,681 9
Total other intangible assets$4,800 $3,108 $1,692 N/A
June 30, 2022
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,272 2,165 1,107 
Trademarks, trade names and patents552 360 192 
Developed technology and other1,038 574 464 
Total definite-life intangibles4,862 3,099 1,763 
Total other intangible assets$4,873 $3,099 $1,774 
Total amortization of intangible assets was $71 million and $78 million for the three months ended September 30, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $212 million, $258 million, $233 million, $206 million, and $174 million.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Obligations and Other Short-Term Borrowings
 3 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Long-Term Obligations and Other Short-Term Borrowings
5. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both September 30, 2022 and June 30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $28.4 billion and $27.1 billion at September 30, 2022 and June 30, 2022, respectively.
During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10 million loss on early extinguishment of debt. The early redemption was funded with available cash.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.
In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments, Contingent Liabilities and Litigation
 3 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingent Liabilities and Litigation
6. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.
The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision.
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the fiscal year ended June 30, 2021 based on the probable estimated payment amount. In the second quarter of fiscal year 2022, we paid the State of New York $20 million, our portion of the assessment for calendar year 2017. As a result, at September 30, 2022, we had an accrual of $20 million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory
agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our
Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.
Opioid Lawsuits and Investigations
States & Political Subdivisions
National Settlement
As previously disclosed, in February 2022, we, along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and other political subdivisions. The Settlement Agreement became effective on April 2, 2022.
In addition to the Distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of November 3, 2022, over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation.
Under this Settlement Agreement, we will pay up to approximately $6.0 billion, the majority of which is expected to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors’ controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.
Other Settlements
West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.
In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160 million to the State of Washington and its participating subdivisions and approximately $95 million to the
State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. The terms of these agreements are consistent with the terms of the Settlement Agreement.
As of October 2022, a sufficient number of subdivisions in each state had agreed to join their respective agreement, and the court in each state ordered the cases to be dismissed. We are in the process of finalizing the consent judgments in each state, and each agreement will become effective upon the entry of the relevant consent judgment. When each of these agreements is finalized, Washington and Oklahoma will become subject to the Settlement Agreement and 48 of 49 states will then be subject to the Settlement Agreement.
We are engaged in resolution discussions with the Attorney General for the State of Alabama.
In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.
During the three months ended September 30, 2022, we made our second annual payment of $372 million under the Settlement Agreement. In total, we have $6.03 billion accrued at September 30, 2022, of which $608 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.
Department of Justice Investigations
We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.
Private Plaintiffs
The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 454 lawsuits as of October, 2022. Of these, 151 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.
A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial date has been set for January 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.
Insurance Litigation
We are involved in ongoing legal proceedings with insurers related their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September 30, 2022.
Cordis IVC Filter Matters
Product Liability Lawsuits
As of November 3, 2022, we are named as a defendant in 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,215 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 7 lawsuits involving similar claims by approximately 8 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.
These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.
At September 30, 2022, we had a total of $527 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07 billion, net of estimated insurance
recoveries. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. The court granted our motion to dismiss, and the indirect purchasers filed an amended complaint. We intend to vigorously defend ourselves.
Active Pharmaceutical Ingredient Impurity Litigation
Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. We have been named as a defendant in an MDL alleging API impurities in certain generic blood pressure medications; however we no longer believe that these matters are material to us and we will no longer report on them.
Antitrust Litigation Proceeds
In October 2022, we received net cash proceeds resulting from the settlements of a lawsuit in which we were a class member or plaintiff of approximately $66 million, which will be recognized in litigation (recoveries)/charges, net, during the three months ending December 31, 2022.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 3 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Tax Disclosure
7. Income Taxes
Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Tax Effects of Goodwill Impairment Charge
During the three months ended September 30, 2022, we recognized a $154 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12 million for fiscal 2023.
Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.
The tax effect of the goodwill impairment charge during the three months ended September 30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September 30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September 30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September 30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.
Effective Tax Rate
During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The effective tax rate for the three months ended September 30, 2022 reflects the impact of tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items.
Unrecognized Tax Benefits
We had $940 million and $943 million of unrecognized tax benefits at September 30, 2022 and June 30, 2022, respectively. Both the September 30, 2022 and June 30, 2022 balances include $858
million of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.
At September 30, 2022 and June 30, 2022, we had $49 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $75 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2016 through the current fiscal year.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $77 million and $75 million at September 30, 2022 and June 30, 2022 respectively, and is included in other assets in the condensed consolidated balance sheets.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
 3 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements
8. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
September 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,477 $— $— $1,477 
Other investments (1)88 — — 88 
Liabilities:
Forward contracts (2)— (5)— (5)
June 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$2,425 $— $— $2,425 
Other investments (1)97 — — 97 
Forward contracts (2)— 15 — 15 
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments
 3 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Disclosure
9. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During three months ended September 30, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $100 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Pre-tax gains recognized in other comprehensive loss were $4 million for the three months ended September 30, 2022. Pre-tax gains recognized in other comprehensive loss were immaterial for the three months ended September 30, 2021. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $22 million and a $5 million for the three months ended September 30, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million and $6 million during the three months ended September 30, 2022 and 2021, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $6 million loss and an immaterial gain during the three months ended September 30, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are the Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2022 and June 30, 2022 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)September 30, 2022June 30, 2022
Estimated fair value$4,838 $5,049 
Carrying amount5,267 5,315 
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Equity
 3 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Shareholders' Equity
10. Shareholders' Equity/(Deficit)
During the three months ended September 30, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program is expected to conclude in the second quarter of fiscal 2023.
During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares.
We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive loss, before reclassifications(58)(2)(60)
Amounts reclassified to earnings— (2)(2)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million
(58)(4)(62)
Balance at September 30, 2022$(160)$(16)$(176)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2021$(46)$12 $(34)
Other comprehensive loss, before reclassifications(25)(1)(26)
Amounts reclassified to earnings— (1)(1)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax(25)(2)(27)
Balance at September 30, 2021$(71)$10 $(61)
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share Attributable to Cardinal Health, Inc.
 3 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Earnings Per Share Attributable to Cardinal Health, Inc.
11. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
Three Months Ended September 30,
(in millions)20222021
Weighted-average common shares–basic271 287 
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units2 2 
Weighted-average common shares–diluted273 289 
The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for both
the three months ended September 30, 2022 and 2021 were 4 million
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information
 3 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Information
12. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
Three Months Ended September 30,
(in millions)20222021
Pharmaceutical Distribution and Specialty Solutions (1) (2)$45,547 $39,614 
Nuclear and Precision Health Solutions (3)281 208 
Pharmaceutical segment revenue
45,828 39,822 
Medical distribution and products (4)3,140 3,567 
Cardinal Health at-Home Solutions638 582 
Medical segment revenue
3,778 4,149 
  Total segment revenue49,606 43,971 
Corporate (5)(3)(3)
Total revenue$49,603 $43,968 
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.
(4)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
Three Months Ended September 30,
(in millions)20222021
United States$48,477 $42,841 
International1,129 1,130 
  Total segment revenue49,606 43,971 
Corporate (1)(3)(3)
Total revenue$49,603 $43,968 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•surgical gown recall costs/(income);
•shareholder cooperation agreement costs;
•state opioid assessment related to prior fiscal years;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets, net;
•litigation (recoveries)/charges, net;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt;
•(gain)/loss on sale of equity interest in naviHealth; or
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $7 million for the three months ended September 30, 2022 and 2021, respectively.
The following table presents segment profit by reportable segment and Corporate:
Three Months Ended September 30,
(in millions)20222021
Pharmaceutical$431 $406 
Medical(8)123 
Total segment profit423 529 
Corporate(286)(114)
Total operating earnings$137 $415 
The following table presents total assets for each reportable segment and Corporate at:
(in millions)September 30, 2022June 30, 2022
Pharmaceutical$27,253 $26,409 
Medical11,338 11,632 
Corporate4,796 5,837 
Total assets$43,387 $43,878 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation
 3 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation
13. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following table provides total share-based compensation expense by type of award:
Three Months Ended September 30,
(in millions)20222021
Restricted share unit expense$17 $18 
Performance share unit expense6 6 
Total share-based compensation
$23 $24 
The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended September 30, 2022 and 2021, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20222.7 $46.03 
Granted1.2 69.95 
Vested(1.2)49.62 
Canceled and forfeited(0.2)54.94 
Nonvested at September 30, 20222.5 $59.43 
At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $119 million, which is expected to be recognized over a weighted-average period of two years.
Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share
units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20221.2 $54.32 
Granted0.3 76.79 
Vested(0.4)59.04 
Canceled and forfeited(0.2)57.50 
Nonvested at September 30, 20220.9 $72.01 
At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").
Recent Financial Accounting Standards
Recently Issued Financial Accounting Standards Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as
material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted in the three months ended September 30, 2022.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring and Employee Severance (Tables)
 3 Months Ended
Sep. 30, 2022
Restructuring Charges [Abstract]  
Summary of Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
Three Months Ended September 30,
(in millions)20222021
Employee-related costs$19 $8 
Facility exit and other costs10 10 
Total restructuring and employee severance$29 $18 
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2022$56 $10 $66 
Additions20 3 23 
Payments and other adjustments(11)(10)(21)
Balance at September 30, 2022$65 $3 $68 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets (Tables)
 3 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill by Reportable Segment
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)PharmaceuticalMedical (1)Total
Balance at June 30, 2022$2,673 $3,182 $5,855 
Foreign currency translation adjustments and other— (26)(26)
Goodwill impairment— (154)(154)
Balance at September 30, 2022$2,673 $3,002 $5,675 
(1)At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion
Schedule of Definite and Indefinite-Lived Intangible Assets
The following tables summarize other intangible assets by class at:
September 30, 2022
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 N/A
Total indefinite-life intangibles11 — 11 N/A
Definite-life intangibles:
Customer relationships3,206 2,157 1,049 10
Trademarks, trade names and patents546 361 185 8
Developed technology and other1,037 590 447 9
Total definite-life intangibles4,789 3,108 1,681 9
Total other intangible assets$4,800 $3,108 $1,692 N/A
June 30, 2022
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$11 $— $11 
Total indefinite-life intangibles11 — 11 
Definite-life intangibles:
Customer relationships3,272 2,165 1,107 
Trademarks, trade names and patents552 360 192 
Developed technology and other1,038 574 464 
Total definite-life intangibles4,862 3,099 1,763 
Total other intangible assets$4,873 $3,099 $1,774 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
 3 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
September 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,477 $— $— $1,477 
Other investments (1)88 — — 88 
Liabilities:
Forward contracts (2)— (5)— (5)
June 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$2,425 $— $— $2,425 
Other investments (1)97 — — 97 
Forward contracts (2)— 15 — 15 
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments (Tables)
 3 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)September 30, 2022June 30, 2022
Estimated fair value$4,838 $5,049 
Carrying amount5,267 5,315 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Equity (Tables)
 3 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total
Accumulated Other Comprehensive Loss
The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive loss, before reclassifications(58)(2)(60)
Amounts reclassified to earnings— (2)(2)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million
(58)(4)(62)
Balance at September 30, 2022$(160)$(16)$(176)
(in millions)Foreign
Currency
Translation
Adjustments		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2021$(46)$12 $(34)
Other comprehensive loss, before reclassifications(25)(1)(26)
Amounts reclassified to earnings— (1)(1)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax(25)(2)(27)
Balance at September 30, 2021$(71)$10 $(61)
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)
 3 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
Three Months Ended September 30,
(in millions)20222021
Weighted-average common shares–basic271 287 
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units2 2 
Weighted-average common shares–diluted273 289 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Tables)
 3 Months Ended
Sep. 30, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]  
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents revenue by geographic area:
Three Months Ended September 30,
(in millions)20222021
United States$48,477 $42,841 
International1,129 1,130 
  Total segment revenue49,606 43,971 
Corporate (1)(3)(3)
Total revenue$49,603 $43,968 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Revenue
The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
Three Months Ended September 30,
(in millions)20222021
Pharmaceutical Distribution and Specialty Solutions (1) (2)$45,547 $39,614 
Nuclear and Precision Health Solutions (3)281 208 
Pharmaceutical segment revenue
45,828 39,822 
Medical distribution and products (4)3,140 3,567 
Cardinal Health at-Home Solutions638 582 
Medical segment revenue
3,778 4,149 
  Total segment revenue49,606 43,971 
Corporate (5)(3)(3)
Total revenue$49,603 $43,968 
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.
(4)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments
Segment Profit by Reportable Segment
The following table presents segment profit by reportable segment and Corporate:
Three Months Ended September 30,
(in millions)20222021
Pharmaceutical$431 $406 
Medical(8)123 
Total segment profit423 529 
Corporate(286)(114)
Total operating earnings$137 $415 
Assets by Reportable Segment
The following table presents total assets for each reportable segment and Corporate at:
(in millions)September 30, 2022June 30, 2022
Pharmaceutical$27,253 $26,409 
Medical11,338 11,632 
Corporate4,796 5,837 
Total assets$43,387 $43,878 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Tables)
 3 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Total Share-based Compensation Expense by Type of Award
The following table provides total share-based compensation expense by type of award:
Three Months Ended September 30,
(in millions)20222021
Restricted share unit expense$17 $18 
Performance share unit expense6 6 
Total share-based compensation
$23 $24 
Schedule of Transactions Related to Restricted Share Units Under the Plans
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20222.7 $46.03 
Granted1.2 69.95 
Vested(1.2)49.62 
Canceled and forfeited(0.2)54.94 
Nonvested at September 30, 20222.5 $59.43 
Schedule of Transactions Related to Performance Share Units Under the Plans
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20221.2 $54.32 
Granted0.3 76.79 
Vested(0.4)59.04 
Canceled and forfeited(0.2)57.50 
Nonvested at September 30, 20220.9 $72.01 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Divestitures (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Long Lived Assets Held-for-sale [Line Items]      
Proceeds from divestitures, net of cash sold $ 0 $ 927  
Cordis Divestiture [Member]      
Long Lived Assets Held-for-sale [Line Items]      
Proceeds from divestitures, net of cash sold     $ 923
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Restructuring Charges [Abstract]    
Employee-related costs $ 19 $ 8
Facility Exit and Other Costs 10 10
Total restructuring and employee severance $ 29 $ 18
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2022
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning Balance $ 66
Additions 23
Payments and other adjustments (21)
Ending Balance 68
Employee- Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 56
Additions 20
Payments and other adjustments (11)
Ending Balance 65
Facility Exit and Other Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 10
Additions 3
Payments and other adjustments (10)
Ending Balance $ 3
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring and Employee Severance Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Restructuring Cost and Reserve [Line Items]    
Severance Costs $ 19 $ 8
Facility Exit and Other Costs $ 10 $ 10
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2022
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 5,855
Foreign currency translation adjustments and other (26)
Goodwill impairment 154
Ending balance 5,675
Pharmaceutical  
Goodwill [Roll Forward]  
Beginning balance 2,673
Foreign currency translation adjustments and other 0
Goodwill impairment 0
Ending balance 2,673
Medical  
Goodwill [Roll Forward]  
Beginning balance 3,182
Foreign currency translation adjustments and other (26)
Goodwill impairment 154
Ending balance 3,002
Goodwill, Impaired, Accumulated Impairment Loss $ 3,600
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible $ 11 $ 11
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 4,789 4,862
Accumulated Amortization 3,108 3,099
Net Intangible $ 1,681 1,763
Weighted- Average Remaining Amortization Period (Years) 9 years  
Gross Intangible, Total other intangible assets $ 4,800 4,873
Net Intangible, Total other intangible assets 1,692 1,774
Trademarks and patents    
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible 11 11
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 3,206 3,272
Accumulated Amortization 2,157 2,165
Net Intangible $ 1,049 1,107
Weighted- Average Remaining Amortization Period (Years) 10 years  
Trademarks, trade names and patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 546 552
Accumulated Amortization 361 360
Net Intangible $ 185 192
Weighted- Average Remaining Amortization Period (Years) 8 years  
Developed technology and other    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 1,037 1,038
Accumulated Amortization 590 574
Net Intangible $ 447 $ 464
Weighted- Average Remaining Amortization Period (Years) 9 years  
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]      
Amortization of intangible assets $ 71 $ 78  
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 212    
Finite-Lived Intangible Asset, Expected Amortization, Year One 258    
Finite-Lived Intangible Assets, Amortization Expense, Year Two 233    
Finite-Lived Intangible Assets, Amortization Expense, Year Three 206    
Finite-Lived Intangible Assets, Amortization Expense, Year Four 174    
Goodwill [Line Items]      
Goodwill impairment 154    
Goodwill $ 5,675   $ 5,855
Medical Unit [Member]      
Goodwill [Line Items]      
Discount Rate, Fair Value Input 10.50%    
Terminal Growth Rate, Fair Value Input 2.00%    
Net Assets $ 6,700    
Goodwill 1,800    
Medical      
Goodwill [Line Items]      
Goodwill impairment 154    
Goodwill $ 3,002   $ 3,182
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Debt Instrument [Line Items]      
Debt, Long-term and Short-term, Combined Amount $ 5,300   $ 5,300
Accounts Payable 28,400   $ 27,100
Loss on Early Extinguishment of Debt 0 $ (10)  
2.616% Notes due 2022      
Debt Instrument [Line Items]      
Repayments of Notes Payable   572  
Loss on Early Extinguishment of Debt   $ (10)  
Commercial Paper [Member]      
Debt Instrument [Line Items]      
Line of Credit Facility, Maximum Borrowing Capacity 2,000    
Revolving Credit Facility [Member]      
Debt Instrument [Line Items]      
Line of Credit Facility, Maximum Borrowing Capacity 2,000    
Short Term Credit Facilities Member      
Debt Instrument [Line Items]      
Other Short-term Borrowings 0    
Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]      
Debt Instrument [Line Items]      
Line of Credit Facility, Maximum Borrowing Capacity $ 1,000    
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments, Contingent Liabilities and Litigation Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Nov. 03, 2022
lawsuit
numberOfUSTerritories
plaintiff
states
Jul. 31, 2021
lawsuit
Jul. 31, 2022
USD ($)
plaintiff
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Oct. 31, 2022
USD ($)
lawsuit
states
Jun. 30, 2022
USD ($)
Loss Contingencies [Line Items]                  
Gain (Loss) Related to Litigation Settlement         $ (27)   $ (18)    
Pharmaceutical                  
Loss Contingencies [Line Items]                  
Judgment for lost profits           $ 16      
Subsequent Event                  
Loss Contingencies [Line Items]                  
Income from Settlements of Class Action Lawsuits       $ 66          
Opioid Lawsuits [Member]                  
Loss Contingencies [Line Items]                  
Payments for Legal Settlements         372        
Opioid Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Loss Contingency, Number of Eligible States | states               49  
Product Liability Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Loss Contingency, Pending Claims, Number | lawsuit 7                
New York Opioid Stewardship Act [Member]                  
Loss Contingencies [Line Items]                  
Loss Contingency Accrual         20        
Aggregate Annual Assessment         $ 100        
Estimated Liability for New York Opioid Stewardship Act             $ 41    
Loss Contingency Accrual, Payments           $ 20      
CVS Health                  
Loss Contingencies [Line Items]                  
Long-term Purchase Commitment, Period         10 years        
Product Liability Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Loss Contingency, Pending Claims, Number | lawsuit 450                
Minimum | Product Liability Lawsuits [Member]                  
Loss Contingencies [Line Items]                  
Loss Contingency Accrual         $ 527        
Alameda County [Member] | Product Liability Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Number of plaintiffs | plaintiff 5,215                
Other Jurisdictions [Member] | Product Liability Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Number of plaintiffs | plaintiff 8                
WEST VIRGINIA | Opioid Lawsuits [Member]                  
Loss Contingencies [Line Items]                  
Loss Contingency, Estimate of Possible Loss     $ 124            
OKLAHOMA | Opioid Lawsuits [Member]                  
Loss Contingencies [Line Items]                  
Loss Contingency, Estimate of Possible Loss                 $ 95
WASHINGTON | Opioid Lawsuits [Member]                  
Loss Contingencies [Line Items]                  
Loss Contingency, Estimate of Possible Loss                 $ 160
Native American tribes [Member] | Opioid Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Loss Contingency, Estimate of Possible Loss               $ 136  
Total Opioid Litigation [Member]                  
Loss Contingencies [Line Items]                  
litigation settlement liability recorded         6,030        
Loss Contingency, Estimate of Possible Loss         6,000        
Total Opioid Litigation [Member] | Accrued Liabilities                  
Loss Contingencies [Line Items]                  
litigation settlement liability recorded         608        
Total Opioid Litigation [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Settling States | states 46                
Settling U.S Territories | numberOfUSTerritories 5                
Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Loss Contingency, Lawsuits, Number | lawsuit               454  
Private Parties [Member] | GEORGIA | Opioid Lawsuits [Member]                  
Loss Contingencies [Line Items]                  
Number of plaintiffs | plaintiff     21            
Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event                  
Loss Contingencies [Line Items]                  
Loss Contingency, Lawsuits, Number | lawsuit               151  
Product Liability Lawsuits [Member]                  
Loss Contingencies [Line Items]                  
Loss Contingency, Claims Settled, Number | lawsuit   1,300              
Product Liability Lawsuits [Member] | Maximum                  
Loss Contingencies [Line Items]                  
Loss Contingency Accrual         $ 1,070        
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2022
Income Taxes          
Income Tax Expense (Benefit) $ 1 $ (97)      
Effective Income Tax Rate Reconciliation, Percent (0.70%) 26.30%      
Unrecognized tax benefits $ 940       $ 943
Unrecognized tax benefits that would impact effective tax rate 858        
Unrecognized tax benefits, interest and penalties accrued 49       48
Goodwill impairment 154        
Medical Unit Goodwill Impairment [Member] | Subsequent Event          
Income Taxes          
Income Tax Expense (Benefit)     $ 22    
Medical          
Income Taxes          
Goodwill impairment 154        
Forecast [Member] | Medical          
Income Taxes          
Income Tax Expense (Benefit)       $ (12)  
Minimum          
Income Taxes          
Estimated range of decrease in unrecognized tax benefits within the next 12 months 0        
Maximum          
Income Taxes          
Estimated range of decrease in unrecognized tax benefits within the next 12 months $ 75        
Federal | Minimum          
Income Taxes          
Open Tax Year 2016        
Federal | Maximum          
Income Taxes          
Open Tax Year 2023        
CareFusion [Member]          
Income Taxes          
Indemnification receivable $ 77       $ 75
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements Narrative (Details) - Recurring - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2022
Assets:    
Other investments $ 88 $ 97
Forward Contract (5) 15
Level 1    
Assets:    
Cash equivalents 1,477 2,425
Other investments 88 97
Forward Contract 0 0
Level 2    
Assets:    
Cash equivalents 0 0
Other investments 0 0
Forward Contract (5) 15
Level 3    
Assets:    
Cash equivalents 0 0
Other investments 0 0
Forward Contract 0 0
Fair Value, Inputs, Level 1, 2 and 3    
Assets:    
Cash equivalents $ 1,477 $ 2,425
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Derivative [Line Items]    
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments $ 0  
Foreign Exchange Contract [Member]    
Derivative [Line Items]    
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 22 $ 5
Interest Income (Expense), Nonoperating, Net 4 6
Cash Flow Hedging [Member]    
Derivative [Line Items]    
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 4  
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap    
Derivative [Line Items]    
Notional Amount 200 $ 100
Other Nonoperating Income (Expense) | Not Designated as Hedging Instrument | Foreign Exchange Contract [Member]    
Derivative [Line Items]    
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net $ 6  
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying Amount of Long-Term and other Short-Term Borrowings $ 5,267 $ 5,315
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair value $ 4,838 $ 5,049
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Equity Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Oct. 04, 2021
Sep. 30, 2022
Sep. 30, 2021
Class of Stock [Line Items]      
Payments for Repurchase of Common Stock   $ 1,000 $ 500
$500 million share repurchase program      
Class of Stock [Line Items]      
Payments for Repurchase of Common Stock     500
$1 billion share repurchase program      
Class of Stock [Line Items]      
Payments for Repurchase of Common Stock   1,000  
Treasury Shares      
Class of Stock [Line Items]      
Payments for Repurchase of Common Stock   $ 800 $ 400
Treasury shares acquired (using cost method), shares   12.0 8.0
Treasury Shares | $500 million share repurchase program      
Class of Stock [Line Items]      
Treasury shares acquired (using cost method), shares 2.0   7.8
Treasury shares acquired, average price per share (in usd per share) $ 51.10   $ 51.53
Treasury Shares | $1 billion share repurchase program      
Class of Stock [Line Items]      
Treasury shares acquired (using cost method), shares   12.0  
Treasury shares acquired, average price per share (in usd per share)   $ 66.74  
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period $ (706) $ 1,794
Total other comprehensive loss, net of tax (62) (27)
Balance at end of period (1,780) 1,396
Other Comprehensive Income (Loss), Tax 7  
Foreign Currency Translation Adjustments    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period (102) (46)
Other comprehensive loss, before reclassifications (58) (25)
Amounts reclassified to earnings 0 0
Total other comprehensive loss, net of tax (58) (25)
Balance at end of period (160) (71)
Unrealized Gain/(Loss) on Derivatives, net of tax    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period (12) 12
Other comprehensive loss, before reclassifications (2) (1)
Amounts reclassified to earnings (2) (1)
Total other comprehensive loss, net of tax (4) (2)
Balance at end of period (16) 10
Accumulated Other Comprehensive Loss    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period (114) (34)
Total other comprehensive loss, net of tax (62) (27)
Balance at end of period (176) (61)
AOCI Attributable to Parent    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period (114) (34)
Other comprehensive loss, before reclassifications (60) (26)
Amounts reclassified to earnings (2) (1)
Balance at end of period $ (176) $ (61)
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares
shares in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]    
Weighted-average common shares–basic (in shares) 271 287
Effect of dilutive securities:    
Weighted Average Number Diluted Shares Outstanding Adjustment 2 2
Weighted-average common shares–diluted (in shares) 273 289
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) - shares
shares in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]    
Weighted Average Number Diluted Shares Outstanding Adjustment 4 4
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information Narrative (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Gain (Loss) Related to Litigation Settlement $ (27) $ (18)
Number of operating segments | segment 2  
Number of Reportable Segments | segment 2  
Project Costs On Investment And Other Spending $ 6 $ 7
Total Opioid Litigation [Member]    
Estimated Litigation Liability $ 6,030  
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Revenue by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]    
Total revenue $ 49,603 $ 43,968
Operating Segments    
Segment Reporting Information [Line Items]    
Total revenue 49,606 43,971
Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total revenue 45,828 39,822
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total revenue 3,778 4,149
Corporate    
Segment Reporting Information [Line Items]    
Total revenue (3) (3)
Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total revenue 281 208
Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total revenue 45,547 39,614
Medical distribution and products [Member] | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total revenue 3,140 3,567
Cardinal Health At Home Solutions [Member] | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total revenue $ 638 $ 582
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings $ 137 $ 415
Operating Segments    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings 423 529
Operating Segments | Pharmaceutical    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings 431 406
Operating Segments | Medical    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings (8) 123
Corporate    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings $ (286) $ (114)
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Assets by Reportable Segment) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2022
Segment Reporting Information [Line Items]    
Total assets $ 43,387 $ 43,878
Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total assets 27,253 26,409
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total assets 11,338 11,632
Corporate    
Segment Reporting Information [Line Items]    
Total assets $ 4,796 $ 5,837
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information Disaggregated Revenue Within Reportable Segments (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue $ 49,603 $ 43,968
Operating Segments    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 49,606 43,971
Operating Segments | Pharmaceutical    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 45,828 39,822
Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member]    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 281 208
Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member]    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 45,547 39,614
Operating Segments | Medical    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 3,778 4,149
Operating Segments | Medical | Medical distribution and products [Member]    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 3,140 3,567
Corporate    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue $ (3) $ (3)
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information Revenue by Geographical Segments (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Segment Revenue by Geographic [Line Items]    
Revenue $ 49,603 $ 43,968
UNITED STATES    
Segment Revenue by Geographic [Line Items]    
Revenue 48,477 42,841
Non-US [Member]    
Segment Revenue by Geographic [Line Items]    
Revenue 1,129 1,130
Operating Segments    
Segment Revenue by Geographic [Line Items]    
Revenue 49,606 43,971
Corporate    
Segment Revenue by Geographic [Line Items]    
Revenue $ (3) $ (3)
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation Narrative (Details)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Reportable_Segments
Sep. 30, 2021
USD ($)
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Tax benefit related to share-based compensation $ 3 $ 4      
Restricted Share Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period (in years) 3 years        
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 119        
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years        
Performance Share Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 28        
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years        
Vesting Period in years for Shares | Reportable_Segments 3        
Performance Share Units | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Target performance goal (as a percent) 0.00%   0.00% 0.00% 0.00%
Performance Share Units | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Target performance goal (as a percent) 234.00%   234.00% 240.00% 240.00%
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation $ 23 $ 24
Restricted Share Unit    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation 17 18
Performance Share Unit    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation $ 6 $ 6
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units
shares in Millions
 3 Months Ended
Sep. 30, 2022
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
Restricted Share Units  
Nonvested at beginning of period (in shares) | shares 2.7
Granted (in shares) | shares 1.2
Vested (in shares) | shares (1.2)
Canceled and forfeited (in shares) | shares (0.2)
Nonvested at end of period (in shares) | shares 2.5
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 46.03
Granted (in usd per share) | $ / shares 69.95
Vested (in usd per share) | $ / shares 49.62
Canceled and forfeited (in usd per share) | $ / shares 54.94
Nonvested at end of period (in usd per share) | $ / shares $ 59.43
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Performance Share Units  
Nonvested at beginning of period (in shares) | shares 1.2
Granted (in shares) | shares 0.3
Vested (in shares) | shares (0.4)
Canceled and forfeited (in shares) | shares (0.2)
Nonvested at end of period (in shares) | shares 0.9
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 54.32
Granted (in usd per share) | $ / shares 76.79
Vested (in usd per share) | $ / shares 59.04
Canceled and forfeited (in usd per share) | $ / shares 57.50
Nonvested at end of period (in usd per share) | $ / shares $ 72.01
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 28
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
XML 70 cah-20220930_htm.xml IDEA: XBRL DOCUMENT 0000721371 2022-07-01 2022-09-30 0000721371 2022-10-31 0000721371 2021-07-01 2021-09-30 0000721371 2022-09-30 0000721371 2022-06-30 0000721371 us-gaap:CommonStockMember 2022-06-30 0000721371 us-gaap:RetainedEarningsMember 2022-06-30 0000721371 us-gaap:TreasuryStockMember 2022-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000721371 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000721371 us-gaap:TreasuryStockMember 2022-07-01 2022-09-30 0000721371 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000721371 us-gaap:CommonStockMember 2022-09-30 0000721371 us-gaap:RetainedEarningsMember 2022-09-30 0000721371 us-gaap:TreasuryStockMember 2022-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2022-09-30 0000721371 us-gaap:CommonStockMember 2021-06-30 0000721371 us-gaap:RetainedEarningsMember 2021-06-30 0000721371 us-gaap:TreasuryStockMember 2021-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2021-06-30 0000721371 2021-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000721371 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000721371 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000721371 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000721371 us-gaap:CommonStockMember 2021-09-30 0000721371 us-gaap:RetainedEarningsMember 2021-09-30 0000721371 us-gaap:TreasuryStockMember 2021-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2021-09-30 0000721371 2021-09-30 0000721371 cah:CordisDivestitureMember 2021-07-01 2022-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2022-06-30 0000721371 us-gaap:FacilityClosingMember 2022-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2022-07-01 2022-09-30 0000721371 us-gaap:FacilityClosingMember 2022-07-01 2022-09-30 0000721371 us-gaap:EmployeeSeveranceMember 2022-09-30 0000721371 us-gaap:FacilityClosingMember 2022-09-30 0000721371 cah:PharmaceuticalMember 2022-06-30 0000721371 cah:MedicalMember 2022-06-30 0000721371 cah:PharmaceuticalMember 2022-07-01 2022-09-30 0000721371 cah:MedicalMember 2022-07-01 2022-09-30 0000721371 cah:PharmaceuticalMember 2022-09-30 0000721371 cah:MedicalMember 2022-09-30 0000721371 cah:MedicalUnitMember 2022-07-01 2022-09-30 0000721371 cah:MedicalUnitMember 2022-09-30 0000721371 cah:IPRDTrademarksandOtherMember 2022-09-30 0000721371 us-gaap:CustomerRelationshipsMember 2022-09-30 0000721371 us-gaap:CustomerRelationshipsMember 2022-07-01 2022-09-30 0000721371 cah:TrademarksAndPatentsMember 2022-09-30 0000721371 cah:TrademarksAndPatentsMember 2022-07-01 2022-09-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2022-09-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2022-07-01 2022-09-30 0000721371 cah:IPRDTrademarksandOtherMember 2022-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2022-06-30 0000721371 cah:TrademarksAndPatentsMember 2022-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2022-06-30 0000721371 cah:A2.616Notesdue2022Member 2021-07-01 2021-09-30 0000721371 us-gaap:CommercialPaperMember 2022-09-30 0000721371 us-gaap:RevolvingCreditFacilityMember 2022-09-30 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2022-09-30 0000721371 cah:ShortTermCreditFacilitiesMember 2022-09-30 0000721371 cah:CVSHealthMember 2022-07-01 2022-09-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2022-09-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2021-07-01 2021-09-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2021-10-01 2021-12-31 0000721371 cah:PharmaceuticalMember 2021-10-01 2021-12-31 0000721371 us-gaap:SubsequentEventMember cah:TotalOpioidLitigationMember 2022-11-03 0000721371 cah:TotalOpioidLitigationMember 2022-09-30 0000721371 cah:OpioidLawsuitsMember stpr:WV 2022-07-31 0000721371 cah:OpioidLawsuitsMember stpr:WA 2022-06-30 0000721371 cah:OpioidLawsuitsMember stpr:OK 2022-06-30 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2022-10-31 0000721371 cah:OpioidLawsuitsMember cah:NativeAmericanTribesMember us-gaap:SubsequentEventMember 2022-10-31 0000721371 cah:OpioidLawsuitsMember 2022-07-01 2022-09-30 0000721371 us-gaap:AccruedLiabilitiesMember cah:TotalOpioidLitigationMember 2022-09-30 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2022-10-31 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:ClassActionLawsuitsMember cah:PrivatePartiesMember 2022-10-31 0000721371 cah:OpioidLawsuitsMember stpr:GA cah:PrivatePartiesMember 2022-07-01 2022-07-31 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2022-11-03 0000721371 cah:AlamedaCountyMember cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2022-11-03 2022-11-03 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2022-11-03 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2022-11-03 2022-11-03 0000721371 cah:ProductLiabilityLawsuitsMember 2021-07-31 2021-07-31 0000721371 cah:ProductLiabilityLawsuitsMember srt:MinimumMember 2022-09-30 0000721371 srt:MaximumMember cah:ProductLiabilityLawsuitsMember 2022-09-30 0000721371 us-gaap:SubsequentEventMember 2022-10-01 2022-12-31 0000721371 srt:ScenarioForecastMember cah:MedicalMember 2022-07-01 2023-06-30 0000721371 srt:MaximumMember us-gaap:InternalRevenueServiceIRSMember 2022-07-01 2022-09-30 0000721371 us-gaap:SubsequentEventMember cah:GoodwillImpairmentMedicalUnitMember 2022-10-01 2023-06-30 0000721371 srt:MinimumMember 2022-09-30 0000721371 srt:MaximumMember 2022-09-30 0000721371 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember 2022-07-01 2022-09-30 0000721371 cah:CareFusionMember 2022-09-30 0000721371 cah:CareFusionMember 2022-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000721371 us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000721371 us-gaap:FairValueInputsLevel12And3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-09-30 0000721371 us-gaap:CashFlowHedgingMember 2022-07-01 2022-09-30 0000721371 us-gaap:ForeignExchangeContractMember 2022-07-01 2022-09-30 0000721371 us-gaap:ForeignExchangeContractMember 2021-07-01 2021-09-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000721371 us-gaap:FairValueInputsLevel2Member 2022-09-30 0000721371 us-gaap:FairValueInputsLevel2Member 2022-06-30 0000721371 cah:A1BillionShareRepurchaseProgramMember 2022-07-01 2022-09-30 0000721371 us-gaap:TreasuryStockMember cah:A1BillionShareRepurchaseProgramMember 2022-07-01 2022-09-30 0000721371 cah:A500MillionShareRepurchaseProgramMember 2021-07-01 2021-09-30 0000721371 us-gaap:TreasuryStockMember cah:A500MillionShareRepurchaseProgramMember 2021-07-01 2021-09-30 0000721371 us-gaap:TreasuryStockMember cah:A500MillionShareRepurchaseProgramMember 2021-10-04 2021-10-04 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-09-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2022-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-09-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-01 2021-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-01 2021-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-01 2021-09-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2021-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2022-07-01 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2021-07-01 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2022-07-01 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2021-07-01 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2022-07-01 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2021-07-01 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2022-07-01 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2021-07-01 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeSolutionsMember 2022-07-01 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeSolutionsMember 2021-07-01 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2022-07-01 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2021-07-01 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000721371 country:US 2022-07-01 2022-09-30 0000721371 country:US 2021-07-01 2021-09-30 0000721371 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000721371 us-gaap:NonUsMember 2021-07-01 2021-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2022-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2022-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2022-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2022-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2022-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0000721371 us-gaap:PerformanceSharesMember 2022-07-01 2022-09-30 0000721371 us-gaap:PerformanceSharesMember 2021-07-01 2021-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2020-07-01 2021-06-30 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2019-07-01 2020-06-30 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2020-07-01 2021-06-30 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2019-07-01 2020-06-30 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2021-07-01 2022-06-30 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-07-01 2022-09-30 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2021-07-01 2022-06-30 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2022-07-01 2022-09-30 0000721371 us-gaap:PerformanceSharesMember 2022-06-30 0000721371 us-gaap:PerformanceSharesMember 2022-09-30 shares iso4217:USD iso4217:USD shares pure cah:states cah:numberOfUSTerritories cah:lawsuit cah:plaintiff cah:segment cah:Reportable_Segments 0000721371 --06-30 2023 Q1 false 10-Q true 2022-09-30 false 1-11373 Cardinal Health, Inc. OH 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 Common shares (without par value) CAH NYSE Yes Yes Large Accelerated Filer false false false 262134053 49603000000 43968000000 47989000000 42326000000 1614000000 1642000000 1197000000 1114000000 29000000 18000000 71000000 79000000 -153000000 2000000 -27000000 -18000000 137000000 415000000 -2000000 4000000 25000000 40000000 0 -10000000 110000000 369000000 -1000000 97000000 111000000 272000000 1000000 1000000 110000000 271000000 0.41 0.94 0.40 0.94 271000000 287000000 273000000 289000000 0.4957 0.4908 111000000 272000000 -58000000 -25000000 -4000000 -2000000 -62000000 -27000000 49000000 245000000 1000000 1000000 48000000 244000000 3492000000 4717000000 11039000000 10561000000 15891000000 15636000000 2274000000 2021000000 32696000000 32935000000 2339000000 2361000000 7367000000 7629000000 985000000 953000000 43387000000 43878000000 28362000000 27128000000 578000000 580000000 2619000000 2842000000 31559000000 30550000000 4689000000 4735000000 8919000000 9299000000 500000 500000 0 0 0 0 755000000 755000000 327000000 327000000 2576000000 2813000000 -301000000 -280000000 65000000 54000000 3880000000 3128000000 -176000000 -114000000 -1781000000 -709000000 1000000 3000000 -1780000000 -706000000 43387000000 43878000000 327000000 2813000000 -280000000 54000000 3128000000 -114000000 3000000 -706000000 110000000 1000000 111000000 -62000000 -62000000 -2000000 -2000000 0 37000000 1000000 48000000 11000000 200000000 12000000 800000000 1000000000 131000000 131000000 -1000000 -1000000 327000000 2576000000 -301000000 65000000 3880000000 -176000000 1000000 -1780000000 327000000 2806000000 1205000000 36000000 2186000000 -34000000 3000000 1794000000 271000000 1000000 272000000 -27000000 -27000000 0 40000000 1000000 39000000 -1000000 100000000 8000000 400000000 500000000 141000000 141000000 -1000000 -1000000 327000000 2666000000 1335000000 43000000 2547000000 -61000000 3000000 1396000000 111000000 272000000 171000000 168000000 -153000000 2000000 0 -10000000 23000000 24000000 29000000 12000000 508000000 214000000 264000000 129000000 1234000000 -292000000 926000000 495000000 23000000 -646000000 0 927000000 70000000 67000000 2000000 0 3000000 2000000 1000000 4000000 -70000000 862000000 7000000 587000000 -14000000 -28000000 142000000 149000000 1000000000 500000000 -1163000000 -1264000000 -15000000 -5000000 0 109000000 -1225000000 -944000000 4717000000 3407000000 3492000000 2463000000 <div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K"). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2022.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div>In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K"). <div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2022.</span></div> <div style="text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibd18cf751e3b4588bcfe40175c3f40a1_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div> 923000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September 30, 2021, restructuring also included costs related to the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 19000000 8000000 10000000 10000000 29000000 18000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 56000000 10000000 66000000 20000000 3000000 23000000 11000000 10000000 21000000 65000000 3000000 68000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.839%"><tr><td style="width:1.0%"/><td style="width:44.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,002</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,675</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September 30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September 30, 2022 after recognizing the impairment charge was $6.7 billion, of which $1.8 billion was goodwill.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,206</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">361</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,789</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,681</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,800</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,692</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873 </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774 </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $71 million and $78 million for the three months ended September 30, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $212 million, $258 million, $233 million, $206 million, and $174 million.</span></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.839%"><tr><td style="width:1.0%"/><td style="width:44.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,855</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,002</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,675</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion 2673000000 3182000000 5855000000 0 26000000 26000000 0 154000000 154000000 2673000000 3002000000 5675000000 3600000000 0.105 0.02 154000000 6700000000 1800000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,206</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">361</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,037</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,789</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,681</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,800</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,108</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,692</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,862 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,873 </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,099 </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774 </span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11000000 11000000 11000000 11000000 3206000000 2157000000 1049000000 P10Y 546000000 361000000 185000000 P8Y 1037000000 590000000 447000000 P9Y 4789000000 3108000000 1681000000 P9Y 4800000000 3108000000 1692000000 11000000 11000000 11000000 11000000 3272000000 2165000000 1107000000 552000000 360000000 192000000 1038000000 574000000 464000000 4862000000 3099000000 1763000000 4873000000 3099000000 1774000000 71000000 78000000 212000000 258000000 233000000 206000000 174000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both September 30, 2022 and June 30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $28.4 billion and $27.1 billion at September 30, 2022 and June 30, 2022, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10 million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant. 5300000000 5300000000 28400000000 27100000000 572000000 -10000000 2000000000 2000000000 1000000000 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the fiscal year ended June 30, 2021 based on the probable estimated payment amount. In the second quarter of fiscal year 2022, we paid the State of New York $20 million, our portion of the assessment for calendar year 2017. As a result, at September 30, 2022, we had an accrual of $20 million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">National Settlement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in February 2022, we, along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and other political subdivisions. The Settlement Agreement became effective on April 2, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of November 3, 2022, over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this Settlement Agreement, we will pay up to approximately $6.0 billion, the majority of which is expected to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors’ controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Settlements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160 million to the State of Washington and its participating subdivisions and approximately $95 million to the </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. The terms of these agreements are consistent with the terms of the Settlement Agreement. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2022, a sufficient number of subdivisions in each state had agreed to join their respective agreement, and the court in each state ordered the cases to be dismissed. We are in the process of finalizing the consent judgments in each state, and each agreement will become effective upon the entry of the relevant consent judgment. When each of these agreements is finalized, Washington and Oklahoma will become subject to the Settlement Agreement and 48 of 49 states will then be subject to the Settlement Agreement. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged in resolution discussions with the Attorney General for the State of Alabama.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we made our second annual payment of $372 million under the Settlement Agreement. In total, we have $6.03 billion accrued at September 30, 2022, of which $608 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 454 lawsuits as of October, 2022. Of these, 151 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial date has been set for January 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in ongoing legal proceedings with insurers related their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September 30, 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 3, 2022, we are named as a defendant in 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,215 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 7 lawsuits involving similar claims by approximately 8 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, we had a total of $527 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07 billion, net of estimated insurance </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recoveries. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. The court granted our motion to dismiss, and the indirect purchasers filed an amended complaint. We intend to vigorously defend ourselves.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. We have been named as a defendant in an MDL alleging API impurities in certain generic blood pressure medications; however we no longer believe that these matters are material to us and we will no longer report on them. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div>In October 2022, we received net cash proceeds resulting from the settlements of a lawsuit in which we were a class member or plaintiff of approximately $66 million, which will be recognized in litigation (recoveries)/charges, net, during the three months ending December 31, 2022. P10Y 100000000 41000000 20000000 20000000 16000000 46 5 6000000000 124000000 160000000 95000000 49 136000000 372000000 6030000000.00 608000000 454 151 21 450 5215 7 8 1300 527000000 1070000000.00 66000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we recognized a $154 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12 million for fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended September 30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September 30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September 30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September 30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The effective tax rate for the three months ended September 30, 2022 reflects the impact of tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $940 million and $943 million of unrecognized tax benefits at September 30, 2022 and June 30, 2022, respectively. Both the September 30, 2022 and June 30, 2022 balances include $858 </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and June 30, 2022, we had $49 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $75 million, exclusive of penalties and interest.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2016 through the current fiscal year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $77 million and $75 million at September 30, 2022 and June 30, 2022 respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div> 154000000 12000000 2023 -22000000 -0.007 0.263 940000000 943000000 858000000 49000000 48000000 0 75000000 2016 77000000 75000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets. <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets. 1477000000 0 0 1477000000 88000000 0 0 88000000 0 -5000000 0 -5000000 2425000000 0 0 2425000000 97000000 0 0 97000000 0 15000000 0 15000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September 30, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $100 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive loss were $4 million for the three months ended September 30, 2022. Pre-tax gains recognized in other comprehensive loss were immaterial for the three months ended September 30, 2021. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $22 million and a $5 million for the three months ended September 30, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million and $6 million during the three months ended September 30, 2022 and 2021, respectively.</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $6 million loss and an immaterial gain during the three months ended September 30, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are the Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2022 and June 30, 2022 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,838</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315 </span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div> 0 200000000 100000000 4000000 22000000 5000000 4000000 6000000 -6000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,838</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,267</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,315 </span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4838000000 5049000000 5267000000 5315000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity/(Deficit) </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program is expected to conclude in the second quarter of fiscal 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(160)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(176)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000000 12000000 66.74 500000000 7800000 51.53 51.10 2000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(160)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(176)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -102000000 -12000000 -114000000 -58000000 -2000000 -60000000 0 2000000 2000000 7000000 -58000000 -4000000 -62000000 -160000000 -16000000 -176000000 -46000000 12000000 -34000000 -25000000 -1000000 -26000000 0 1000000 1000000 -25000000 -2000000 -27000000 -71000000 10000000 -61000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings Per Share Attributable to Cardinal Health, Inc. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">273</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for both </span></div>the three months ended September 30, 2022 and 2021 were 4 million <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares–basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares–diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">273</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 271000000 287000000 2000000 2000000 273000000 289000000 4000000 4000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,547</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,614 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,828</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,822 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,140</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">638</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,778</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,841 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,129</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shareholder cooperation agreement costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for/(benefit from) income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $7 million for the three months ended September 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,253</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,338</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,796</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,387</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 2 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,547</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,614 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,828</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,822 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,140</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">638</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,778</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div>(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments 45547000000 39614000000 281000000 208000000 45828000000 39822000000 3140000000 3567000000 638000000 582000000 3778000000 4149000000 49606000000 43971000000 -3000000 -3000000 49603000000 43968000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48,477</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,841 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,129</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,606</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,971 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,603</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,968 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 48477000000 42841000000 1129000000 1130000000 49606000000 43971000000 -3000000 -3000000 49603000000 43968000000 6000000 7000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 431000000 406000000 -8000000 123000000 423000000 529000000 -286000000 -114000000 137000000 415000000 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,253</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,409 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,338</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,796</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,837 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,387</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,878 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 27253000000 26409000000 11338000000 11632000000 4796000000 5837000000 43387000000 43878000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended September 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.62 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59.43</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $119 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.</span></div> <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 17000000 18000000 6000000 6000000 23000000 24000000 3000000 4000000 P3Y <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.03 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.62 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59.43</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2700000 46.03 1200000 69.95 1200000 49.62 200000 54.94 2500000 59.43 119000000 P2Y 3 0 0 2.40 2.40 0 0 2.34 2.34 <div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.32 </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.04 </span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72.01</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1200000 54.32 300000 76.79 400000 59.04 200000 57.50 900000 72.01 28000000 P2Y EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( 'I)9%4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !Z2615L D8Q^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.FDG#E'7"X@32$A, G&+'&^+:)HH,6KW]K1EZX3@ 3C&_O/Y ML^0&H\:0Z#F%2(D=Y9O1=WW6&+?BR!PU0,8C>9/+*=%/S7U(WO#T3 >(!C_, M@:"2\A8\L;&&#:?F6G^11I*RZ37^N[^]V#:"M95852A=SL5*V5TAOY/KO^\+L*^V#=WOUC MXXM@V\"ONVB_ %!+ P04 " !Z2615F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M 'I)9%51L1CBP@4 ,$> 8 >&PO=V]R:W-H965T&UL MM9G_<]HV&(?_%1V[V[5W(5@R7]*.<$=HTN;6-C1DVW6[_2!L@7VU+2;+D/SW M>V6#33?YA?/5_:'!X/>#'LN2'JSQ3JIO:2"$)L]QE*37G4#KS=M>+_4"$?/T M4FY$ I^LI(JYAD.U[J4;);B?%\51CSG.L!?S,.E,QOE[9@OR,WT.Q2X]>$X.RE/*;.;CWKSN.:9&(A*=-!(<_6S$34622H!W_ M[$,[Y7>:PN/7A_2['!Y@ECP5,QG]$?HZN.Y<=8@O5CR+]*/^+H05QF!1_^?/^0AP5N'4%;%_ _E- ZPK<(UV2!ER) M=-S3$&P^[GG[D)LBA-6$N.233'20DMO$%_[W]3UH4-DJ=FC5#4,#%V)S25SG M@C"',4M[9GCY@Z>AG-K*OVN.6UXD-\]ST8OTUW29:@7WW=^V*U0D].T)9C"^ M33?<$]<=&&VI4%O1F?S\$QTZO]CP?E#8=[#]$K:/I4_>22^#<:K)T\M&V$CQ MTI>,*RU4]$(>Q48J;,/S M\.9"A=(WHY# 9&#M/#RI''>U P^M;\@Y*CE'9]Z9BL,ZDB\#]?V(9ZUXE%H[ M$BUK"'A5 EZAC;I-=*A?R%T8"?(YBY="V<#P#-JEU!VY-C2TL"':FQ+MS3EH MCV(=FDD4.O$SCZUW*)XSX\H/$QZ1#X)'.K@@]XEW:8-%8QK"4J=:59US<&=P MMRIH[#VLB\_D5_%B75OQ* ?^C1CT*;5AXL5-.8_L@>+=D2EE1N1=F'K ^55P MA4X_)^*Z76?8=1TK*%K9%)15H.R\N>>8] [>M.L2'@:3JW6 XF5-&2O+H:A7 M_(]QOYS44^)Q7^PW;!MN0RNYH;B>3 '0+R COK92X0&U"P=>UQ2L4AR*B\E^ MQH'I4"I8$KE9'2_(0L- )%*1FQ^Z-%R%7LZ-+)XG(EW:==X,KH;#H96W#?NAE?Y0W%GVO%/?A_3TXO"" M?(3SR$-B[U<\<@2+"RG7U'D$C;>"MV%%M-(B>I87E> S)4DE9SEZYTINP\3:-SNUH),/4] $,3X1:25N TY8I4KPWG897S,-Q/GD(=@>.L"&6OEJ_)0GB9 EXKX8E'0S*.P?V+ M30SR:A?J0&::;."'^I9'F7AMI6]#A-Q*A%Q<6YX4]_-EY25>RLBZKX 'S*96 MO\.KFF)5UN/BTG+H17+[[ 4\@2FS[FG?B:#/7Q>W5KXV],>M],?%S>6@!\4= MM]#2^P:V7MQX#YD&F4U,MUJ!?Y#8[*]#D3;(T\R6[7;"AHRZ?6?@CGO;8\C> MT2:AF33SO=.4>.;!0+%?6+Y;[L].\UW)7G5ZL;G[B9LY-R616$&I%,B? YRLI]>' ?$&Y:SWY%U!+ P04 " !Z M261595=&6=H% !,%P & 'AL+W=OZ\-T*:[K]M=:;\R!0\1HRIL[$!G)\ MLQ0R8QIOY2I0&PDL*92R-*!A. HRQO/>[*)X=B=G%V*K4Y[#G21JFV5,/EU# M*AXN>U'O^<%7OEIK\R"876S8"NY!?]O<2;P+*BL)SR!77.1$PO*R=Q6=S^G$ M*!02?W-X4(UK8EQ9"/'#W-PFE[W0(((48FU,,/S9P1S2U%A"'#_W1GO5-XUB M\_K9^I^%\^C,@BF8B_0[3_3ZLC?ID026;)OJK^+A(^P=&AI[L4A5\9\\[&7# M'HFW2HMLKXP(,IZ7O^QQ'XB& MIQ*]"] FTK##H4^GN%?N%HB:QPZX9I-KN0 MXH%((XW6S$41FT(;O>&Y6<9[+?$M1ST]FXL\P46!A."5$BE/F,:;>XT_N%I: M$;$D[YG,>;Y2Y)1\N[\A1^^.B5HS"8KPG'SF:8H+HD[(N^;M1: 1GOE($.^A M7)=0: >4/ODL(=6?CB:5U &J885JZ$4U%TJ;W/X@1*((RS'GT6\>8U+?BS1QH2T-#ILX MQM/)M(76(47[=.1&.ZK0CKQH/TBA%-:]7/'I1F%-4J$7[E4FI.;_ ML9+Y$:W0:Y X _S<1 M1[3V@7I]^(1!7I7A/Y(0"TP1#NHXB'$,6($',;43IIW?#IG.C*FY-O)26K,O M[8<7)[R^_>F^A<\6&D3##H U*49^5OQ29/ 1+X:"XV#?);H#.; #V<9IBYQV MM(FH9LG(3Y.WN0;LHIJ\"-#F/3IL(W1P8]B!L&;&R$^-G_9UA.NKGL4^@U#EI B1,E_,$6Z08 M3$%R@7'-M13%9(%1+NO/Z0FUZS)E,>(Z$]A%8JMES;&S19Z-K RT"4U[4\/_CH6M*93 MZJ?3&YYNS?CW$N*!"W$;L$OHE8!K8J5#;P9^+PZ8(#EE9MQ> ;43^:O2SN;EJDURKN$)AW<0FOR MIG[R?FV:V71,Q^U!W24TZ2)PNDG3A%F8C4Z)^S2 M].2P.J;#]D3<(1>VI_:@<2Z9 6X4S'&M0AC;7)?'>-73ZDCXJC@(;3V_CL[G MY<%N;:8\9_Y<'(DHDL(2389G8PRG+(]NRQLM-L7IYT)H+;+B<@TL 6D$\/U2 M"/U\8SY0':#/_@=02P,$% @ >DED5=+Q]JZ) P /0L !@ !X;"]W M;W)K96.Y-IP)N%=$KZN*JN^WP.5V$L3!;N$C6Y;&+H39>$67, /S:76O/^>(?^UHE',7.J82KY/ZPPY208!:2 !5US\U%NWT$C MJ&_QY)M8QL%)%]K(ZO&&1E43-1O^M $8L\!.0=!W2$PZ]QJ'G MA-;,G*S7U-!LK.26*&N-:';@8N.\40T3-HTSH_ K0S^33:4H,"E0$!QIR5E! M#4YF!E^8+:.)7."G"O=(:9.W ?)>Y+("\I)\FKTFSY^^($\)$^2.<8YYT>/0 M("T+'N8-A=N:0G*"0H_<26%*3=X@E>+0/T0YK:9DI^DV.0LX@]4EZ447)(F2 MQ,-G^OON\1DZO3;$/8?7.X6WB^7)4/Y[,]=&X8[^[(M>C9[ZT>TQO]8KFL,D M0& -:@-!]NQ)/(A>^:0_$MA!(-(V$.DY].P#5B6@2C"QU.%S+K5^X=-;@PP< MB*U"FRR.,0^;?1G'-LDP:6T.V/5;=OVS:?K3E*!(?I ?R_':Q['_F#EY)+ # MU8-6]>!L3K 68J436&J4 I%_)[@/A>:TKK'%%ZQ =1F@HB#2AL@7COH?_;UT MO.R/.BGSV"1]?\J&+?GA+S?46N#MQ=E_6+26>&LU^XH@^P(4VU![2V!]PO.U M=D(NB !W$@U]\$D9'M-,.TH\)B?VWJ@5,CHKY"]I**_#Z]F!OZ(\.N8S2#J< M/3;)T$_ZJB5]]1ND#^DR5]!\)*^."*17'8[')DEZ8H?$T<_[+3K+\@_ (^QE M2:@QBLW7ALXY$".)D+@NC))XDXDE6AG V?\5UIT'-!ND3IO$),>6&OFTNOF/BHG*;=X^NQ2=*THR;<:T0J4$O7GVEDNQ:F MOK_;U;8'O'&=3V?]UO:&KL'Y"5,WEG=4+?$X$PX+A(PNAQA>5?=J]<3(E6MW MYM)@\^2&)?:WH*P!?E](:783^X.V8\Y^ %!+ P04 " !Z26158QUJ7R0& M .&P & 'AL+W=O>#BA]PRIM!#EN;R:K)5:GW8GE)2]4FN3L3B!99!D5CQ]8R@]7$W?R].!+ MLMFJ\L%L>;FC&W;/U+?=G8"[6>,E3C*6RX3G2+#UU>3:O;@A\]*@0GQ/V$%V MKE$9RHKS'^7-;7PU<4I&+&61*EU0^+=G-RQ-2T_ X^?1Z:1Y9VG8O7[R_GL5 M/ 2SHI+=\/3?)%;;JTDX03%;TR)57_CA$SL&Y)7^(I[*ZB\Z'+'.!$6%5#P[ M&@.#+,GK__3AF(B.@3L?,6EX E8XG.T+?[ MC^C7M[\AN:6"293DZ.N6%Y+FL9RBM^7]YR1-86#DY4P!K]+[+#IR^%!SP",< M[MGN'!%GBK"#L<'\QF[^9Y&/F<\@&TU*<),27/DC8RDIA&"Y0E1*B/W"%$_M M8&YV4,Z\"[FC$;N:P-223.S99/GNC>L[[TW1O9*S7JRDB978O"]OJ-PB&$3$ M?A;)GJ80MW$ :R]^Y:5<&?9+,E] LO?=0'30/'"#!M0C.&\(SJT$OPH:,U@O M(@;T5BF#:LN9,E&L_7B=M[NN0Q8#C@:4X_FNF:37D/2L)&_S/22.B\1"S]-? M[(4+=T#/A/*);Z;G-_1\*[T[P78T@3%^V)53758#SM66"1-17Z. <3 ?\#2 M'#R2Q:"A&=B'FBN:PIK7G7TF@H'V;H+]A3]@:$(MB&>FTPQ.9!/T4ZK&9 M,CM0-#4ZYJ&>):)5I DT5I"+AN?"RO,/SN,#K,?M2,,*K6B^2:Q3:*%1"8@? M#/@:0#Y>F/FZ3BM#CI7Q/Q7)Z]%!/YIW7[L(O0$U$\@C(]0Z"ND^HR['Z_%H MWGWKG)!PF#8ZM)&7,_3 MJ!I@CN>-9;750-0,J&--&MQ5'UZZ. M']F: <,8M";B&4.*/G2;C9.9#[7^$1HDC;N.6N#%F/ZT@NDNK*LH]$A'\O4. M9PK[, 4[',@V%0@ZXX*95U6K$+]X57TE;_U]3RO"V"[";1+N%8]^3&'[5^WV MK@M(A4C^8[%Q,Z2KKNH3;J49VZ5YC/"ME,4(65V%-:HV2)]H9TMI MU4.=Z/>RHJ8VHEBK2C.V2#+UFD15I=2X6LW42)<8N$^NB>D:< MX0;?A,)CS1ANI1?;I?>K8%06XK&742-+73[/2!AJ V^"C?;"N)59;-^8#GG6 MI6HDJN\S?=.4TF'>?+1 22N%Q"Z%W4&ONQ=H:6"]V98GV'L&';PT'Y0Y>N)< MK5*-*'<^0KJ50_*H-%7&2P\4G1E.UA7F51^?UBK[E:LL]_-9G@6I1R-)?5=9IG-8QR98X(P<_)%6S,B)X].*:Z?QKMKQ+O=W M;T+L!N^M%3'7#W8-!QQ&F'[ ,>M\K"B_%'VF8I/ [C=E:[!SS@/(@:@_OM0W MBN^J[Q3?7X&)L9#0 M0-+S,C:Q^K2D/FJD0P_GSSS[FF\9$^A;$J?YQ6 KQ.[S>)ROMRP)\D]\QU+Y MRX9G22#D9?8XSG<9"\+2*(G'9#)QQTD0I8/+\_)OM]GE.=^+.$K9;8;R?9($ MV7Y+GAD]TS\O;O-Y-7XB!)&"4OSB*V)+%<8$D M^_%O!3HX^BP,3[^_HOOEX.5@'H*<+7G\3Q2*[<5@,4 AVP3[6-SQY_^R:D"S M F_-X[S\%SU7;2<#M-[G@B>5L>Q!$J6'S^!;-1$G!MAI,2"5 >EJX%0&3M-@ MT6(PK0RF30.WQ6!6&"\R^6LD[<3EDJ>A)!8+D?R6\S@* R$O[H7\D(P3 MB&_0_3;(V);'( MV:WOF)!K5X[>"[(T2A]-_?:^TV^9#O)]]G*8,Q. ;P>X^FMY@ZZ$R**'O0@> M8H8$1[<2*Q4&,&H'^Y.G:YZ*C,LPI(_H)A5,=JH!-):,.=*&'&E#2N1I"_)U M$ ?IFJ% H ?V&*7%=!54V;$LXB'Z((-_H,7'HLEO^_03PY(NS#@X<$^".<+SLZD:RZ6A%5E,W$;$35AD,E-; M>=8A]0VE[M)I])T:>N49Y_-'%DKN5:,L>-N[O54=_00X)YD& ^)!@% E-"OSB& M?O'=T-_(DT?"T"'PP^(RWH?%W>269Z4&T3SC=#JK'#BS,'"&-#AC[6%?SD"" M>9!@/B08U><5FS>B9TWVF[]3(O,$$:Q?[,@$2S(,$\SM,!05RJ' !3VJE:6)EPT$203=YOF?A ML%)(JL]1(2>&,M(OY2;C*LN"]+'<< Q1L)&I /D\V[!([#-F5).LKOON-2JT MT\ELJ@>@#CV#0ZP?.$!]4B@TE0TGNB.VLL%+=C%_80SEQ6X2[>3!(S\(TW(W M.43I(2]4VN)S)+9;%H=HPS/$7BU%\,THL5U7KLV9K HQUC?P4RW(UB'T#K+! MI7/6C#&D2PJ%IL:X%@FQ726LU= BQO62OUK+,T/&0F/L0+5 4+05*)J'=:%R MM#"L>E Y$ I-940M"&*[(E@E^+QW^ND(^G:Y9<[*6 M6%?3L*;\VOO8.XRZRZD>1$B7% I-#6(M+V*[OKB2.3ID:6C.O;IZAJ=:]@45 M_[JX]$!=^J!H% I-C6/8>2J;=?_[]G.KNW:_?2^-[O='M2!>O5 T7Q0- J%IO*D M5NRP7;)KY4DG;LP-3]><,[>9& S-B.LV']5A71>4:$[S69U]0+V#J3MU&XF- MFCK6\K@.UWH9M@MFQ@UV[FC?K:Y:& M1B.RP$XS[KHZ1Q8-0W1=#N.FP&OO8V_N@$I\ MH&@^*!HU36[+'K/6[8A=M_OA93;$('JYS8HK>R=[,P*T3@\4S>\R'13*I(9NCUY'OMJ8GS*1PRBFT8( M4-$0%,T#1?-!T:A];E4^U((AL0N&/[+XRNZZ]\94KV33E"-0:=#@T%!\!>J3 M0J&I_RVK5@8=NS+X(XNO'%W^&VG;AZJ1>NAKB+$K^R#ZAMGDII<5JU.5QG1E'][)WL'4G>YT*,(*B%"H:E1//EOM78)T5J Y>AU4]4#0/%,T'1:.. M7DO85H#EU**=8Q?MWE* 993['5W6,SZ"[=AN9>]W[[B":G:@:!0*365 K=DY M;RS!ZQ1U5UOO>-Y\8KHTM!J1V5Q["8+>S)EHN1I403/VO]$O:NI^V\*KE3'' MKHR]K[#*' R3^#,S+$%0.0P4S>LX!A_4*X5"4[E0*V+.NXOL.L5_83BY+O35 M""I^@:)YW8;@@SJE4&B'Z(]/WGA5O#+MCR![C-(?YI+;V>$M9(<+ MP7?E2[ >N! \*;]N62 W7$4#^?N&<_%Z4;Q7Z_@NN,O_ U!+ P04 " ![ M2615_EP&68P' #;)@ & 'AL+W=O.@$C2L=D^WNPBT=Y_=Q&U]F\1=VRUPO_YL)S2M MXQJ(RA?:A/%DGL?CF<=N+AX8_RF6A$CPF&>%N.PLI5R=]WHB69(!D?MFY@N=Q M&.D!QN)O2A[$SG>@H_/WC\9\ K,# LR9=D_-)7+R\ZH U(RQ^M,WK&'SZ0"U-?^$I8)\Q<\ M5+9!!R1K(5E>#581Y+0H/_%C1<3. .7'/0!5 Y ](#HP(*P&A/: P8$!437 M4-TKH1@>8BSQY(*S!\"UM?*FOQ@RS6@%GQ9ZWN\E5_^E:IR<3%F1JEDD*5#? M!,MHBJ6ZN)?J0TVO%(#-P12+)?BD4D2 +OAQ'X.3#Z?@ Z %^$JS3$V?N.A) M%8QVV4NJ!U^7#T8''AR"KZR02P%N5 "I8WSL'P^1QT%/L;"E CU3<8V\'N_) MZB,(@S. H0< 4U?/QRZ\/B'_[DN#CU]#TVXG=C0^ L/3:R>L[F9LSEG.5"5 M@F-)BT6YU*BD1)R[IJUT&[G=ZC)T+E8X(9<=56<$X1O2F?S^&QP$?[@H.Z:S M^$C.]NB,MG1&/N^3;ZH$$\P+1:#HG61,B%,7>:63@7&B2^YF J%*ALTN)TT; M-$3[-K$WF)90^UNH?6_F7*7_JKI3+G[)5'%/6)'0C(!BAP/]'WV=Z#1;<;:A M:A&"V5/O9*V+"2U.7Y]Q_6-FW#&=Q4=RMC<-@^TT#+P9%Q/E-*&X;(]%"G#. MN*3_F1LN&DMW_=W<&]JYY[ 9C*S<\X;5$O1P"WKH!?TE7V'*R]S3F$\62KJ< M]O1Z XJ&E(H5$SC330D+0:0XTUGH8F/81-H/+3::-EU[(7K#;4G&:$O&R$O& M7Q5JM>:R)T >]5I:4['4]&@&4C)S0A\U8 46\*8%M$QB;V@M@8^WP,=>X/=+ MS$E7R[D4)"Q7&E<1.ES +VBS[C.(9S4S' M, M<9SN9S]5>H5(S./FE5@+525&.2-7N04@JU_Q DZD".E*7.:JW^%C>]B<# MU9.!_$6W2-2649CID!RG1/=\0C=XEA%W$J)FX>P'(SL-'58(VBO/'UM;[+5* MAE[5N(>=%AM561FG!U"'#CR#R$;ML(+V$HW]4;5%78M9Z%>SSZA[)RDIOYUJ M G"2L+5NO2O\I"??R4+D*"YA@X6F51>-&T7H/60NK'4N].JWR7>Y)%R#YFNR M5W-,1:D+$U5;X<-"HWK('M0Q&MB$.*RB<=\FY#T$)ZP5)_1+SF]O%_1.1IHJ ML]&3'3;=032P^7@/+0IK,0J';]I#ZP(A7K.C@4>2C157Q_06'\O;/J>UIH5^ M4:NT3D)(6C&ZV[:WG=ZDH&"9ZU3H&KZL;ATF8S2T4^L]!"ZL%2[T2]RK-*W4 MB]I(J^6FEI9\,G6'*&6STA+?B;ZI9;O#!GZ'T:"!_STD+ZHE+WI1\NZE0;VO M>ST9R*&%+2H<)O9&QQ]H6R)J)8R\XFYRN^;)4C5@<]!:%ABS_74"A@TT=EUU MF-A=UQ]06\"UVD1^M;D_\R\A;FI(^TC#86)K3']$;1'7&A/Y->8+;=7559Q< M.)1E8^T[C$:#1@:\A_I$M?I$T9O:ZIP6N$A>T5;1D?1B1=4QO<7'\K;/::UE MD5_+WI%T7?Z2ILI(QHI%5Q*> S;+Z,*,<%$:-5NJTLC>V_L#: J_5)7I!75;=5*\"J3>V M:_[D0]Y4BET8!(VBZC#KVU:Q/[2VT&M%B?R*Z[9R5OV7?*%FYP9E6 M'6?@3G5?3A/]LW=IHH6G=7-_Q)05JE^O-;7?RSWQ@?H:-N5G%UJ;_JG+R#X8 M\*-NRVHM4D._2#44W)$DPT+0.56DJ%W+57E>^YEDJ3FWOL?N$Z.P*4GM!>8P M@8%=6OPQMN6@UJVA7[?J]?5\6J:7EUEKSWN4*C6<\!W'H!"A1A8XS,:1O;K\ M,;;E8.>= K^2G3HP RS!C"QHH7\7-ALXPBES[MW#ICB-AM 6' ZK, ILP5%9 M#0Y9[2.LM6GH/QD]A)#H$T$OMN;/^F%DGWA.'58HLDMM[+#:XZG$UMMYZRGA+ '.&6;[UL[V[?T+HR[R59]Z_A^;1\SZIV4[[V]15S-;$"9&2N7 8? MAVI2>/DF57DAV!D[=H-W=)Z73$,^T!+9YNI1*HD M%Q1SM';^4U@11755E38<9ZL8ZQ>C43\?C9J-+&9B='\NSG5+KU<7:0=0_>F^4J\H/1R5&MES2C^*$^][@;]5X*4Y$-QEGE:7&< M30]>G#[A];+@=T/KL'.M.).Y=]Y?2>[(9:X#G;GRHRGBZCA[GJF"%KHIXWNW?DUM/D_97^[*('_5 M.JU]]EVF\B9$5[7&0% 9FW[U5SBR:D.)BBW4.>> MFH$U>V4+-4)GXW,TMK%B;7 M-JIIGKO&1F.7ZMR5)C<4CD812-C?*&^CGJ:HDUNB'JJWSL954"]M0<6^_0@9 M]&E,NC1.)WC;^_ ^V3'NV3N[S_;T6\.^K!4/T7 M@6]Q\FOC5>[0'C90P5:>3"%T1YH!H*>C<(.;&,C^=Q5M;8;A1ZP08NH MA+2Z2M%6^I+4G,@J*@UFE9T/U6\ A,2@$H)GW@3P& (2U_GGQO@$J#"A=IPI M0_;4I5/@0E*Z#Q4+[RHQXC7L,'&"8,$(MXC7U"JZO44)@2X'C+8F4; [ L,C6-,A4YAJ/'TX^(--2>U5[9T%#2(!1T'>-]F"MW,!#[7Q4",Q" MJ@[&C]\I;"<2_7-:I8B%0&&,D<0<]]TLJT?B+.LMLV^$'T YT[Y ^J5Z3;J, MJX%Z8_.A8#(@X1XU5XTM49&.YTA7$1Q(;5 R//5K$V@H+;DP(4?(#6G!'#BK MGQI+ 'R=JG8ILC@45)).*F>X7T';A!G?3OS 'B27$=?"V2PC;G[9'*]LO<= ML6U_0\-J[5-W\K#Y JL)6U=<"WF&BAH+96W:D4*FUWLG[#>/U'AGWHU-7R>=^*"5\]*%ANO7%K)0\TVG M"\Q9[>' U*B[6I(ECXF7]]R _=!]L(;O9DQ! -@?I]-SH.7>%44PU0Y17I#" M=QKY1%'"A.FZ1;.8=<:.1DWL<8AM\S7"1J4_D:(03<4X!NJB*99M8[#Z!'Q0 MU2UU*QV57BQ0XUZ5$JZ'*8GXSUOA8]JL X(A9#PV6-F%J/0&G".L[[4G;!'W M CG$A"HHAW*UL< [$)W5Q04^S42UC?<0EI:/+5'ER>2]9KT(+V*X4NSUWOA2L=T8&2 MM"X*4=[!7K^D/:%-C]&+)B+NKG)TC5;CKRLD)(K0,V70M@8RD&N>ZHZ>SK?T M U=GCG)<\>CW82 E#7*ZIF>,>T]%I)D?(%>-U4TATP-2!JU(P'NY&:BPBTCGX-^UJ:=2%DB'BHSC1)*ZGEMN:BUW[#^WHI^W?.Q3 M<4U/92HLM\?B 3'<*VY7J"^3NH[--Q8;1S_JO(+^64RT. D.DHV#_M#]+3='[<+D^G M\+?:+[$;JY(6,!T/OWV:*9].MNDFNEI.DW,7<3:5RQ6FF#POP/N%PP"V-QR@ M__?"R=]02P,$% @ >TED5;8$MEXY P Q 8 !@ !X;"]W;W)KA>,7BY>9,^<,R>-9[\-WKHDB_&BLXWE1Q]A> ME"6KFAKDL6_)R<[:AP:C3,.FY#80ZIS4V+*:3,[+!HTK%K.\=A<6,]]%:QS= M!>"N:3#\O"+K^WEQ4CPN?#*;.J:% M7)Y<7)VF^!SPU5#/>V-(2E;>?T^3&STO)HD065(Q(:!\'FA)UB8@H?'O%K/8 ME4R)^^-']'=9NVA9(=/2VV]&QWI>O"Q TQH[&S_Y_IJV>LX2GO*6\R_T0^SY MM #5PLO)$PG5-J'*O(="F>4;C+B8!=]#2-&"E@99 M:LX6A=KAK=. MD_YO?BE,=G2J1SI7U5' >VK',)V,H)I4U1&\Z4[>-.--GY3'2A@:UY&&CRT% M3'>! 9T&V6L]HX7WP77U$Q>E.Q>DQ],7_F([@QBG;:>,V\(3 4=ZPGN5<#ZDY7J\:P_Z] MD')PV6WD,J9C.1E!3\#>:H@UP=(';1A6'0L(,T0/U_+&&G3P')OV-;P+AG2: MBH- &[PBT@Q^#7^\JJ9RI:T5PB-P8D"RJ)!KD%-PO*802(_R44G!0%$L1D0J M"FF47WOJ@,+61.D-*N4[)PX%2Q1*3I:N"6VL 2W[W_E"07TED57!1 MA'\B! 2PH !@ !X;"]W;W)K(+45J)&7'^_6[HV1%31PW M&V#0)'5\]XY\=^1\8^Q75R)Z>*B4=HNH]+X^CV.7E5@)-S8U:OI2&%L)3T-[ M'[O:HLC#HDK%:9+,XDI('2WG8>[&+N>F\4IJO+'@FJH2=GN)RFP6T23:3=S* M^]+S1+R[]#_5M]8&L4]2BXKU$X:#1:+170Q.;\\8?M@\+O$C1OT@2-9 M&?.5![_DBRAA0J@P\XP@Z&^-5Z@4 Q&-OSO,J'?)"X?]'?J'$#O%LA(.KXSZ M0^:^7$1G$>18B$;Y6[/YB%T\IXR7&>5""YO6=OHN@JQQWE3=8F)02=W^BX=N M'P8+SI(7%J3=@C3P;AT%EN^%%\NY-1NP;$UHW FAAM5$3FH^E#MOZ:ND=7YY MB\[;)O.-E?H>A,[ANJJ5V2+"':[1"IWA//;DB>WCK$.];%'3%U"G\,EH7SJX MUCGFWZZ/B6%/,]W1O$P/ MYA/89I,H(T2=,#>-,^[&G F[XJ[*M2V'MT\.?% MBJ9)*'_M"[E%/-F/R,ES[FJ1X2*B['!HUQ@M?_QA,DM^/L#WI.=[<@C]?Q_3 M0=3]G*=C>(TW^%PB%$915K.1%RN%76K+?V@O[3,,W&&X'B,SSKMS@K(T/90, M^:D]5BNTX=3?2$WB5XKRV+T-&N!FTM,ZMJB$IV4!$(Y@\A,U9_!!9%))OP5\ MD#Z0,+XDS-9LDO#OL_%"O8[N$:2,.SE[R7%M)<>OMC2FNN4\F (\6DI<$8K0 M"C46,EB:M>1 O>D].=B4!DJQ1K)##5*OC6JT;Q%W,)B/(&]J)3/J0RVVE@ZA M\\^\+7K4K3.C&T>H4F>-M>0K;Z,CB1.Y8%*CE29WX^_LU-ZX1)91<;4A_!Q) M0)D,08YV9)PS/$6?-]*7L!:9T!Z*UI-$-^)=*-!Q@1\3;9IKZMI8#SD5=>;0TCJ'QW1/M ET[,2:0!U4*!QOPW\F^HR?4,ZP;%23]]I^PG&P M34'D-'5E;"X=K!I'=<81C>^4B' CL^8&T$J*52>/9P)Z38Z>/ZD5?:(^*OR: M%=YF_:50(;&%AU\;C8\'=P2G,\[TA)K9#"[R/*C)T5>80CJ%&['E W(#A8K\ M"]W7[>R;R>0M-0DU*?4&?O:HA%R<4C/ESAGLNRWBP05?(=U5_(QQ=#!4'=J[ MOI_M7TH7[0/AT;Q]9GVBJTY2( H+6IJ,WYU&8-NG2SOPI@[/A97Q]/@(W9)> M>VC9@+X7QOC=@!WT[\?EOU!+ P04 " ![2615$< 5D=4& #H$0 &0 M 'AL+W=OW. M,&,],6B\5^H"7:XHY$JB25Q/WU>RYE*4[BI.YB/]@BI?LX]TWI M\M[8;RZ7TM-#66AWUO+<._67E^:VA=*RUM+KBY+8;N[TUL24K8[[QYF-V MU8L8D"QDZEF"P.5.OI-%P8( X_>=S%ZGDAGWUZWTOP7;8$_F_N_RYT]4Y:7FL*%?[IO:*?C'J6U\Z;<,0-!J71S%0\[/^PQ M+*)7&)(=0Q)P-XH"RO?"B^M+:^[),C6D\2*8&K@!3FD.RA=O\52!SU__:$QV MKXJ"A,[H9Y]+2Q^U%WJC5H6DI7/2N\N1AR:F'Z4[J3>-U.05J6/Z9+3/'7W0 MF\H^ L(.9M#!ODC<%?I'5D,;1@)(H2=Z0-^[,'@=YXV/,?F$PO53DYW_WOHD-Y>EBN(.P@QBAJ(L_DT6+<\Q#$(;FV=T/DO3>NRA@4R>_3O M'C!DB*-[X:@_'LYHU?AV2.]K&P()B3ZW4E+9U+/D>OY3Y;]HY2D%A](UR+TA M^5!)JV0P-[N3UB%=E(;Y"N0H#?10AVN#$_1*KQNO8U $N.G.Z;>W']!T2U[R MK[(J!5 &+)F/45CEOC7$-?19C\GDE7PB'F1 L"]7:.A,,=;XON[DG*W9> B0 M .G)0@#53F8M388B"^G+3P9T+RG,FT;+:EL)UR3_[[4HE!<\@0CWI'-==L,Q M/%N9!#AW-(="Y8& @P+J%]X>TL^UA6. $T.BR5=4%),Q5QD,7T,2W8D"KMH] M>Q(PY<)\0V(CUQ&^VIHJ M:(>OH V:G<\[TJ2E.QT$2C2.;](_4R7=D)99ID)>%,4V^!O>1,4R%78\@AD, M)"ZB3O4N+UI\H$V%RVF-;D6E]+G)!L#ZG'Q3JTQR8Z2J7A4J98]40F\[%L;Y M%EOH':(Y?#0\P] GGW<^^9!*R67%[(\Q@G6Y@G^;ZFA23B#AY9D7#_MY@<9J M-\&+??25MC\>3)-6)A>\E:G9:+3GC+*_6.U-5^96GA9UUD![!-04U,D&=7 -,ZS'PT5[.]"U+6/XZK0^,*3=XY3>S3/UR-;$B5V9 M%MS(A+\X9,S3H?RCY8@O]\;.3PCS;Z$T979&2W1_G/;IL^17!@:R+(WUZH^F MU=QB3!ADSS\1;$C[B+3 H%!>GA5J+??0N0OZ:@6/ KOK]A6T<:;T*8[QUX[< ML/UIM-R="=3K$IFPY=KQO']=^[MP. ]A;$:5RU7E,*V3:(;9'4_G% ^BR3GW MB$>D VX+F20M2OD4]G0RH_$LIG@QI044W^&%J>*N(--SVEZ M'M%D,J?SG6VO6S89S!?G?-B)%N"=+>*.Y[6H]\&SB*+FB 2N/O.=)\$K3P]3 MQ\3__Q7'OQK#_RE^\X3C-YO"XCB:'Q>\:8+@113#0T>$;D'3^80FL\D1@5O, M$CX"GB.1!O/9^)BPM<=&\'#8YO-6C]@O-;22E_RAX\SC;HHP[OY\\6*J'#\G ML(@'/,4J&=[ B^V0/G1G$J%U?12P5K$-?2.#%I"MT<_!#15C1F3J3#=7AH=>VT=[;-_)I$[XQ. J# MIGD1[^YVGS&6S=O[(WGS#>03NK[2C@JY!FLTG$][F$#ANT*S\:8*[_(KXY&\ M89E+I*1E CQ?&^/;#2OH/NY<_Q=02P,$% @ >TED5=T/=SNX!0 &ULK5=M;]LV$/XKA)<6&^#( MMO+2H$T,.,FR=FC7H.G6#\,^T-+9(D*)*DG9\7[]GCO)+TF3K!CV)9$HWG// MW3UWI$^7SM^&@BBJN])6X:Q7Q%B_'@Q"5E"I0^)JJO!EYGRI(U[]?!!J3SH7 MH](.TN'P>%!J4_7&I[)V[<>GKHG65'3M56C*4OO5.5FW/.N->NN%3V9>1%X8 MC$]K/:<;BK_7UQYO@PU*;DJJ@G&5\C0[ZTU&K\\/>;]L^,/0,NP\*XYDZMPM MO[S+SWI#)D26LL@(&O\6=$'6,A!H?.TP>QN7;+C[O$:_DM@1RU0'NG#VB\EC M<=8[Z:F<9KJQ\9-;OJ4NGB/&RYP-\E#.$K4?W*_8R6)_D*JT+F*+FJK+'^+_,UM M$?O*5)EM9X3;%+K5XL'S M+>*HKY8$B)RHY.QR&9H8(OPPS-[1JQ1CMV54 SDS-8JL2]=44L0T.1X=OU"_ M2<[RAEIR+=6HM""7=>S,,VJ5P D<#8&P%"/&PA^4$FS4);V2/CH":OI7%D MRPSWC?YZ1D":62L[:V &M%4G3N(HTV2XT5WFRI)\9E",6@,2:75SKS%==';+ MY5@]M/"T<'8ACA&SB6JF,VX+J!MO@,.T6XFCTP)&)W$Y(."$4Z8R@^>\6 M8?)8&TB9>()6KE-,N"=;3K67?GPJFO[3K)&TK>V_$T1YM@0WY#"L:BS8 M?-=(&L_X?+_6GJ.#_@I<'GW@LP7;F2EZ$>Y-+B-5^N+Q4\3PY95;$MU![<9? M)I/KOH2%]M6@!S> 49;FL$9+<$IGWI7/'$SR^=[,7H$SIA8'&QY& U_)VF%. MP2SPJX@\;\#WF4/8 MW0L[V/S.&O\#4$L#!!0 ( 'M)9%4H\#=AWAD %-+ 9 >&PO=V]R M:W-H965T![,](QD[E]_7U7U:X:D; .[!VS6(F>ZN[JZ'E\]FL]O MVNZ36QO3J\]UU;@71^N^W_SPX($KUJ;6[KC=F 9/EFU7ZQX?N]4#M^F,+GE0 M73TX/3EY_*#6MCEZ^9R_N^Q>/F^'OK*-N>R4&^I:=]N?3-7>O#B:'X4O?K.K M=4]?/'CY?*-7YLKT?VPN.WQZ$&FJF@BD/&WG_,H+DD#\[_#[&]X M[]C+0CMST59_VK)?OSAZ>J1*L]1#U?_6WOQL_'X>T7Q%6SG^?W4C[SXZ/5+% MX/JV]H-!06T;^5=_]GS(!CP].3#@U \X9;IE(:;RE>[UR^==>Z,Z>ANST1^\ M51X-XFQ#AW+5=WAJ,:Y_>='6M>W!Y=[-U$7;]+99X8-Z9_7"5K:WQBG=E/C< MVY4F1CY_T&-=&OV@\&O\)&N<'ECCH7J/B==.O6Y*4X['/P"]D>C30/1/I[=. M>&4VQ^KAR4R=GIR>WC+?P\B$ASS?PR\S@3<;^5#0]E]95U2M&SJC_N=\X?H. MDO2_^[@@BYSM7X2TZP>WT85Y<03U<::[-DRVV?]- MYWC[&H^/U;%5N]%@ZC%QY'Q8P5:0/LR9)QK\AJXI+*KTJC.&^*_Z5IG//9ZH?FV$UG[= MM<-J#98VAH8_.U9_8CAVVIF_!]MA#HRJ]2>C_AZPJNE V49OY3SQ:,*+.#$H MI;]UUVF("+U^/-&K7V&R_QLF6WW8V-:6ZJHW-[J#6[$;=5[TO*U-9RLZZ:FOTO/CCY8J?5E5X%$S+'%< MD)).E*"T,!9V,?0MOJAL 5=#FXPJ$J(32C4\2Q@5'0*U:K<$!I(Z()>$0BYM8D!/ZEONVQYQI* MN89-$%ZL.ETKFOU:5RP,KL62HUV5^794.70D_[PH!!RBOJB,*FATJ3O6EQE( M7MFFH?'9KR86FSY+3(6Y NP-TC/!4T8)1[*C7^Z M)CW/9/1870T+!TZ!2]5VMD=V&WP#(]:3(/1KW8/3I5U:+[_9":U:X@Q6)4GF M0Z\LC&L0=.P#Q]S?M&)\U%UB(+]&F_5BSOL0\D'D^68#Y75I)P:[AP>T73'8 M'N)S#6GV\Y=A<\S-[QW03V$9G>%_FZXM#(X8#%O!I#2E&*8W9M'!;FR]:=JS M!#:^]0N8Y=(([^@3CH-V"_A9TK^07(-3H>5HDV$G5P.\:6W\CO $)!,8W%T) M!$/+&DS E'TH^E;D(!"V9S[LD+Q@.9DX;%R,95%T XMH9MPL&6IE'?%EP8+. M!ZMQ8.(IMTE48:V&KC-RH'SB-1@(-FNR^^3?;$U6Z5C]9 H]N*B6T\-BAK'] M[_"D*Z>&C"G% 6'XG;-Y-&ET]B,U=&HD.+GF+@&&, .]I<3%L.?P8&R>; B] M'/<>MQ!!H,/T ML:1@H1KVNL6_1*\#O2XY0*7?3&=@EI2&?#ZY M!J8=YUX.M'D\8@2%MS)W14X"$> GN.NR54T+>T?A)W'*;:!92[@&-NRSG 3O MR3SVQ!2;(: ^F!!B!YF0N>C-2GF5MD2P^U2_&!/?X-ID#IQ*5T^ MPCHWR.[ /CH\42%244)#<&%="WA"7T+7.L/A)4>99!>N!@B!?'"0&#RIO!,6 MWI"&PD%A)T7K!$EU!N+="16;"G!0:;:'I#6>H;!3IB9@3/0UX'DW;&0)V\29 M651F\6,R.$6E;2W0I-(W;K ^W"$[4R&@)R*$9/)YD17@ZFO 7Z7AQ$ASF\!% M1X#4#]X+8MNPP-W-;+^!BL!0(ND^2+2+& M&D5?+8#M#'A!$R5]&QT!V,DK1)[N8]I$L0(S$%Y\K8[!=^BR9$@PVS5MP0\: M&@))V[2FT9X]P&*D=&18;2.9+7:$-,>U[FP[X*$!^-:,TQU[&QU\>\Y>-N^# M@^ES/+>')NFK)4R-Y'%,-Y/0SIHN'9]M2CSMMCLQG9>-Q".QB%^WDX+Q?VF) M917++=8)GX*N![<3_9!7.0\%<6@PMH6$CGA:L8?99!Y&KR#L<&V#)X8\)UDB MAY-F9U-)D24)/M@RF""%QKQL:V*X/2\OF[S,S. M/.:0=X-J;P;*)/3>MHU#Z9TC7K6 NXUW,10_K+Q'6P(CF\"?M"$PP9MQLNG)-:8%C&UHX-VD18_Y=OE]%T/SMV(QETI MV/+Z3=O0ABI22H'J PL@Y(-\U7@#)"9$ @Z5>-#>-$&.HAF?B-*8M#PN6(HK MR&(#MA^"!KX!>_U;0@I/:=42%R2\Z(QVB',7, Q[(HV>#S*00.)I&["$0UD< M)F*E$A$A4T-+#X2"DK'[R-EZ #V!%X M3ID)MG=^/3FN,N:!A1&Z!"%X(F%U8C",H !]YC+)'H+Y)686P\<,#9P.9!;M MJK'_(N:R&PUOJL1-;) ?D2%.HG+CW6\P+-ZDMX78SD*[-3MN\+B?KI6",A&' M$6M8:N$92&>_+)KT=4YZ(CL=^H3R\;QWB2QH#Y:^]Z!8ZVY%.@&-)93$1T+Q MH22^*#W35K9DTMEN>Q%;*H1#E#MR/ZHU J=K\KBT-Q,.,JS!M !WDRHM"1$R MU4$91:]8/&EUXBF":1BB;LNI#PG HXL7I? )1\)8Y $-2Z:?'[@5[#2?-5"0 MF84YOR;FI9U?3K+#HZDY<06<94D](.>VWNC"NTVM[LP?QR@_: L?[6CSF3TB MM9QLE2QK1;'L(-Y_8\BD=E3M\I[C.*18W^51Q=L1<)&(W:GOP(,?U65+9T^[ MN1H6I;WF9(I3OVJ?P?E!22KMD$'3^+&2=NX^A5]L+1/0)-AO)/8NX8CEZSUW6)0-IK_C%F MVR7!G&\E/,+,G 6F)[SNM7;D^OYJ.Y_:E'3P)$P3B+#@\(91AA.>TD,?ST2^ MNHRO8J#V$4*P'9C,)][(@+0QZ2X9CQ'*#J QY](L(BW_<.\Z7C_4V6-/]"R; M2%)^%[ 3]<)JWLXC2<91A&NQ"L.]*0AFX:'J?CZH MNX0EVPU9+S9FY(>J8A#I'V*R?=\.[HE1H-Q/. YH_M!>_Q!)4A,[Q9K""OS M[:_6J_U>_A#0(%1)8\: L"QA0ITHM(!4H%+K*H^*0HD WG+?Q!P$W< "N[?SP]G3_Y,<#-BCF]H(P/)4@H(,7Y MP@=9R4%35<*)O:U;-LPI*/)925DNIE#W,:TS2X&^9'])RFC"6LU/[O_7*$UX M^RPU&=FHPD%L,@GY>A7.8@XPI[92., @JG_RT40EQ18P\+RF M>BN<'(F7H?PD1(02D)JM6#C.Z"^279\%;I.&.H.W215#+3 =54 V9++ M_@8*A.6HD&26))(ZQIWDDIG-8^HIRB+H9G);?Z$75#6\()0I*9(+KZ,_2^JH M)XOF^38UTIR+$H!B8_G\='Z<%=/)DNH$$O :@[C DM%LA#D,!5P4*8RGV'FW MHZIE*$1DA>C,^TT,:L$5>%HC@BB!J"2] :B!W7\B>@B"A0D_?*KTNJTUF4?*TT?@ MU(J9N/[B:<(7Y@9/*#^$66+QVYF,SAD4@0%J%;H.QH,A]=67.FGC)VP=A8R2Q\.I?R M\I7]5RB($DMH"RD9,5I*Z.#/R0(P(/,9\V0&AHT'*'BER^P=+(JF:O!D(9][ MYZGWG9=U@52*E@[)1$Y*5HXY"%1I\-E36O#L6=!EGJ,G8A9?-4EDKN",\DM M@^8Y[V&X&K.5%C)H?VQ8""IW7NF%KK4X)-UD<>&.^?.^B\ (C+KT*TD++*]W M "R,[1Q5ZB1($PLW[2F06K'Y; INA-%R&/LCQ;C+Z1Z& MF,>G:10/Y)/=G@I;Z(J#(I9DEU*X>[)[_XD\[J2)X3^2OA4C%Y(C*7T8\I!?2N@2 M5=^EL6/5=<\(I0LJ%?;E-'?"?U@)=MF)9FV MS>#K15P)TZ&64P:O2+*5)ZBHQ'+(%1'\+\EZQ$QPJ%E0MR*M65)O&TP&Q59] MT/1?!NP5,CU))H:JHD][ES&B0O@/0OX:NFU6*.5N!-\&.#9ZX^(JW)^75H*]V[X[M&K#[]0 M9VK8*B=1XGX+8*3J"X5LL1^8!O,2P7+8"\JY7/O:D9S4A N^;T%1IE<'%\%"T7J"8GYW#_'Q[:$)VN)- MF\0FJ8BBFVV2U>DDE[Y\>,G='# #[G!VJVRQ359/2=7%/.UV6HN>C;N3$54V M,;20PUK[D(93#=62^S*HE7*F$#MM+#7ANBVDK=X=Q$T9\N?X/N2-/WCFSM3\T9S/ MQ)=0)2BDPDEH$OB=8?C@).ST+4C2F1"U$*>T2:?!=7(+;ZQ]RP6%EOD(;@XK MLB&4C)$T3$JO2%\<<>)TGL^^@+7C"I5$"S&"^*=INY4D:&+*@^:M6:"II*VY M*194D0ROL=F*B8=UYD)^*4:VLUSOO/CP\>VK^_-G/@3A")-[@66R4H(>7]&% M0V$USZ#MPRCM6>I,TFHT?!@I0#E;LC1Y7Q1Y6X:S;N@8^V3W M3F( YWL?"3PUTD"]V\GBO8&3YOV8BIZ&ERV$*IA)#@=LO> BV2 VF)GO3- X M4S?ZE!'(#$J;/;H9$__7V0,##]G?/Q] L1YF$:'3.C5P&FVSC=LXX4+Q+S@C&12 M@X(GHSRV8X]FI_-'N>Z+2$OKS]@^LCM+M?5X@KXAFUBU%%:%=DW8AD9L]).T MG413,&"':'LZM7BA%3Y&'$25(P45.SJ]"/1U@3-AE??FLRW:T%341!OL\\G! M0V=['%UWF7F?1L0-H74J8[O$:&DA@*@_8#*@7)=TPXG "=W)F>$Q=D.U)<%+ M=$^'=,E_\M3\KC\C&"19Q',/XS.$NMVXHK$?&J?P1^'#)",4C/77E*!&;O[VQGU_EXFR"(].GZ1K M73YV]\T1P1^+IPAFG0WY;&)C]RC^/BOV;;'["*A3D2 4T;0AX?9\*'P?/R@LL# U( 2:,82-(66+<_6.SPHKG(A=N<,3U4(=! M^0#>7[:(X52!8F%99C2)"$X36\?#LHW1S4,?U.=WH4L]2PJXS)*R47+ZBRW7KMBJYBEG MBC/W7I[\=+7\UO4E!_ WL;&T3WH^[4 MJQZ-_$YAA7I.0FA&W80^_4MA)B?K*:CTS5^QV3YRH>%K:;Z8]"W7YCZL;9N( M)J28]UER66SH"N!B;G9?>JVJ88[DSB+AY?Z&K-U[C?>(?X^81BJ,R5T9MLA2 M'3O)$YV0M)8*U*6:SY\]4U>OW_X1+R23=7H==QG8SIP&HN&6ZFB%/)0?:7BX MD9OX?A.[>,&S9+*(J)";F@X17.)B\)YP%)7/6Q%-GV1P:GYR=W'/W^*ZJ^]E MM\:"P-&SUY_!3-*V<^'__-G#,\(BM?[$9MZZSO"%]:8/#I;TU.=RIH@3XO4W M2:GO\>O-*N40]FF<(&5*^?$M'>JE\K>?UUKNM #HUBZW.9,I9KX#RWSRF)RU M?N23O2L6205YO6]-9&4)PBB\+6G#65/A:*_A+FHZ#M>.SR1EP+)HY[93PM&< MAQ&CDUAXDTV-@G2QULLV-4I-]-3U;3&Z7A MP\N[_-VAI_N* M(Q:+B#?AN+8A1=I_[NV(L?BZ",Q0A(^3:F;P 168]#;,D/ M'2$7G!;+S&CXP8%)#^4EOB-:S[%DWY&5'9O>_)(PC._D?OZHBS 'OM)/ C E M84YV[))S8.I&5MC# V\'%MMX36-BY,(O!93=L,HN'(6L4.AOA:VN K71[^U. MZ;,?+C:]:%53^CM>\,U"15_RY83"4E[;5"/I'FTH1)8CV^<5=U^B%(:T<=OJ M6B-<.TAN'@9EES)N.Q;3D)@REAQ?S.>[ G3-W_$M@<)?E:.T61GN/-5RT_A: MWI"(*R57^?<0IG?];2VML=1%GS!LN/@3ZO/A;H37(/3J_?'MT;QIB+@$H^;IG*0'=Z"%=GBP^@>_TH1SUIR;5 M(,9-;R/MZ&F*27R:CFI3'/CQAQPCB;$-&7MLVUM;A' MCSSW7J#:S:! #MZ_>I?";O!O0D$@.1B21=6VM H<*.'A;"?R0TGI=?FY*8!#L(J0VQ)#3XZ?/#J2IO;PH6\W_+-) MB[:'#O.?:Z \T]$+>+YLVSY\H 7B[VB]_#]02P,$% @ >TED5&ULG5A=;]NX$OTK MA#=8)$!B.W;29-LD0).VNUF@V"*YO7VXN ^T1-O<4J1*4K'=7[]GAI(L)T[6 M+5 T,L7Y.G-F.-3%POFO8:Y4%,O"V'#9F\=8OAX,0C97A0Q]5RJ+-U/G"QGQ MT\\&H?1*YBQ4F,%H.'PU**2VO:L+7OODKRY<%8VVZI,7H2H*Z5?7RKC%9>^X MURSO0:LEUX6R03LKO)I>]MX>O[X^H?V\X;]: M+4+G65 D$^>^TH_;_+(W)(>445DD#1)_'M2-,H84P8UOM:Y($N\^-]@\< M.V*9R*!NG/FB\SB_[)WW1*ZFLC+QSBW^4'4\IZ0OYNK?%-^ M $]:=T:-.]>C%Q7>J[(OQL-#,1J.1B_H&[?AC5G?^%_#$^]TR(P+E5?B?V\G M(7H0XO_;0DX:3[9KI")Y'4J9JJB H_Z!Z5[_^TK[= MWVU.OJSFK"^ZB14?3)7%2E(=!*&M<)47I7.)'-I9TI=D?;J+QE]Z01TN;B<_^^+T*$J'BJ+: ;!%0=C+*[ M[,VD"@ A!!3)DE7DP,\K*-!1%:'/F+YG78$B^-VY?*&-$;=%*;5'GXGB9BX] MXGM7>5(=YS Y]TJ)(I%<$:Q8M&C2TV1J0T"'1C^> M]HY'K74R-P444 5?QWTH- 23M P,;<_ "ITKKSJ@350FJT#@T8[*5J&"!NC2 M=NK5MPH>'R:$X!%%D45"E58:M>"0J0BQFG J1%VPQ]):TO8TLWWQ9:Z28X&Y MTD$5J7#5;+ZK*DZ*+$NSVE6B0;[E\T0!/+59"P0G;5IAUU%T1SD)HC:TXT1@ M9UEAA1G9J:CM2K+*>TK]MTIZ5 #3=HOBE/XUT,S?37H_!@N0PX!&W#9J;%O5 M*XVK^+68ZVQ.:P H@R=K*PF:)IW;N%I3+?_!0A$+^5.TZ+*15%@7NZ1]AITS MJ*"@96SJTY/9;?%HJE*]KA1*0DB ;'+;.GL$)>BF>F*ZV%@D \-!GABT0TA/ MZO(M<;6!;?D@%!,>Z.VMQS6'$H0U;$_S_J:@4A)F3XXPN]L@?YAB M5$. "JG-A5J69"GPHHN$J Q!Q7_S92*-M)D2/%9!.FXQ1.S@)O<4,V:$5P_* M$V71@JM(4T==Y1S?1N;?M^R@,^J.\OVC1Q!'B(?CU)2W\(WJ9G_8/SMH3O(D M\JH_;A8.B2=EDC.KQ/YGB+N[7YBQ#1^Y<;.6UG"%1)5387MZDCXLC-L%^%YU-6P$LI4HK.//RJK.O+ )]#4\97QV$6[( MV392L7=^>KZ;?]0+#X6>=DX*U+"K3([(D6/J!W6*[#,\0I_:-?);YMP MGIRO&T@7B$-F&8J5<<7M&4%QGZ*NIOA7FQ*AY$&QGH&?#;MI4=TAK MC\.=A^"?Z5Y<0^@!;G[5\![A-5P,C[M!/;44UXA\T7-_O MW=[=]P[HT$_1PQR?:56<.\^*#M=AH.E'HQHRR2KGN394M(G"1M\)S5NUU('[ MR_/1U/S$^:)]ZE.0(PY4,?EO=*%CNF_UJ;$T$T&+)XK)IJL4T[#Q)1)QTVRZ*QG<.SM=%Z!:@E^!*AQOUG5%DDW)]<5?## URX\R M\A&&D*;:=&=CP(A3SK;,X^Q-%28T).]O'&-/NI4O3,;FX!O, #EA84"QI3DJ/A'YP-U>1OFF6)8)STR6H+4;K#&(]^ MZ&#'K]H;1W=4[^SBQ)(17(YQLJ_8"$-1U"C)&8Y(IA7E3-Q@\X>*N\V-\Z6K MJ;/?6[_H'2!D\AJSK99^15FY1@ $VSN=?=4HXM1&;W#30->@ RU7OKV*/3%] MV#4+@KB)T;.F9VK(%E9/5R+!VYZ=/&@N2_[\D-@00=@@TZ>TU'C2Q PM-,6W M \WQ4(12VR,WG9+S:^/U.%U;Q-TVIN]ZF=(/DKA/$\K>V=GF8;'FZJZGZ^,S MA9C\Z-;QLY-@?]L7GD'GXUNA<"VB3XQTJ49/3-_AVM7V*^;;]/%NO3U] OV( M6Q4R+(R:0A3#VFE/^/19,?V(KN1/>1,7HROX<:XD\D\;\'[J7&Q^D('VV^[5 M/U!+ P04 " ![2615VX+B>X(# !*" &0 'AL+W=O+"$4J)&6E_?6]HQ351A,/ _;%?+F[YYZ'NB.]:HV].2N_K M91R[K,1*N)&I49.E,+82GI9V&[O:HLA#4*7B9#Q^%5="ZFBS"GLW=K,RC5=2 MXXT%UU25L-\N49EV'4VBQXV/)K=N; RM)C;GCQ5_Y.AHS(528>480-.SP"I5B(*)QWV-& M0TH.W)\_HK\-VDE+*AQ>&?5%YKY<1XL(<[ MG460-^G/8"UB,GPE(^H D\.X2!99OA!>;E34M6/8F-)X$ MJ2&:R$G-'^766[)*BO.;MT):^"Q4@W"-PC46Z<2]6\6>P-DESGJ@RPXH>09H M"M=&^]+!'SK'_# ^)E(#L^21V65R%/ 6ZQ%,QV>0C)/D"-YT4#H->--_5_I& MNDP9%NO@ZT7JO*7B^.(\[5##IQZ0?I_#)>*'@(F1>PI5P)>!](XE5T/ ;3,YFY^'\7:/Q?U>7G,V2^3/J.MO3ZGX__T4=;1T7-)GO3QF%*\3\@I\*)72&M)>I M)J?:V#>R[,8WI*IH=.[.H"UE5H(I"M((A6HR,O*='%SI"D7+A9.9BIX:%RRP M5ULCYN#P +//Q_%5PFEZ":U M=\0I$[6DKR"_=\G97M)U#O>4D($+^4 $2:RID BG?B_5J&NBH4\XM0^$#\[$ M49Q'2UV6LZ $D'K["@T/'H?!Z![5ZN;N%-'5X+.BYZ>\*TI,<>+3N0O3!$ MNE]P@N'OP^8'4$L#!!0 ( 'M)9%7L/:V/5@L )@D 9 >&PO=V]R M:W-H965TF'Q7Z@)=IB*XDJ2<7)_/H]]U(/2I;3=-H"@VDLDY?W>>ZYE,]WQGYR MF5)>7!=YZ2YFF??5X^72)9DJI%N82I7X9F-L(3T^VNW255;)E#<5^7)U?/QP M64A=SB[/^=D;>WEN:I_K4KVQPM5%(>W-4Y6;W<7L9-8^>*NWF:<'R\OS2F[5 M.^7_4[VQ^+3LI*2Z4*73IA16;2YF3TX>/SVC];S@#ZUV+OI;D"5K8S[1AU?I MQ>R8%%*Y2CQ)D/CG2CU3>4Z"H,;G1N:L.Y(VQG^WTE^R[;!E+9UZ9O(/.O79 MQ>S13*1J(^O-WZ( M-CPZ/K!AU6Q8L=[A(-;RN?3R\MR:G;"T&M+H#S:5=T,Y75)0WGF+;S7V^&U*GSGQHDQ5.MR_A$J= M7JM6KZ>K6P6^4]5"G![/Q>IXM;I%WFEGYRG+.ST@[[FR^DI2!L2&"EFFXC>5 M;G6Y%4\H0;37RHGGVB6Y<;55XK]/UEB.Y/G?E%?"H6?3AU)!/7:53-3%#!7C ME+U2L\N__^WDX?$_;C'IK#/I[#;ITZ&+5)_2]W:)ORS$M- /2M1>Y_I/A8SO M'+GIUNIHK3?(SQ(%+=1U%7R(1XFR'A AK':?'*HYEUZE](6IK3#EUE $ #56 M4K&ZA7B?*5%934C1; I2L2FSIMYF^!=:.27,)E8J5D6725ZG],PK^-\+2%>* 5&GI0*>W);M-.I$U21NM MFHN=$C)W1BBREZPVAP3Z3/I(:@@%R82$QA'K.JP@@[]X-L?KL%=(CDP_ L[" M2<'Y7FRDMN)*YK7JHJJD+2$<>SQ[2"$><(Z222:0'MJD' F2R/G5"#0UV5Q) M"U\F5B%X;(8@X,_SV]V[0.DGQE+,\AOV8B:Q @DCU[D&MJ:<%=3B.(>Q42=^ M\LQMK5-%916@Q93YS1VBL=,^"ZDPJBGM:RZ'/EZ6@Z#+*VA'F\46R:8HU=;* MXYPX3=D*"IS>Z$1B;5R0LD32E6IH!>D,\]W A@"@J*2KR%;O!N\%ESJ%6?:VU);DXU;F%)C9Y@21@21&ZM4HW77[5E^9;*\BT=])IK MG W;#S*IHPO@J2>%AD4=:AA"_TUXLOZHDN#E&(_NL)_R)9$N$QNPE1##4*;V M$PA2R-0FE];& K I51N 26N/C;ZVH:= ,FW;Z&N5'O&9O*)7KU4! M&3;0C3V%\@G^9E]'*34TP^UDQ29O:@O%;2N;3HZC/]QU):T.N#M&YM[(X N# M/-A!+*/V%44W[]<@YH[B^JR%UA51:GA:HXS:14ZA'3.H'9(?RXI/IT4 RJ#GI41U@>_3B4+"KD&YO5N"6. M42K* HJ@@2!XE[:$V(1^)+TPT*D*3@_1>=9UX;?0#?TA8_99]M(U=_Y#@8R%]1I^''HY*?M.@7G3N#TZ$J,/TN;#+5"G@ M)*?7N1H!8L]P]LNG\=J4;6"*U+O_X 0A!JV8)4::5/+F"%Z3/E"%290*C(/4 M&$4N(@9PXA@S(0E#%Z>C-05B R"I&P";0,_W30Q:=XS9%&+\N9:YWMQP@?1' MLWIC?Y-Z6W(+((J;(IR#;Q5U^^#1+QF.5$O1(A.?$^_;H'[$^B;R MDP= !3 M7>JB^0T))29!5=[QKMV^-B@]YVD'2%C"#2T#M_V@MQ )I:GHL2 M)S2A)>"GAT2S2V=RG7(40+9\( ;AY%" 2#/#U('XH4(C#E.FHBE38$;$EC42 MKAT4V6C\<<)A@J$[!+0T!S2-^V"C*27 *!6G>O\!'M<$\PL")H/Y'#0!'[[6 MRK;XV>]W*3H.HS<>'15L+;1661 '9+_?6QT?@\#D.=^8X)A[)_V#.<6^"GB9 MW[1UUR/*7B&UWN-R%GTYM_V\&=,@ E*-H [",5\ MHHM.3)T#6+L#-@/=2B>3?GZ^?1X[C(!]P[L; #:X-PU#/#)4QC9)(&&W=;!2UE!ZOWEAUA&1E#P6LP?SU9TCJ M@Q9R]=P[ZRIO\S6@]RUGZJ*@(8WFS:\Y\V0A?N6SF/9!FAH?^ST"^RT:]B") M[,60LAVKVUQ!H 5WL$-Y3?PU=/H_:9]6W$+G3E3B! 37AO81W/SY"KC1Y.:; E[2W^8S#$6S(/?]I(H[EB3[F>LR!G#_P+PH2OKO,&E MG"]Y*!J>1BF40ZX_U]3C>%+8HQ5['GT?+E"08CQQD"^^Q<=\P:2W&5UP,0A" MZ_FP&UK+FK3,,"!'69P"/K MN*LQGWS8?4Q;RONM?GH!:TVA$_'3[Z8\>MXE\/UIAK>7#=&EB8DOS/:N2CK> M%]V2466Z ?>:AR!1XM"\U-SHDJ71HHC*#@@JDQW?/S3W^ E?[8:#E>1H[C.YK[^SO^.\.+[/#V]T;ANCEC8O1;F]4 M)H,E!2,,NZQH2,8#-8_*0)*TR$:23#]&A&E&X*G/59O37YZMO[,2[/,UC?4Q M@H4L^2D,0O>7<>'SS7.W5L;5U1$L6<84E7TL7>X(IV_*[NEIHC MFTF39]@"G@'MZ,V!G8L7M35S\2RC^R^RLH3CUGH."L3+;%VI<&/X/I,:593Y MP:44 CC],I.4[II3-/LR?>,;2-03TCN\4_/\?@4^5GB&WH5'364YFK;IT3PJ M9GQG:S6X"Z4B.>#3?]885_HG567-M:98Q<-S6K<-$X]BO'$!6=&KT18(2S_;N9 M/C?V_2O]8TKA-CW=_2F7#-WQ8DKA>^)L_NCT$?Y],#\^^P59,S@(3U!*=\)UN!1KT#Z6<@C%I*\Q8R_G-MZ*L&'7F"[ULLCY5$WS3LE^A#SM5$ M?&USIBZKVKL -FV/E5<2:RF0C4Q=AM_@A)= /)5BLJ;?%;"#Q;\4BE* E?20 MM)CZF<$R^K5(H>R6?Q/CPHO \,.1[FGWLYLGX=TED5>(I<&Z+! PPL !D !X;"]W;W)K&ULK5;;;MLX$/T50BVZ-A#8DGP+TL1 +EVTQ18-DG;[L-@'6AI;1"E2 M(:DXV:_?0U)1G#8)VJ(/-BF2<^;,F>'E<*O-5UL1.7932V6/DLJYYF \MD5% M-;T)2;X^2++D;N!";ROF!\?*PX1NZ)/>Y.3?X&ORTOJK_WA7'B6I)T22"N<1.)IK.B4I/1!H7'682>_2 M&^[V[]#_#+$CEA6W=*KE%U&ZZBC93UA):]Y*=Z&W;ZF+9^;Q"BUM^&?;N#:' MQZ*U3M>=,;YKH6++;SH==@SVTR<,\LX@#[RCH\#RC#N^/#1ZRXQ?#33?":$& M:Y 3RB?ETAG,"MBYY67%#55:EF3L'^S-52O<[>'8 =G/CXL.Y22BY$^@3-@' MK5QEV1M54OG0?@Q&/:W\CM9)_BS@)34C-DGW6)[F^3-XDS[,2<";/($7 V/_ M'*^L,ZB$?Q^+,4),'X?PN^/ -KR@HP3E;\E<4[)\]2*;IZ^?(3CM"4Z?0__A M/#R/DJ4C]AC2>'!&:U$(-V1GK1%JPUQ%^!DB5L?,D<\<@^Z.ZA697OP]MB5, M.C*8%LIIQOU>*K"O#'<8L]X?]F?3FJ+"_F"#Y/CR(AFRQNB-X36#R)N-H0W@6+^N,:(@IM?L939*V4I(B4T\8E^\JX*PDTMO*)1P@DOL M0XDA<^L-LAP&=33XQEUK?>S^$*QD@/A9.^["G,6K&'8"NM6QK@@#^$/6,P %W0@?;8/DN M@3L_60H&%N>O9X.D<"1 ?1/$D\40)%BW(1D^1_?26IS!K@('+B1?24C-;14C M>BC#O0D8@U9%L@S%@>O1MO"/C*T(:F'>)VA#"F%)H)A&FRY+C;:>S'%1M'4K MPY;Z"#Z&G>H:!TWE+\!K8G]I:P.%M9:X24-E>7*VNT_%?Q3" !VUP6A7HRLN MN8J9X3L>=/!0// @O8?5;1C5"H6(NHCA:,?E 1N@VREIAPQW(I*EV&>%8"6\ MEX^$<-)Y1X[?MXKZ0X6]9(,LS8>A[9IL.NRLOJ>U!QDA8"A9R:T5.,RXO]4M M&\SVAVP C,$\';+C6K?*V9UU<>L2-PJ26?;JQ7Z>Y:^C!7Z??&Q/R\&=,V+5 M!J4]SBDW92BQMPC:57OLG2I&>TSA]02%';\)!X:RL407?>5%EE//$DYW9/G^ MP UB^%A"&YL%VM\G?^8QIP$Z"^XFORA]/@.MS LY_QGILVCUVZ6/?$)B%\^+ M'!189$&!U/?GV?"Q2WR\\["JR6S"\]&"+2*-;ZQ^M'^A'L>'V?WR^+S]P,U& M0#1):YBFH\4L828^&>.'TTUXIJVTPZ,O="N\LLGX!9A?:^WN/KR#_MV^_!]0 M2P,$% @ >TED57MU_TS^ @ 60< !D !X;"]W;W)K&ULK5513]LP$/XKITQ"FP1-DP)EI:U4&!,\("'8QL.T!S>Y-!:. MG=D7"O]^9Z<-12H5F_:2V.>[[[ZS?9_'2V,?7(E(\%0I[291252/XMAE)5;" M]4R-FE<*8RM!/+6+V-4611Z"*A6G_?YQ7 FIH^DXV&[L=&P:4E+CC0775)6P MSV>HS'(2)=':<"L7)7E#/!W78H%W2-_K&\NSN$/)987:2:/!8C&)9LGH[-#[ M!X$"C/R"()_CWB.2GD@IO%[A1EU*7W@YGB- M_C74SK7,A<-SH^YE3N4D.HD@QT(TBF[-\A)7]1QYO,PH%[ZP;'V/AA%DC2-3 MK8*9025U^Q=/JWW8"#CIOQ&0K@+2P+M-%%A^$22F8VN68+TWH_E!*#5$,SFI M_:'55R7$TO1!62[UP<(,6[DIA$69$5LX;$G.%0 ;.A']A&C MZ=Z'Y+A_NH/L84?V2H% 1+](?$:0ZZ%.P,$/N*K2+(.J.:VHTM%1!+85\G9"I@[BR618BL.PY+ !H1?WU?79!D+0L.\ET.OU@F2*QB]UGWQZ(UUMC M/[N-4EY\*?+2O1YLO*\NAT.7;E0AW:FI5(DG*V,+Z?'5KH>NLDIF+%3DP\EH M-!\64I>#FVN^=V=OKDWM..C7F\\W1C>7%=R MK>Z5_ZVZL_@V;+5DNE"ETZ845JU>#]Z,+]_.:#TO^+M66]>[%N3)TIC/].4V M>ST8D4$J5ZDG#1+_'M0[E>>D"&;\T>@3U8#$2F5K+._4>S?:\:?\Y(7VIRQY]B&]9.+@8BK9TW12,,"PI=AO_R2X-# M3V Q>D9@T@A,V.ZP$5OYD_3RYMJ:K;"T&MKH@EUE:1BG2PK*O;=XJB'G;^[5 M&A![<5N& .IZZ&'8GH\3!LE;X.2R3-*IN*#*?W&B9_+3&6/Y8KDTE4R5:\'* 2G[(,:W/SXPW@^NGK!UEEKZ^PE[=\:D1>5'#9Q/#D5 M![2+7VLK4.66OSDAK1*5U66J*YGG.V1;B?+,!-40'IBL3CU6E9D@O3I5CNI" MAULDG)H"\HY$5L)O350.V%W8WB5BN]'IAI?[C1).%DI()PQ,L1PDNF51:W0AJ3\@$(!]_(Z"YO# MP5)9W&J,"@XS3.I!YK7TA>VFOE3CE>>W@T M?HE,(ZOULB:+EU92.;(A:P4/=2JJ1V*)<)5*M\](4?Q07)$"V7N# G 0>6Z#/)F MWP)@55-4 8P-:/:V;Q0T 7_6BVC85;=CLV+7CW+?BHUQE?:P,D# F4O1%+DN MV*NR+I;P&;%J5"$F29-/'.GV+L&!6!04H,9D.:'ZTZ KZKJJ M,#?2#3AA5UL\,-JKWA.;8?+^E/WD-2W+<@4)LG M=GL*8O*@REJ%468P3K8\O'AF\0"GF66;152/2B+IG@XVJD0GUVNKUI+,BB(T M:6 PF44#^=!$9'0,AAIUI4M88I5ZQ.O '2JON/D1-3N"OD+G.7ERS$2-/L;[ MD^FG-H6)/V"/^[99=T 18O!*SL^1L=HZ+Z44R'\_$WYKF2))W%I)\ M&F@0[2F8PH3%&!8LGAN-$0KLL)@L2/\")L>VD>V;V8;^:'8LILEX-L+GV?S\ M&\(ZGR[$V6+RI"5%"Z;)^?E"S*#S0GPR_I"-<'XT%[-I0^L55]2Y!TG_3*TZE V MUA1$;*%HQ_/6:O1=C4YE51ZJUX@2Y\C& 32BXW9 M&H8H%I,_U/*HM^JRC0NL-.LR-/2FD,,496LP_^ L-9?(M]G/5*$XB3SP^0_[ M8;+S8043@M+Q"8K[F788ON]I2)1I7=Y%;XCQ$:N(3%41*0HS@6YI:MDG^\G< MM>IXIS0^-D/+F@S^GH>^MW_'WU^_^*0#PEHG^LM!>_J_8@U+K:/]#0 MSR)\/FP?LAS-=8,(-AP'14ADK-,>5HG>(&[,2[C.VKNI<5Q?;6,AHK6WIM^_ M06@48ERND\ M&V(C,SH3TJF??@@21X/[/_\HB^KJS> 855*ITO6-BP_;1^V1 MT:%EJ9/@,U%H/ WX-RNI1VYA /WO,$[;4+8*^>A"RC*Q0J?A$NR?)#J1/M7N M[JX0>,"?-!>Z\;/K&DQ*PP:Q#R=B4T-;=TZE#;N? KQ*-Z7)S7J7!#(('M%H MA:>Y#OOU3&PZ%1U#UD%%AFE!*%#4@.>[IW[S^?&YY.N2"<0N8]I/H7Y0.:7 M$O&DG&F87M9/;1DZ13R,0T.A_,9DY(Y635^!WW5.L\F'=&$1ZONFY"9K.'%" M'2FJLS 7K6'-CU?IJ?4GUDYE%-L4M=#T-W*7B\T+SM?M3@23J_PJ!Q_@1Z M5]KBPM3P&*EQ-/CK[2^_#HX);Y0%LV,,&-!C-SS"3,,QP1U?M4I:$K\FK@Z3 M:3!P$(9H>PB?ZB^FK-B@C'BXM#_^8""A@[9%YWH"U!IQ9M5&QY\UFHK-8Q3# M:%UI1T;0A.V)$Y:VC@=7"II".IF=HL#CC$=YU:U&V[!>_UNV9"Q$6*9_U!A/ M=/[1&=AX/]U<&LB.ZP2?"]13&5Q.''T33@!28"8@& X.6&T869F5KV5N_Y U?X M)*< #(A8NQ5RJ90/.LSY*TJFJ( +AVD3BGYX%.N)V,BQ"(Y@XGY!E?:.HDE; MYY2)SH!-QDTV/N3?5HE&D$5D"I.4DRT*E53C%O7=1RVS"VY4QP7WE?%T M^]2*V.GS7>S3+M0@EQ3S/5[ZB%\!C'_Q#R9^(RF5@:)E4RW7 /*D\[<]\%&S MY/QIP*%L:G_?[.;(6Q1@3<.@(L@;8@=YI[IM,?DR159QK&F J+1FD/H-?TL- MB.T-XET?]5UW/0Q*TZ^Z'KS%3'HUCQR(X7]UWGYM3*13+ JS"#Q*'>!1S)Q( MF-A30M5=*7Z]DN^^0M\>MTYB<4_/HO^KHRA1JS%]@II%QGRT.!;CR72/QS76 MS?#@#%2O1^ FBSGHVW@\BP2N%WMIZ2=GXH_C*9/'\=G+8'C6$!K12Z?ZQX @ M[I=[+A^(SE_J4G7?GB Q.4\F9\0V)_-D-KIH\1B/DRF.K_@WGTYZ>\Z2\XNY MP-$9GGWJF\U\=;HX#Q<+'&P/O0,9]MY0@9JL^3V<$SS>P\NJ]F[[JN]->,/5 M+0_O"3^@$VLTF5RM(#HZ/3\;"!O>O84OWE3\OFMI/'@07Q*54)86X/G*&!^_ MT ;M"]";_P!02P,$% @ >TED5=Y&Q6=&!0 @PX !D !X;"]W;W)K M&ULS5?;;MLX$/V5@1L4">#(LB0[<2X&DNP=Z")H M>GE8[ ,MC2TBDJB2E!WWZW>&E!6[M=/V81>+(!(ES9RYG1F:5RNE'TV.:.&I M+"ISWM,K M]^Y>3Z]48PM9X;T&TY2ET.M;+-3JNC?L;5Z\E8O<\HO!]*H6"WQ ^[Z^U_0T MZ% R66)EI*I X_RZ=S.\N$U8W@E\D+@R6VO@2&9*/?+#[]EU+V2'L,#4,H*@ MVQ+OL"@8B-SXU&+V.I.LN+W>H/_B8J=89L+@G2H^RLSFU[WS'F0X%TUAWZK5 M;]C&,V*\5!7&76'E99.X!VECK"I;9?*@E)6_BZ/%WA'HOUL0L"S=:BVJ!;OW7SU_P'CO9C\VM)UCWK#H%YB;_KZU7 <7K[@>=)YGKR$_D-%>AEI& =P" T^(G ;6_H'(E[Z M"+)**3/4-E 7HC)P3'1S_;3$8MT'FR.\?G4>1>'E/7]WZ^'E"="PH M'=N.RO>S\$40Q7Q*7 A^I%4]=-C46@MVPZC#&2A@XBC>!N-0>)=WCIC[6):/T MR< ]R7#ALS*GH$^63;TI?["=$<$^!FOV),K"@3N-W#9GQUAUG8$%1:5$4 M:UB2(E$.\%-#$8NJXINL#,5?<(<:4$NGRDZO46@3'#(FTE0W"*DP.1&,*!),1O#!:QW3FQ-()L$X@COFA//>W\UYU#AVH0*4L<8B;*56+BNJ8^9X9#B>;0O1AEOV;-@NW_Z987Q'M!8<[4\9 MB+$[\=:.'P'N9TXN<>EW-#+._2IIU.[H+)0HR)O;C0ZG'I\LJU!\/FA7#J$7 MR-W$#/2X61_:O#H_#>T8:W![*,RU*N$S:L4@41*RR;1UXQG--U5+Z&X0S:5) MJ?+$A+ ;-WYB^&VA@XV3#O9KW6Y4Q:UN<#"S_YL!41]P\,LQ>=Q5>$\>SU.6#?^8/$L[H]G;XAUM!=#@7-2#8.S40^T/_+X!ZMJ=\R8*4N'%K?, MZ92(F@7H^UPINWE@ ]VY<_H/4$L#!!0 ( 'M)9%7\H[5C304 -@- 9 M >&PO=V]R:W-H965T'?OWKT[ M4F<;ZS[Z-7.@VZHT_CQ;AU"_&(U\ON9*^:&MV>#-TKI*!=RZU"EVQ\=H:R?JXX"_-&[]W39+)PMJ/J*<.UW;SF-I\(,+>EC[^T:=>.,\H;'VS5&@-!I4WZ5[3=7*^,7NI-"=JLZ,J6.M?LZ5%W]?AL% !*7(_R%L!% M C"Y!\ IO;4FK#V]- 47=^U'2*;/:-)E=#$YZG#.]9!.QP.:C">3(_Y.>X9. MH[_3>_P=2OB?V<('!T7]>RCAY._I87_292]\K7(^SVKAW-UP-OW^NY/GXY^. MH'W:HWUZS/OA>AX">=3-89"'M?)'XRBW*)[Q7,B5!TN%"KA9:J-,KE5)'HL9 MO1P\:9.73<$4UHR>C-Q&IZHL(>S_K--A^\1N#.RMN^O/-PNO"ZT<:C"((A4C MOZ=.;0*[W%:U,EM"A8Q7L?M]6EVE:&MUP[1@-L2E1E.)\R']"4!(#.T<\2P: M#U*\1[E5_JG1+@$JM*^M9"J0'7?I%+B(*3V$BJ6S5322->(P<8)@7D=N$:^I M*=@[BQ("50X$;16=9 M;YD]COP RJ5R!=(OZ36K,JP'],;DPXA)@X0'U)P:4Z(B'<^!;P,XB+5!R?#4 M;;3G893D4OL<(;>L(F8O6?W:& ;@SZEJER*+TX@JII/*Z1]6T#9AP;<7WPL MF1^VHZ\%,MC%W'\R^;RR#VVQG;[1O+5R29W2;*[ :L8>$]81Y?OA?(ABY@TJ M( 0+E)>W^5J9%=.EK2KMX_;[*)N_O$1%M<'<:]J60J:?:\??%4^L\5Z_:Y.. M$=T> RGGI?6-U*\M9$&+;3<7A+/:P8&N47=:L6&'CH_O18!]T[TW6N[F0@&V MH^R7V>P*:$6[<2+H:H\H%Y'"=VKY1%'"A.ZZ9V8)ZX(=0DWL28B=^)K(1J4^ M,K$/NA(< _JO*5:M,&3Z>)Q\ZI:ZM0JDEDO4N)]*"=>W39+H/V\'G]!F+! , ML5N'!BN[$)7:@G.$=?WL\3O$_8 1HE"F MP%3PAW:FKW$+#;P!G8!\W#_];@/]C;/MK+!1,!]8ZM -$25/I? :Q.5I[KLN M@$X!]K3H>[?0J-A_(?B%Q1_D^&HVOX <16 /[&3E:8,3J_Q+A9R\;NHBRAR" M@W9OM&U\FU.T&9#&SF2V@U1BNYN%<:YUS?E;5#_FU49^C#V<9\L!%+D_)*-Z M-QJXXJ11.VR)QV_(5&9RRWM7JB^0>Q>]P?F_1W$P%=6Z;;LKK!TS5>GL>=^F M-CS4!Z.]TW;%;A6_*3S%D.G@W3_M/UMFZ;2^6YZ^>=XJM\)(I9*7,!T/?X#V M7?J.2#?!UO'LOK !7P+QWDB _F-N^C]02P,$% @ M>TED533JY<$7 P ^P< !D !X;"]W;W)K&UL MG55M;],P$/XKIS"A38+EI6L9I:W4CB% ($WK@ ^(#VYR;0Q.'.S+NO'K.3MI MUD&I*J3(\=L]?L[/^6ZTUN:'S1$)[@I5VG&0$U7#,+1ICH6PI[K"DE>6VA2" M>&A6H:T,BLP;%2I,HF@0%D*6P63DYZ[,9*1K4K+$*P.V+@IA[F>H]'H2R0)+*W4)!I?C8!H/9WVWWV_X+'%MM_K@ M/%EH_<,-WF7C('*$4&%*#D'P[Q8O4"D'Q#1^MIA!=Z0SW.YOT-]XW]F7A;!X MH=47F5$^#LX#R' I:D77>OT66W\\P50KZUM8MWNC -+:DBY:8V90R++YB[OV M'@XQ2%J#Q/-N#O(L7PL2DY'1:S!N-Z.YCG?56S,Y63I1YF1X5;(=3:[1DJE3 MJHTL5R#*#"Z+2NE[1)CC+1I1I@C'-V*AT)Z,0N(CG6&8MO"S!C[Y!WP//NJ2 M<@N798;98_N0J79\DPW?6;(7<([5*?2B9Y!$2;('K]?YW_-XO8/\O\B%6:&% MK],%3W/$?-OELXWNV#WTR M;QX/Z"4<(MTN^GL/V$W_)D=8:L4OV!U%+AK:9RQ_\769OYC@AHGM@BC5ENP0 M;G+#T]M1P6PKPF*!Q@M[+$L.=*7XS=H3+[-KXLZYYP:5(#;S@' $\4MNSN&- M2*62= ]X)\F3T)0S9K,MCMQWHTFHP^@>0>)PXW/8HUJ_4ZV_7S7.I5G-E\:R M35T>-NASTW.=W>$1;B7D M CFEN+)C.13KDIKG* MI_>%)BX6OIMS=4;C-O#Z4FO:#-P!7;V?_ 902P,$% @ >TED51]DMC]! M! &0L !D !X;"]W;W)K&ULK59M;]LV$/XK M!S4H$L"-7JPWN[8!)]FZ#DL7)-F*8=@'6CI;7"52(^FXZ:_?49(5![,-;]@7 MB2?=RW-WSY&<;*3ZH@M$ U^K4NBI4QA3CUU79P563%_*&@7]64I5,4.B6KFZ M5LCRQJ@JW<#S8K=B7#BS2?/M3LTFV'>[XJ MC/W@SB8U6^$#FE_J.T62VWO)>85"YZZ_W[)G?*9<$T7LOR M,\]-,752!W)WQ!EN\5\%1AP]87\+0&T#@!<$1?\,^_V'C;WA*_O_, M_(;KK)1ZK1!^GR^T4<2B/_:5H8T2[H]B)VNL:Y;AU*'1T:B>T)F]?>/'WOLC M.81]#N$Q[[,'FM1\3:#E$OI\%L]PC[54QK8.'G!%DV3V(3_J>S_RQP)A*4L: M:"Y6T$9HIYI_0PW$(L@*JB2MN6A%IM2S56:57 MCD:YVD.H67M,$:R$-*\=P M3LN*-&AZ]07<%8RF,,.UX1DKX1;SYGWN7\"CU8AY+<0XB> (.Z*> M'=')[+C!)1?<8,?VO!/?_40[XQ[Z[Z/+T6 GTT6_\*6K+'\)SMK9(UYD):VI M9.-]-7M-CP]*DNH\R];5FEI(Z7RB(^USLRMC_@[F3ZCHE*&AL$>5!3*O:#KX MM[;==ZBXS.'\-V2*O.W4IN1+W$&GQ_"H6$Y>Z-ALZEA3-,N2,_!]>FR;WXB? MW'G'3G[8HU7<6G4V-X>C7S>' A5"84M57?!:$V\"+R86^5$"_L +1^![.T@' MEMPY@F 5OH8=A3$,8Q_\-(*4 C_105U3^0QFA9"E7#WO\)\\#Q.(1AZ$80*C M+K?#F86#)!W9L?-2LHU3O[L*%6+57,HT9/9D:&\N_=?^WC=OKSLOZNVE\9:I M%1<:2ER2J7>9T/:DVHM8*QA9-Y>?A314]699T-T5E56@_TLIS5:P ?K;\.QO M4$L#!!0 ( 'M)9%75J?7+E , %\( 9 >&PO=V]R:W-H965TZ"D MDT6$$A62LM/]];NC9$5&'>]E+^*/N_ON^\@CJ<5.FR>;(SIX*51IET'N7#4/ M0YOD6 A[H2LLR9)I4PA'0[,);650I#ZH4&$T'%Z&A9!EL%KXN3NS6NC:*5GB MG0%;%X4P/]:H]&X9C(+]Q+WC^7K"_M[AN\2=[?6!E<1:/_'@MW09#)D0*DP<(PAJMGB#2C$0T7AN,8,N M)0?V^WOTSUX[:8F%Q1NM_I2IRY?!+( 4,U$K=Z]W7[#5,V6\1"OKO[!K?"_' M 22U=;IH@XE!(Y2?AQ&IA] X,>Q,:=[Q4 M'TWD9,F;\N ,627%N=5G(0U\%ZI&N$5A:X.TXL["V:.(%=KS1>@H"_N&28NX M;A"C-Q#'<*M+EUOXM4PQ/8P/B5U',=I37$GT'N$!W!M+=+VB#*%KU+$4DDGB7R[=RE0H=]C4ALCRPVLA97V MF)K3^1YSA$PK.J\,XGPA@-=5.G!L9$);)F3)T8!X)76F7EF=0]&C)>@,[XG% M3 R$FP-MKL,B1M/M,)S)DBI=*3JT!/$5MZA@U+91VX[A43NAVN68PXVP.>!S M+8F5K]_W,!I,KJZH_?!N%HVBCP>]QO:-M!B0Y1:M:ZM^= ZS6>>X;VFJM]AS MH/M@)TP*"14Z5PP%1N>=]]GTL/][7>+_KBX:3*+I&^H:VW%UOUS]I(ZF3@L: M3?M=1N$*T3_AQT*),D&:2U2=4FWTC2R[=C6IRNHRM0/8Y3+)06<9:81,U0D9 M^:+VKG2OHN'"271![X_U%NC5U@5SL'B V>;C>*Y27C#W RQ777-*=.;Q1,F# MG70YQ*0"E# ;]-5K"Z$47:_FB3@EHI*T"_*?)CG;<[KCX9D2,G F7X@@B=4% M$N'8]5)Y>KUSPJF=)WRP)I;B'!JZUPFIMGPTGFOM:-!RJ(Q,".W8)1+V+OT" M20$_;98$UJ5K[O]NMGL]KYM'X]6]>7IO:0$D+;S"C$*'%U?3 $SSG#4#IRO_ MA-!RT8/DNSG] :!A![)GFDBW T[0_5.L_@502P,$% @ >TED5;L,&[?< M @ 708 !D !X;"]W;W)K&ULC55M3]LP$/XK MIVR:0&(D35M@75NIY44P#8$H8Q^F?7"2:V/AV)GMM+!?O[.3IH!*M2_Q2^Z> M>Y[+W66X4OK1Y(@6G@HAS2C(K2T'86C2' MF#E6)DM[,E2Z8I:->A*;4R#+O M5(@PCJ*CL&!/*O-B#4Y(H]>@.5]DH MB!PA%)A:A\!H6>(I"N& B,:?!C-H0SK'E_LU^H773EH29O!4B9\\L_DH. D@ MPSFKA+U3JTML]/0=7JJ$\4]8-;91 &EEK"H:9V)0<%FO[*G)P_\XQ(U#['G7 M@3S+,V;9>*C5"K2S)C2W\5*]-Y'CTGV4F=7TEI.?'5]PR63*F8 K::RN*-_6 MP-X]2P2:_6%H*8:S#-,&;UKCQ>_@=>%:29L;.)<99J_]0^+6$HS7!*?Q3L 9 MEH?0C0X@CN)X!UZW%=SU>-UW\,Y0\R5SI?!*,9,97&*VX'(!$U!4%273!&85D!G<'_TN=P'+!5.'<*EVN%JM(@6I7JC4KE59J-RF2C,GVC M4F]4IFN5S*LD+#N /2ZI%85PX/M !6JQ2 A]7:7PK9*X.9UO(_P1>@>Z^]O;=G9.ZI&Q,:\' M[S735/8&!,[)-3H\[@>@ZV%6'ZPJ_0!)E*5QY+SY6RZX,+T/Y1 MQO\ 4$L#!!0 ( 'M)9%5O0NS.40, &$( 9 >&PO=V]R:W-H965T M65M;"V(AW83NZU%48:@6L59DHSB6D@=S29A[M;.)J8A M)37>6G!-70O[N$!E=M,HC?83'^6F(C\1SR9;L<$5TJ?MK>51?$ I98W:2:/! MXGH:S=.;Q=#O#QM^E[AS1WWP2G)C/OO!NW(:)9X0*BS((PAN[G&)2GD@IO&E MPXP.*7W@<7^/_DO0SEIRX7!IU!^RI&H:74=0XEHTBCZ:W5OL]%QYO,(H%_YA MU^U-(B@:1Z;N@IE!+77;BH?.A^\)R+J +/!N$P66/PL2LXDU.[!^-Z/Y3I : MHIF&TV5@S>ZQ/)I?,S4#ORR/;]%=A9PA=M+&"07D"59=@9O<- ["'B# M9_ ZA7_.67XF_3FEL(8:G(7R9W+BM*' :<1TXM/<8S5Z]2$?)ZS,$AP>" MPW/HLQ677=DH!+.&927T!AU(#50A+(02N@@K\Z)HZD8)PA(^\)J%I:F93>7+ MY1[A-^, MGK!L[Z<@^+71>'C-X"7TTB3KA[9KTF&_B_HWK0O(D8]'Y$.J4,(YN9:%\&>. M@][5=1]ZC-$;)7V8UZ;1Y([V,1Q/(" "\!@ &0 'AL+W=OJ/YP*WW"WYPW)H/;7!.8J5>7.<8%"."'"^-UH M!NV6+O!C>Z?^W7LG+S$SN%#BF: I#)6%4TP$116Q0+!*E@PG7+)!-PB$S8_ MASN9=.#TT,OK/EGVX5]+F!I8RQ?1S?$CXK8=HYV$> M'11<8]F!?O<W,"3P=1_ M1564E468,\,38#*%&RYH((5_[>[S>)!BO\?''"%3@NX]R4.=3[K!)3)+T[(J M8MJ5J).:VM3454.=--1Q2YTVU+BC+BG>1P$[)G%'\)AKQ$\Y")1!%CV)2Z-3 M+NFJ"4'G:YJ0"!P:32W'(T(U@6I5#O1$/W/'D!5;IO:,[IE"C;>.)\UM8JR2V-NP,@ MO[X6RP0_3@)!'D>X.\%HV"?&;[ O"<,/%:5 O?%UTY!<)6U=7-K1MC3/ZHKT M=WE=U^^9WG!I0&!&H=W.\"( 7=?*NF-5Z>M3K"Q5.]_,Z?>"VBV@^4PIN^NX M#=H?UO0/4$L#!!0 ( 'M)9%6 %OK.A04 H/ 9 >&PO=V]R:W-H M965TZ/IY.59*SDJJ)J%F%+VLA2ZKQ*K.IJB6CJ14JBZD_FRVF)>65LSRQ M2(:7?"*74FBFK*D\N&<%6)SZGA./W'-LUR;B>GRI*89NV'Z+M-39V8 L8(EVFB@ M^+MC%ZPHC"+ ^-;I= :31G![W&O_Q?H.7U94L0M1_,53G9\ZL4-2MJ9-H:_% MYB/K_)D;?8DHE'V23;LV"AR2-$J+LA,&@I)7[3^][^*P)1#/OB/@=P*^Q=T: MLBC?4TV7)U)LB#2KH#+5Lɿ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�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�'P0B!UWL9&C?,L,FXR4W(.RJTF;;3A3 MG33!\=R>RMPHFN4D9R;S-5-X=+#4\HF"$1(ZFIC>*)[3EE\#'G1M-OB@K,&F$F2/ -7+U%P[B@UDV3C+9M M#3R'1RZ$W6@4&#+2H@;)P:#[PJ"XP: ./,KTKMNF?5)+71EV#;_+?$?Q0-/.F&OR@38T:N"%;J4G3.0JY_\@3NF.H/;D6+2S%3;T?5*XWJM1U]P!/V2LM]J;^5A1H&$ M*Y[G/%_9Q-X4'KVBE"O"^0W\6QO8A1'%-E%QF=@+?S>)_<$HV-7 #4JX02O< M>PH%B_9:AL$Y0^3']0RW)<-M*\-SX9W7(MR>(]PT,@Q+AF$KPP/+$RI6=$:Y M"_$E\DN8AC5,81-3%%;E(7Q]Z""171XTAQV^B9I> ]E)X8I:4^^3*[B8WDQW MJ.@! 2Z0@*H@PCO&%3PSL44+6Z1F+5KT';(RBBL3XO^?EUN=.B.<@ZVGJQ)4 M:U*QY>#$V=V^'W8:W%W5J*BU2'R5II1*T7>5L67XK8.T?L=?UAMP&Q*@;1!=7@/*4OQ>R?Q5MO MZ'>_C;?@Y(F:H5JYA[B&1&YS4[Q6R]'RL3\MGKC5\N)+X9$IRA0- I_ NI*'GLVNNZ8,%E5U \TLIS;%C-R@_@2;_ 5!+ P04 M" ![26153?3A*=D# Q#0 &0 'AL+W=OF2P*D[>ZV#QV"9NU]5F,F,4ZV,DE)KL-^ M_"@IL3W4-A)LRX=8DD7J(45*]/@@Y#>U0=3P/>.YFG@;K;=W0:"6&\R8\L46 M\IGA0E3884]Z$^&8ZOR83+S1$R'&IC0I&CST^(.=&$W'\<53J%6L:P6K[ MI/VS-9Z,>6,*'P3_FB9Z,_%N/4APQ79!V'*[A2SE(]-L.I;B -+,)FVF84VUT@27 MYF97%EK2VY3D]'2Q81)O[LFN!!Y$1INMF'77U8("(-EQ!+&"&>?PNV3TSOI2 MP3-RIDE$"YBCM,&1+Q&L-GC)4ZWH/T$)>H,PYR1Y#5>/J%G*J773*/0) E"F MKR#-W5BG,O"4J/@9Z),_BD? MD L+/\8G/]['K0H7N/6A&W8@#N,87A:/[2LU"UVK&M7ZC:LU."Z M.A\X1;UZ12;?[]26+7'B44(KE'OTIC_^$ W"GUHP>P5FKTW[]#>1[U&9&&$: MWG"=YGF:KTTP;5&F(H$KVD#GE&OXJ]8]S@BW3.0"V!PR^VGDQ^-@7P/7+^#Z MK7!?*)8-VKD,_8\,H=^M9Q@4#(-6AE?GG7,1!A\1;D*_5\\P+!B&K0P/)HJX MV:,\ 8JJ%::7, UKF1KVYK9@NCT_<)"X+@^9V[KM&M5CC0JL46O:?;7G.R8W MLSU*NJ_ QA#0H8OPF:427AG?H2%U65G'-?H?\C$*RY,^_/<9N5.)M<$ZUWBY M/,)J3UFWY+#BZ7[/[S:$0%2YE:*S$_12I..%%U>8A@-_. K+7]3 %Y=\\;G) M>RE>_!&O/_+#ADR.RFLA:CW.VW+Y4L1N#>+0[S<0EC="=,&5\#&S+Z7L?0B] M8>R'T1G;7%X34?L]X:JC-UL=S=D[5:,:9I)BV#FJN!RNON8>&*2CC<% M'%&POVS?$,*K-2K"[.6,F6)9"UBF9&U-]",-Z-F]7AR6E$LR'LE%>5.:.IBIA30IB;M0X&Z?LY3TX_@_GU_OQLP8X)Z%7]/(%HA<]7-=BF'3\ M,NGGQ7'YJUWY->'4JG7L4XP\]) W3)26>'-N96R(8;N?XU&NY&9;(^("5IF6 M+'BD(B43*OA4E%JK4W*I=)/; M97#?TW;X'K#N@4$N1&=P0%Q@/*JH,4S+&]MI!C?!)U#0MN]7E758:+KJ#R[) MAM#<;)*ITAG379H^68?&(\%RL*-Y,8>[454(H#&JM(V,TT))VGA8,]J&E9TQ M(>[@.?R>[V@O\ZT]Z\&.R:YI#;5-)^,ZH+^MYK2W9:-7Z085?U3FT\).1S9] MJ&UVJUG.ETU_F7<&,/4^KDZK2JP^"E[(DKG)OSCA>$37O&"N-/]ELT&IS&R M:1(\,FWX;#OR4]/JGBW-NIR6.>YY<(2>_^XZ%TPR3<6V:5O[A[S*KW8<7?TK MR\UOE7W#7H_MR_7035X>@\GX&$P>14T.C\%D8I-TF"ZX,)PV?;F/,N8?'*GUX^ZP:G-QF;$ERR9M5Q?3IAG8ALW:7D#81VZ: MRX]@'(?Y$<"P/)@#C.-86)[_:3Y#=#X.P[P-O<@0Y0Q1CF/YD$GSP?+X.8F] M_#--DBB*8VQ%)Q.O@PFV;G$,/WXUS!LPL#R0Z<_6&M]MO$*>KP-L3Y^K$&RF M>"5B,\77&A#_N@$C2?R[C>4!!K8+6.U ?G\>J"D_)XI@5S%OV!.,(TF"(5"+ M_AJ-8V1U8OCX]P=[2J(H2?P(8'X'480A\#3B".8 /&!(%#7OP;WW4;A^3X6; M_^"-?P-02P,$% @ >TED59>*NQS $P( L !?3T\ M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5* M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'[&7BDRV*EI\H<=YPI$\/UOV86_M#_*RU\>-D M%<+Z=##PY0IJZ?^R:S"X9V%=+0-NNN7 KQW(RJ\ 0JT'Z7!X,JBE,LGG3_MC M3=T@WK !RJ"LP<:FX5[!@W_>WVR*K?)JKK0*C^.D_:XA$;4RJE:_H!HGPT3X ME7WXVSKURYH@]:QT5NMQ,MKMN <75/FB>=9 WLFY;UN"G-]*!!DG)T,\X$(Y M']H>[?$E,FX!.^^V-L%>*AW 362 K\YNULHLF\/@60RBTVC'8?^Y&\13]W^& MT2X6JH2)+3Z 31^I=8^$4;6,$[.[1:%_W)5[4XP(%DT M7.Y4X0YW5;6,G#RF N.A$OC-6ZTJY*C$K,'!GT:0*0&9'A'R>QI!9@1D=A3( M+U)+4X*((',",C_F2&819$% %L>$S"/($P+RA!?RB_3*"[L04P<>N[8]A#3( MN:EK&4&^)R#?\T)., CZH,(&&2.B#P31!UZB6^1QFQ*), *WPW51K[5]!! S MV,9!\2,!^9$7\JNUU8/2NN6["2N,V%=XA0>4J%[R(MY;NC"BEC)B==%+6E%)(RJP04L==3$HA*;-"2"%W,:NF=5Q9$PI MJZ3<5ND+VWO(MS$E)9>462Y]\;L7DI),RBP9,I!W;TS*-RFS;WH">>]04K)) MN65S(*(_@<:8E'A29O'$2RKQ9@)!*MT=1$H[*;-VZ'@>K^\S2CO94;43K_ S M2CL9LW9HS"+&I+23,6N'MF/GHI/U,6;MT)B=BTYY)V/V#HW9N>B4>3)F\Y"+ M_VY-E#)/QFP>;O88U+X92%^Q4["D+YBI<1H7]'/*0CEW[:T/\\Q[P.@Y M[\9-RD(YLX7Z,"?*R^72 >9+\;-.RD(%LX7Z,)]OS7@T"\I"Q6M8J&]YOION M,29EH>(U+-1;19CAT:L8D[)0P6PA$K.3%A>4A8K7J,$=Q.R\+D"^+]!::+!_ MNZ:"A3)0?<._\-A>2EU.G6@^=@\!\Z(IW2\V6I]CVXVYMK+:OZRS?]'H\W]0 M2P,$% @ >TED5;P!UL'@ 0 [" !H !X;"]?Z) M0A&.14&#YE36V/+UW_B397O^DG9MV7:'O-GV>7+<[PYYT6Q*Z1]"R,M-VK?Y MINO3X7QDU0W[MIR7PSKT[?*]7:>@T^DL##]G-(_SGS,GKZ<^_65BMUIME^FI M6W[LTZ'\,CA\=L-[WJ14FLEK.ZQ3633AN+ONSN&RD9OSY&;R_+9HAN"X(M!&(+DBT$9@NB+01J"[(M!&X+PBT$<@O2+01V"^(M M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6] ME4!O1;V50&]#O8U ;T.]C4!O0[V-0&\;O2PAT-M0;R/0VU!O(]#;4&\CT-M0 M;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#;46\GT-M1;R?0VTD4#OB'I' KTCZAT)](ZH=R30 M.XX^5OZGWKF<=BE?>[[7>/W_I+JYNZ:OPX681@'QCS^8)J[5-CJ8DC,^-J'>)?-V=6YTL] M)R8&@R'+31.H"?W0UD@FHR>:Z545>L^;>-N7IADGCBJ?]!YW$]NL<:*MKE/MPHNNXRRV MJ9@/VXI\>K[$B1[-;%;F5)A\5<.=.$71*&NTEW1F_/)(>XP[7[YU?E= MF7.!<>;4&>OCB3FZ/.YP).WJOHV%R(7R_",>$V/IJY^/VM,NJ/AE=MS>#^.6 MW7EXUEVNW^.O9WRL?V$? J0/"=*' NDC ^EC"-+'+4@?=R!]W(/TP0&UL4$L! A0#% @ >DED M5; )&,?N *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ >DED59E&PO=V]R:W-H965T&UL4$L! A0#% @ >DED56571EG:!0 3!< !@ ("! M!0X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M>TED55OINW#Q" %TX !@ ("!+AX 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ >TED5;8$MEXY P Q 8 M !@ ("!=34 'AL+W=O0X !X M;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ >TED M52CP-V'>&0 4TL !D ("!-TH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >TED5>P]K8]6"P F"0 M !D ("!+W 'AL+W=OP M>&PO=V]R:W-H965T&UL4$L! A0#% @ >TED56K;E-NM"@ #!T !D M ("!LX, 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ >TED533JY<$7 P ^P< !D ("!F)D 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ >TED5;L, M&[?< @ 708 !D ("!*:4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >TED58 6^LZ%!0 "@\ !D M ("![:X 'AL+W=O((UK4# !/"@ &0 @(&IM >&PO M=V]R:W-H965T&UL4$L! A0#% @ >TED5;T?F,"Z @ 3 < !D ("! MK+L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ >TED57D8^Y27 P GPT !D ("!]<0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >TED51\2IPK: M! $1T !D ("!,=, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >TED5:(?SXJ= P #1, !D M ("!,^\ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ >TED51)X9O&1! *1T !D ("!@/H M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M>TED5:]7 [I_ @ ]P4 !D ("!#P@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >TED5<_*!-Z> P MIA$ !D ("!Z1(! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ >TED5&PO=V]R:W-H M965T[_" , *\+ 9 M " @;PG 0!X;"]W;W)K&UL4$L! M A0#% @ >TED51@!B5K2 P #@T !D ("!^RH! 'AL M+W=O&PO=V]R:W-H965T7!E&UL4$L%!@ _ #\ ,!$ "9 0 $! end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 184 234 1 false 71 0 false 10 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings Condensed Consolidated Statements of Earnings Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity Condensed Consolidated Statement of Shareholders' Equity Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 7 false false R8.htm 0000008 - Disclosure - Divestitures Sheet http://www.cardinal.com/role/Divestitures Divestitures Notes 8 false false R9.htm 0000009 - Disclosure - Restructuring and Employee Severance Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeverance Restructuring and Employee Severance Notes 9 false false R10.htm 0000010 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 0000011 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings Long-Term Obligations and Other Short-Term Borrowings Notes 11 false false R12.htm 0000012 - Disclosure - Commitments, Contingent Liabilities and Litigation Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation Commitments, Contingent Liabilities and Litigation Notes 12 false false R13.htm 0000013 - Disclosure - Income Taxes Sheet http://www.cardinal.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 0000014 - Disclosure - Fair Value Measurements Sheet http://www.cardinal.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 0000015 - Disclosure - Financial Instruments Sheet http://www.cardinal.com/role/FinancialInstruments Financial Instruments Notes 15 false false R16.htm 0000016 - Disclosure - Shareholders' Equity Sheet http://www.cardinal.com/role/ShareholdersEquity Shareholders' Equity Notes 16 false false R17.htm 0000017 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc Earnings Per Share Attributable to Cardinal Health, Inc. Notes 17 false false R18.htm 0000018 - Disclosure - Segment Information Sheet http://www.cardinal.com/role/SegmentInformation Segment Information Notes 18 false false R19.htm 0000019 - Disclosure - Share-Based Compensation Sheet http://www.cardinal.com/role/ShareBasedCompensation Share-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 20 false false R21.htm 0000022 - Disclosure - Restructuring and Employee Severance (Tables) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables Restructuring and Employee Severance (Tables) Tables http://www.cardinal.com/role/RestructuringandEmployeeSeverance 21 false false R22.htm 0000023 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets 22 false false R23.htm 0000024 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.cardinal.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.cardinal.com/role/FairValueMeasurements 23 false false R24.htm 0000025 - Disclosure - Financial Instruments (Tables) Sheet http://www.cardinal.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.cardinal.com/role/FinancialInstruments 24 false false R25.htm 0000026 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cardinal.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cardinal.com/role/ShareholdersEquity 25 false false R26.htm 0000027 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Tables http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc 26 false false R27.htm 0000028 - Disclosure - Segment Information (Tables) Sheet http://www.cardinal.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.cardinal.com/role/SegmentInformation 27 false false R28.htm 0000029 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.cardinal.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.cardinal.com/role/ShareBasedCompensation 28 false false R29.htm 0000031 - Disclosure - Divestitures (Details) Sheet http://www.cardinal.com/role/DivestituresDetails Divestitures (Details) Details http://www.cardinal.com/role/Divestitures 29 false false R30.htm 0000032 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 30 false false R31.htm 0000033 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 31 false false R32.htm 0000034 - Disclosure - Restructuring and Employee Severance Narrative (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails Restructuring and Employee Severance Narrative (Details) Details 32 false false R33.htm 0000035 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 33 false false R34.htm 0000036 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 34 false false R35.htm 0000037 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets Narrative (Details) Details 35 false false R36.htm 0000038 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) Details http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings 36 false false R37.htm 0000039 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details) Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails Commitments, Contingent Liabilities and Litigation Narrative (Details) Details http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation 37 false false R38.htm 0000040 - Disclosure - Income Taxes Narrative (Details) Sheet http://www.cardinal.com/role/IncomeTaxesNarrativeDetails Income Taxes Narrative (Details) Details 38 false false R39.htm 0000041 - Disclosure - Fair Value Measurements Narrative (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements Narrative (Details) Details 39 false false R40.htm 0000042 - Disclosure - Financial Instruments Narrative (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments Narrative (Details) Details 40 false false R41.htm 0000043 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 41 false false R42.htm 0000044 - Disclosure - Shareholders' Equity Narrative (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity Narrative (Details) Details 42 false false R43.htm 0000045 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 43 false false R44.htm 0000046 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 44 false false R45.htm 0000047 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 45 false false R46.htm 0000048 - Disclosure - Segment Information Narrative (Details) Sheet http://www.cardinal.com/role/SegmentInformationNarrativeDetails Segment Information Narrative (Details) Details 46 false false R47.htm 0000049 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails Segment Information (Revenue by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 47 false false R48.htm 0000050 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails Segment Information (Segment Profit by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 48 false false R49.htm 0000051 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails Segment Information (Assets by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 49 false false R50.htm 0000052 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details) Sheet http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails Segment Information Disaggregated Revenue Within Reportable Segments (Details) Details 50 false false R51.htm 0000053 - Disclosure - Segment Information Revenue by Geographical Segments (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails Segment Information Revenue by Geographical Segments (Details) Details 51 false false R52.htm 0000054 - Disclosure - Share-Based Compensation Narrative (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation Narrative (Details) Details 52 false false R53.htm 0000055 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 53 false false R54.htm 0000056 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 54 false false R55.htm 0000057 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 55 false false All Reports Book All Reports cah-20220930.htm a23q1_10qx093022xex3113.htm a23q1_10qx093022xex3123.htm a23q1_10qx093022xex3213.htm a23q1_10qx093022xex9911.htm cah-20220930.xsd cah-20220930_cal.xml cah-20220930_def.xml cah-20220930_lab.xml cah-20220930_pre.xml cah-20220930_g1.jpg cah-20220930_g2.jpg cah-20220930_g3.jpg cah-20220930_g4.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cah-20220930.htm": { "axisCustom": 7, "axisStandard": 26, "contextCount": 184, "dts": { "calculationLink": { "local": [ "cah-20220930_cal.xml" ] }, "definitionLink": { "local": [ "cah-20220930_def.xml" ] }, "inline": { "local": [ "cah-20220930.htm" ] }, "labelLink": { "local": [ "cah-20220930_lab.xml" ] }, "presentationLink": { "local": [ "cah-20220930_pre.xml" ] }, "schema": { "local": [ "cah-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 465, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 21, "keyStandard": 213, "memberCustom": 27, "memberStandard": 42, "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.cardinal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings", "shortName": "Long-Term Obligations and Other Short-Term Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Commitments, Contingent Liabilities and Litigation", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation", "shortName": "Commitments, Contingent Liabilities and Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Income Taxes", "role": "http://www.cardinal.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Fair Value Measurements", "role": "http://www.cardinal.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Financial Instruments", "role": "http://www.cardinal.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Shareholders' Equity", "role": "http://www.cardinal.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Segment Information", "role": "http://www.cardinal.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Share-Based Compensation", "role": "http://www.cardinal.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Statements of Earnings", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "shortName": "Condensed Consolidated Statements of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Restructuring and Employee Severance (Tables)", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables", "shortName": "Restructuring and Employee Severance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.cardinal.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Financial Instruments (Tables)", "role": "http://www.cardinal.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.cardinal.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Segment Information (Tables)", "role": "http://www.cardinal.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.cardinal.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Divestitures (Details)", "role": "http://www.cardinal.com/role/DivestituresDetails", "shortName": "Divestitures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i73291183b5c94c569731d6000358a035_D20210701-20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Restructuring and Employee Severance Narrative (Details)", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails", "shortName": "Restructuring and Employee Severance Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "shortName": "Commitments, Contingent Liabilities and Litigation Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i3a25416abfca4ca5a2c8a79563abdbf6_D20211001-20211231", "decimals": "-6", "lang": "en-US", "name": "cah:JudgmentForLostProfits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Income Taxes Narrative (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "iee5307df37214cb5856b80573d7cd236_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Fair Value Measurements Narrative (Details)", "role": "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "iee5307df37214cb5856b80573d7cd236_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Financial Instruments Narrative (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "shortName": "Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Shareholders' Equity Narrative (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ib8fa2946d75244f5af4e048c4b6f80f0_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "id865979318b34ac9a0006dc78693a91a_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "cah:Numberofsharesexcludedfromcalculationofdilutedshares", "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "cah:Numberofsharesexcludedfromcalculationofdilutedshares", "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Segment Information Narrative (Details)", "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "shortName": "Segment Information Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "0", "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "shortName": "Segment Information (Revenue by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "if915e60e430a448e95ac1d3210262b21_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i6de7ec379a8f45abaa3a725e99891e6a_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ic9365f443f224be298ffcc176e64bb3d_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "shortName": "Segment Information (Assets by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "ie81002aafca94fc2b38566fff63f36b6_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i3061556bb3664f40a526ed65a094ef2e_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statement of Shareholders' Equity", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "shortName": "Condensed Consolidated Statement of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i3061556bb3664f40a526ed65a094ef2e_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)", "role": "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "shortName": "Segment Information Disaggregated Revenue Within Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Segment Information Revenue by Geographical Segments (Details)", "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails", "shortName": "Segment Information Revenue by Geographical Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i74b65aec35854386926330a8514839c9_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Share-Based Compensation Narrative (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i4d418325c9cb4eb4a8d45d174bfd4b22_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i22ab637b9b2d4e64a547c5de3c7224a8_I20220630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i217061d4807f455b88c7f795a4fa433d_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i217061d4807f455b88c7f795a4fa433d_I20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Divestitures", "role": "http://www.cardinal.com/role/Divestitures", "shortName": "Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Restructuring and Employee Severance", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance", "shortName": "Restructuring and Employee Severance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20220930.htm", "contextRef": "i2b05f6c142134569a5186e72d5061146_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "cah_A1BillionShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "$1 billion share repurchase program", "label": "$1 billion share repurchase program [Member]", "terseLabel": "$1 billion share repurchase program" } } }, "localname": "A1BillionShareRepurchaseProgramMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_A2.616Notesdue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.616% Notes due 2022", "label": "2.616% Notes due 2022 [Member]", "terseLabel": "2.616% Notes due 2022" } } }, "localname": "A2.616Notesdue2022Member", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_A500MillionShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "$500 million share repurchase program [Domain]", "label": "$500 million share repurchase program [Member]", "terseLabel": "$500 million share repurchase program" } } }, "localname": "A500MillionShareRepurchaseProgramMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_AggregateAnnualAssessment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate Annual Assessment", "label": "Aggregate Annual Assessment", "terseLabel": "Aggregate Annual Assessment" } } }, "localname": "AggregateAnnualAssessment", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_AlamedaCountyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alameda County [Member]", "label": "Alameda County [Member]", "terseLabel": "Alameda County [Member]" } } }, "localname": "AlamedaCountyMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Amortizationandotheracquisitionrelatedcosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Amortization and other acquisition-related costs", "terseLabel": "Amortization and other acquisition-related costs" } } }, "localname": "Amortizationandotheracquisitionrelatedcosts", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "cah_CVSHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CVS Health [Member]", "label": "CVS Health [Member]", "terseLabel": "CVS Health" } } }, "localname": "CVSHealthMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CardinalHealthAtHomeSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardinal Health At Home Solutions [Member]", "label": "Cardinal Health At Home Solutions [Member]", "terseLabel": "Cardinal Health At Home Solutions [Member]" } } }, "localname": "CardinalHealthAtHomeSolutionsMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_CareFusionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CareFusion [Member]", "label": "CareFusion [Member]", "terseLabel": "CareFusion [Member]" } } }, "localname": "CareFusionMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CarryingAmountofLongTermandotherShortTermBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings", "label": "Carrying Amount of Long-Term and other Short-Term Borrowings", "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings" } } }, "localname": "CarryingAmountofLongTermandotherShortTermBorrowings", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cah_CashReclassifiedFromAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Reclassified from Assets Held for Sale", "label": "Cash Reclassified from Assets Held for Sale", "terseLabel": "Cash Reclassified to Assets Held for Sale" } } }, "localname": "CashReclassifiedFromAssetsHeldForSale", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ClassActionLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Action Lawsuits [Member]", "label": "Class Action Lawsuits [Member]", "terseLabel": "Class Action Lawsuits [Member]" } } }, "localname": "ClassActionLawsuitsMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CommittedReceivablesSalesFacilityProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.", "label": "Committed Receivables Sales Facility Program [Member]", "terseLabel": "Committed Receivables Sales Facility Program [Member]" } } }, "localname": "CommittedReceivablesSalesFacilityProgramMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CordisDivestitureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cordis Divestiture", "label": "Cordis Divestiture [Axis]", "terseLabel": "Cordis Divestiture [Axis]" } } }, "localname": "CordisDivestitureAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/DivestituresDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_CordisDivestitureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cordis Divestiture [Domain]", "label": "Cordis Divestiture [Domain]", "terseLabel": "Cordis Divestiture [Domain]" } } }, "localname": "CordisDivestitureDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/DivestituresDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CordisDivestitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cordis Divestiture", "label": "Cordis Divestiture [Member]", "terseLabel": "Cordis Divestiture [Member]" } } }, "localname": "CordisDivestitureMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/DivestituresDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_DiscountRateFairValueInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "terseLabel": "Discount Rate, Fair Value Input" } } }, "localname": "DiscountRateFairValueInput", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "percentItemType" }, "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated Liability for New York Opioid Stewardship Act", "label": "Estimated Liability for New York Opioid Stewardship Act", "terseLabel": "Estimated Liability for New York Opioid Stewardship Act" } } }, "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_FacilityExitAndOtherCosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.", "label": "Facility Exit and Other Costs", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityExitAndOtherCosts", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_GoodwillImpairmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment", "label": "Goodwill Impairment [Axis]", "terseLabel": "Goodwill Impairment [Axis]" } } }, "localname": "GoodwillImpairmentAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_GoodwillImpairmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment", "label": "Goodwill Impairment [Domain]", "terseLabel": "Goodwill Impairment [Domain]" } } }, "localname": "GoodwillImpairmentDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_GoodwillImpairmentMedicalUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Impairment - Medical Unit", "label": "Goodwill Impairment - Medical Unit [Member]", "terseLabel": "Medical Unit Goodwill Impairment [Member]" } } }, "localname": "GoodwillImpairmentMedicalUnitMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_IPRDTrademarksandOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "IPR&D,TrademarksandOther [Member]", "terseLabel": "Trademarks and patents" } } }, "localname": "IPRDTrademarksandOtherMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_IncomefromSettlementsofClassActionLawsuits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income from Settlements of Class Action Lawsuits", "label": "Income from Settlements of Class Action Lawsuits", "terseLabel": "Income from Settlements of Class Action Lawsuits" } } }, "localname": "IncomefromSettlementsofClassActionLawsuits", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_IndemnificationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.", "label": "Indemnification Receivable", "terseLabel": "Indemnification receivable" } } }, "localname": "IndemnificationReceivable", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_JudgmentForLostProfits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Judgment for lost profits", "label": "Judgment for lost profits", "terseLabel": "Judgment for lost profits" } } }, "localname": "JudgmentForLostProfits", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_LawsuitTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lawsuit Type [Axis]", "label": "Lawsuit Type [Axis]", "terseLabel": "Lawsuit Type [Axis]" } } }, "localname": "LawsuitTypeAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_LitigationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Litigation Type [Axis]", "label": "Litigation Type [Domain]", "terseLabel": "Litigation Type [Domain]" } } }, "localname": "LitigationTypeDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_LossContingencyLawsuitsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Lawsuits, Number", "label": "Loss Contingency, Lawsuits, Number", "terseLabel": "Loss Contingency, Lawsuits, Number" } } }, "localname": "LossContingencyLawsuitsNumber", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cah_LossContingencyNumberOfEligibleStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of Eligible States", "label": "Loss Contingency, Number of Eligible States", "terseLabel": "Loss Contingency, Number of Eligible States" } } }, "localname": "LossContingencyNumberOfEligibleStates", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cah_MedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical [Member]", "label": "Medical Member", "terseLabel": "Medical" } } }, "localname": "MedicalMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_MedicalSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Segment [Axis]", "label": "Medical Segment [Axis]", "terseLabel": "Medical Segment [Axis]" } } }, "localname": "MedicalSegmentAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_MedicalSegmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Medical Segment [Axis]", "label": "Medical Segment [Domain]", "terseLabel": "Medical Segment [Domain]" } } }, "localname": "MedicalSegmentDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "cah_MedicalUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Unit", "label": "Medical Unit [Member]", "terseLabel": "Medical Unit [Member]" } } }, "localname": "MedicalUnitMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_MedicaldistributionandproductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical distribution and products [Member]", "label": "Medical distribution and products [Member]", "terseLabel": "Medical distribution and products [Member]" } } }, "localname": "MedicaldistributionandproductsMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_NativeAmericanTribesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Native American tribes", "label": "Native American tribes [Member]", "terseLabel": "Native American tribes [Member]" } } }, "localname": "NativeAmericanTribesMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.", "label": "Net proceeds/(tax withholdings) from share-based compensation", "terseLabel": "Net tax withholdings from share-based compensation" } } }, "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_NewYorkOpioidStewardshipActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New York Opioid Stewardship Act", "label": "New York Opioid Stewardship Act [Member]", "terseLabel": "New York Opioid Stewardship Act [Member]" } } }, "localname": "NewYorkOpioidStewardshipActMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_NuclearPrecisionHealthServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nuclear Precision Health Services [Member]", "label": "Nuclear Precision Health Services [Member]", "terseLabel": "Nuclear Precision Health Services [Member]" } } }, "localname": "NuclearPrecisionHealthServicesMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_Numberofsharesexcludedfromcalculationofdilutedshares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares excluded from calculation of diluted shares", "label": "Number of shares excluded from calculation of diluted shares", "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment" } } }, "localname": "Numberofsharesexcludedfromcalculationofdilutedshares", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_OpioidLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Lawsuits [Member]", "label": "Opioid Lawsuits [Member]", "terseLabel": "Opioid Lawsuits [Member]" } } }, "localname": "OpioidLawsuitsMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLitigationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Litigation", "label": "Opioid Litigation [Axis]", "terseLabel": "Opioid Litigation" } } }, "localname": "OpioidLitigationAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_OpioidLitigationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Litigation [Domain]", "label": "Opioid Litigation [Domain]", "terseLabel": "Opioid Litigation [Domain]" } } }, "localname": "OpioidLitigationDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OtherJurisdictionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Jurisdictions [Member]", "label": "Other Jurisdictions [Member]", "terseLabel": "Other Jurisdictions [Member]" } } }, "localname": "OtherJurisdictionsMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalDistributionandSpecialtyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical Distribution and Specialty [Member]", "label": "Pharmaceutical Distribution and Specialty [Member]", "terseLabel": "Pharmaceutical Distribution and Specialty [Member]" } } }, "localname": "PharmaceuticalDistributionandSpecialtyMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical [Member]", "label": "Pharmaceutical Member", "terseLabel": "Pharmaceutical" } } }, "localname": "PharmaceuticalMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical Segment [Axis]", "label": "Pharmaceutical Segment [Axis]", "terseLabel": "Pharmaceutical Segment [Axis]" } } }, "localname": "PharmaceuticalSegmentAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_PharmaceuticalSegmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Pharmaceutical Segment [Axis]", "label": "Pharmaceutical Segment [Domain]", "terseLabel": "Pharmaceutical Segment [Domain]" } } }, "localname": "PharmaceuticalSegmentDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "cah_PlaintiffTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plaintiff Type [Axis]", "label": "Plaintiff Type [Axis]", "terseLabel": "Plaintiff Type [Axis]" } } }, "localname": "PlaintiffTypeAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_PlaintiffTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Plaintiff Type [Axis]", "label": "Plaintiff Type [Domain]", "terseLabel": "Plaintiff Type [Domain]" } } }, "localname": "PlaintiffTypeDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_PrivatePartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Parties [Member]", "label": "Private Parties [Member]", "terseLabel": "Private Parties [Member]" } } }, "localname": "PrivatePartiesMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of available-for-sale securities and other investments.", "label": "Proceeds from sale of available-for-sale securities and other investments", "terseLabel": "Proceeds from investments" } } }, "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ProductLiabilityLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Liability Lawsuits [Member]", "label": "Product Liability Lawsuits [Member]", "terseLabel": "Product Liability Lawsuits [Member]" } } }, "localname": "ProductLiabilityLawsuitsMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_ProjectCostsOnInvestmentAndOtherSpending": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.", "label": "Project Costs On Investment And Other Spending", "terseLabel": "Project Costs On Investment And Other Spending" } } }, "localname": "ProjectCostsOnInvestmentAndOtherSpending", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]", "label": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Definite and Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "cah_SegmentRevenuebyGeographicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Segment Revenue by Geographic [Table]", "label": "Segment Revenue by Geographic [Line Items]", "terseLabel": "Segment Revenue by Geographic [Line Items]" } } }, "localname": "SegmentRevenuebyGeographicLineItems", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_SegmentRevenuebyGeographicTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Segment Revenue by Geographic [Table]", "label": "Segment Revenue by Geographic [Table]", "terseLabel": "Segment Revenue by Geographic [Table]" } } }, "localname": "SegmentRevenuebyGeographicTable", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_SettlingStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settling States", "label": "Settling States", "terseLabel": "Settling States" } } }, "localname": "SettlingStates", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cah_SettlingUSTerritories": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Settling U.S Territories", "label": "Settling U.S Territories", "terseLabel": "Settling U.S Territories" } } }, "localname": "SettlingUSTerritories", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cah_ShareRepurchaseProgramAggregatePurchasePriceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share repurchase program aggregate purchase price", "label": "Share repurchase program aggregate purchase price [Axis]", "terseLabel": "Share repurchase program aggregate purchase price [Axis]" } } }, "localname": "ShareRepurchaseProgramAggregatePurchasePriceAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_ShareRepurchaseProgramAggregatePurchasePriceDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share repurchase program aggregate purchase price [Domain]", "label": "Share repurchase program aggregate purchase price [Domain]", "terseLabel": "Share repurchase program aggregate purchase price [Domain]" } } }, "localname": "ShareRepurchaseProgramAggregatePurchasePriceDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_ShortTermCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other short-term credit facilities and an unsecured line of credit", "label": "Short Term Credit Facilities Member", "terseLabel": "Short Term Credit Facilities Member" } } }, "localname": "ShortTermCreditFacilitiesMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TaxMatterAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Matter [Axis]", "label": "Tax Matter [Axis]", "terseLabel": "Tax Matter [Axis]" } } }, "localname": "TaxMatterAxis", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_TaxMatterDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Tax Matter [Axis]", "label": "Tax Matter [Domain]", "terseLabel": "Tax Matter [Domain]" } } }, "localname": "TaxMatterDomain", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TerminalGrowthRateFairValueInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terminal Growth Rate, Fair Value Input", "label": "Terminal Growth Rate, Fair Value Input", "terseLabel": "Terminal Growth Rate, Fair Value Input" } } }, "localname": "TerminalGrowthRateFairValueInput", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "percentItemType" }, "cah_TotalOpioidLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Opioid Litigation", "label": "Total Opioid Litigation [Member]", "terseLabel": "Total Opioid Litigation [Member]" } } }, "localname": "TotalOpioidLitigationMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TrademarksAndPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Trademarks And Patents Member", "terseLabel": "Trademarks, trade names and patents" } } }, "localname": "TrademarksAndPatentsMember", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_VestingPeriodinyearsforShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period in years for Shares", "label": "Vesting Period in years for Shares", "terseLabel": "Vesting Period in years for Shares" } } }, "localname": "VestingPeriodinyearsforShares", "nsuri": "http://www.cardinal.com/20220930", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CondensedFinancialStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Financial Statements, Captions [Line Items]", "terseLabel": "Statement of Stockholders' Equity" } } }, "localname": "CondensedFinancialStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r95", "r133", "r146", "r147", "r148", "r149", "r151", "r153", "r157", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r248", "r250", "r251" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r95", "r133", "r146", "r147", "r148", "r149", "r151", "r153", "r157", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r248", "r250", "r251" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case Type" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r165", "r318", "r320", "r536" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r228", "r230", "r231", "r232", "r256", "r293", "r330", "r332", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r534", "r537", "r560", "r561" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r228", "r230", "r231", "r232", "r256", "r293", "r330", "r332", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r534", "r537", "r560", "r561" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r165", "r318", "r320", "r536" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r204", "r228", "r230", "r231", "r232", "r256", "r293", "r321", "r330", "r332", "r360", "r361", "r362", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r534", "r537", "r560", "r561" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r204", "r228", "r230", "r231", "r232", "r256", "r293", "r321", "r330", "r332", "r360", "r361", "r362", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r534", "r537", "r560", "r561" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r105", "r331" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r105", "r110", "r226", "r331" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTable": { "auth_ref": [ "r95", "r399" ], "lang": { "en-us": { "role": { "label": "Condensed Financial Statements [Table]", "terseLabel": "Condensed Consolidated Statement of Shareholders' Equity" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r161", "r162", "r318", "r319", "r535", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r161", "r162", "r318", "r319", "r535", "r549", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r105", "r110", "r226", "r331", "r483" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GEORGIA", "terseLabel": "GEORGIA" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_OK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OKLAHOMA", "terseLabel": "OKLAHOMA" } } }, "localname": "OK", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WASHINGTON", "terseLabel": "WASHINGTON" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_WV": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEST VIRGINIA", "terseLabel": "WEST VIRGINIA" } } }, "localname": "WV", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r31", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts Payable, Current" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r504", "r525" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r42", "r48", "r55", "r56", "r57", "r412" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign Currency Translation Adjustments" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r43", "r48", "r412" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax" } } }, "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r45", "r47", "r48", "r519", "r542", "r543" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r48", "r55", "r56", "r57", "r97", "r98", "r99", "r412", "r478", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r84", "r186", "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r44", "r48", "r55", "r56", "r57", "r412" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r92", "r141", "r148", "r155", "r168", "r238", "r239", "r240", "r242", "r243", "r244", "r245", "r247", "r249", "r251", "r252", "r406", "r413", "r462", "r479", "r481", "r499", "r518" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r29", "r92", "r168", "r238", "r239", "r240", "r242", "r243", "r244", "r245", "r247", "r249", "r251", "r252", "r406", "r413", "r462", "r479", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNet": { "auth_ref": [ "r6", "r544", "r545", "r547", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net assets (liabilities).", "label": "Net Assets", "terseLabel": "Net Assets" } } }, "localname": "AssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r336", "r337", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r428", "r432" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r11", "r86" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r80", "r86", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and equivalents at end of period", "periodStartLabel": "Cash and equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r80", "r463" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r222", "r223", "r224", "r233", "r550" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments, Contingent Liabilities and Litigation" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r97", "r98", "r450" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "terseLabel": "Common shares, without par value:" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock, Value, Issued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r65", "r509", "r529" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r51", "r53", "r64", "r402", "r417", "r508", "r528" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r146", "r147", "r148", "r149", "r151", "r157", "r159" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate", "verboseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r69", "r494" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r88", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r270", "r277", "r278", "r280", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r91", "r95", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r281", "r282", "r283", "r284", "r476", "r500", "r501", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r268", "r281", "r282", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r35", "r91", "r95", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r281", "r282", "r283", "r284", "r476" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r35", "r91", "r95", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r279", "r281", "r282", "r283", "r284", "r308", "r311", "r312", "r313", "r473", "r474", "r476", "r477", "r516" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-Term and Short-Term, Combined Amount", "terseLabel": "Debt, Long-term and Short-term, Combined Amount" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.", "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes and other liabilities" } } }, "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r84", "r136" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Forward Contract" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r40", "r429", "r431", "r436", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r426", "r429", "r436" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r435", "r437" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r420", "r421", "r423" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Notional Amount" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r419", "r422", "r423", "r426", "r427", "r433", "r436", "r443", "r444", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed technology and other" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r335", "r336", "r366", "r367", "r369", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r5", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/Divestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r314", "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r66", "r102", "r103", "r104", "r105", "r106", "r111", "r113", "r115", "r116", "r117", "r122", "r123", "r451", "r452", "r510", "r530" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings per common share attributable to Cardinal Health, Inc.:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r66", "r102", "r103", "r104", "r105", "r106", "r113", "r115", "r116", "r117", "r122", "r123", "r451", "r452", "r510", "r530" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r118", "r120", "r121", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc." } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r463" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Tax benefit related to share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee- Related Costs" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r55", "r56", "r57", "r97", "r98", "r99", "r101", "r107", "r109", "r125", "r169", "r307", "r314", "r370", "r371", "r372", "r386", "r387", "r450", "r464", "r465", "r466", "r467", "r468", "r470", "r478", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r453", "r454", "r458" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r268", "r281", "r282", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r454", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r453", "r454", "r455", "r456", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r268", "r322", "r323", "r328", "r329", "r454", "r484" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r268", "r281", "r282", "r322", "r323", "r328", "r329", "r454", "r485" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r268", "r281", "r282", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r454", "r486" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r268", "r281", "r282", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r457", "r459" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments Disclosure" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r13", "r192" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r187", "r189", "r192", "r196", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r192", "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r187", "r191" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r192", "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted- Average Remaining Amortization Period (Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r40", "r322", "r440" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r84" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r225" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Litigation (recoveries)/charges, net", "terseLabel": "Gain (Loss) Related to Litigation Settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r84", "r285", "r286" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on early extinguishment of debt", "terseLabel": "Loss on Early Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r12", "r171", "r173", "r180", "r184", "r481", "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r173", "r180", "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r84", "r172", "r177", "r183", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r68", "r92", "r141", "r147", "r151", "r154", "r157", "r168", "r238", "r239", "r240", "r243", "r244", "r245", "r247", "r249", "r251", "r252", "r462" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r426", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r61", "r141", "r147", "r151", "r154", "r157", "r497", "r505", "r512", "r531" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r200", "r209" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r93", "r377", "r383", "r384", "r388", "r390", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax Disclosure" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r108", "r109", "r139", "r375", "r389", "r392", "r532" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income Tax Expense (Benefit)", "terseLabel": "Provision for/(benefit from) income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r83" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase/(decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r83" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r83" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other accrued liabilities and operating items, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r83" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedTerseLabel": "Increase in trade receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r188", "r195" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r195" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Net Intangible" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r188", "r195" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r12" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r185", "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Net Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Goodwill and other intangibles, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r59", "r135", "r472", "r475", "r511" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest Income (Expense), Nonoperating, Net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r27", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Other investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r92", "r168", "r462", "r481", "r503", "r522" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r34", "r92", "r168", "r238", "r239", "r240", "r243", "r244", "r245", "r247", "r249", "r251", "r252", "r407", "r413", "r414", "r462", "r479", "r480", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r36", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated Litigation Liability", "verboseLabel": "litigation settlement liability recorded" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongLivedAssetsHeldForSaleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-Lived Assets Held-for-sale [Line Items]", "terseLabel": "Long Lived Assets Held-for-sale [Line Items]" } } }, "localname": "LongLivedAssetsHeldForSaleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/DivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r18" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term obligations, less current portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-Term Debt and Lease Obligation, Current", "terseLabel": "Current portion of long-term obligations and other short-term borrowings" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r35", "r237" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-Term Purchase Commitment, Period", "terseLabel": "Long-term Purchase Commitment, Period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r225", "r227", "r228", "r229", "r230", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r225", "r227", "r228", "r229", "r230", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r225", "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss Contingency Accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Loss Contingency Accrual, Payments", "terseLabel": "Loss Contingency Accrual, Payments" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [ "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss Contingency, Claims Settled, Number" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r228", "r230", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Loss Contingency, Estimate of Possible Loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r225", "r227", "r228", "r229", "r230", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [ "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss Contingency, Pending Claims, Number" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r39", "r92", "r168", "r238", "r243", "r244", "r245", "r251", "r252", "r462", "r502", "r521" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r314", "r404", "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "terseLabel": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by/(used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r80", "r82", "r85" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by/(used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r4", "r49", "r52", "r57", "r62", "r85", "r92", "r100", "r102", "r103", "r104", "r105", "r108", "r109", "r114", "r141", "r147", "r151", "r154", "r157", "r168", "r238", "r239", "r240", "r243", "r244", "r245", "r247", "r249", "r251", "r252", "r452", "r462", "r506", "r526" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Earnings/(Loss)", "totalLabel": "Net earnings attributable to Cardinal Health, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r49", "r52", "r57", "r108", "r109", "r409", "r416" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: comprehensive income attributable to noncontrolling interests", "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Financial Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r97", "r98", "r99", "r314", "r400" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.", "label": "Open Tax Year", "terseLabel": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r141", "r147", "r151", "r154", "r157" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total operating earnings", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r146", "r147", "r148", "r149", "r151", "r157" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r28", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r48", "r55", "r56", "r58", "r464", "r466", "r470" ], "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "verboseLabel": "Other comprehensive loss, before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r43", "r45" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r43", "r45", "r430", "r434", "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r41" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r50", "r53", "r55", "r56", "r58", "r63", "r307", "r464", "r469", "r470", "r507", "r527" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r50", "r53", "r402", "r403", "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r46", "r55", "r63", "r375", "r391", "r393", "r464", "r467", "r470", "r507", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income)/expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherShortTermBorrowings": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.", "label": "Other Short-Term Borrowings", "terseLabel": "Other Short-term Borrowings" } } }, "localname": "OtherShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Payments for Legal Settlements" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Purchase of treasury shares", "terseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r78", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Payments and other adjustments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends on common shares" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r75" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "terseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r74" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Units", "verboseLabel": "Performance Share Unit" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]", "terseLabel": "Preferred shares, without par value:" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20", "r291" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r20", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, Value, Issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from divestitures, net of cash sold" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/DivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from disposal of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r4", "r49", "r52", "r57", "r79", "r92", "r100", "r108", "r109", "r141", "r147", "r151", "r154", "r157", "r168", "r238", "r239", "r240", "r243", "r244", "r245", "r247", "r249", "r251", "r252", "r402", "r408", "r410", "r416", "r417", "r452", "r462", "r512" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings/(loss)", "totalLabel": "Net earnings", "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r199", "r481", "r513", "r524" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r67", "r170" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r481", "r523", "r546" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade receivables, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r48", "r55", "r56", "r58", "r464", "r468", "r470" ], "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified to earnings" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r148", "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Assets by Reportable Segment" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r147", "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r147", "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Segment Profit by Reportable Segment" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r146", "r151" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "verboseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r77" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedTerseLabel": "Reduction of long-term obligations" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "terseLabel": "Repayments of Notes Payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [ "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Share Units", "verboseLabel": "Restricted Share Unit" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r206", "r208", "r211", "r220", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Employee Severance" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeverance" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r84", "r205", "r214", "r217" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "totalLabel": "Total restructuring and employee severance", "verboseLabel": "Restructuring and employee severance" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Abstract]", "terseLabel": "Restructuring Charges [Abstract]" } } }, "localname": "RestructuringChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r207", "r208", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Additions" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r208", "r215" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r314", "r481", "r520", "r541", "r543" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r97", "r98", "r99", "r101", "r107", "r109", "r169", "r370", "r371", "r372", "r386", "r387", "r450", "r538", "r540" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r60", "r92", "r132", "r133", "r146", "r152", "r153", "r160", "r161", "r165", "r168", "r238", "r239", "r240", "r243", "r244", "r245", "r247", "r249", "r251", "r252", "r462", "r512" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "verboseLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r48", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r187", "r191", "r495" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill by Reportable Segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r195", "r197" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": { "auth_ref": [ "r3", "r202" ], "lang": { "en-us": { "role": { "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Schedule of Long-Lived Assets Held-for-sale [Table]", "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]" } } }, "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/DivestituresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r207", "r208", "r209", "r210", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r212", "r213", "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r208", "r218" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r141", "r144", "r150", "r181" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r333", "r334", "r336", "r337", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r19", "r20", "r21", "r89", "r126", "r127", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r300", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r128", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r146", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r157", "r165", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r184", "r210", "r219", "r533" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r128", "r130", "r131", "r141", "r145", "r151", "r155", "r156", "r157", "r158", "r160", "r164", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Distribution, selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r84" ], "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance Costs", "verboseLabel": "Employee-related costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled and forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at end of period (in shares)", "periodStartLabel": "Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Share Units", "verboseLabel": "Performance Share Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in usd per share)", "periodStartLabel": "Nonvested at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value per Share", "verboseLabel": "Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r336", "r337", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Target performance goal (as a percent)", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r128", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r146", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r157", "r165", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r184", "r201", "r210", "r219", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Operating and Reportable Segment" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r38", "r55", "r56", "r57", "r97", "r98", "r99", "r101", "r107", "r109", "r125", "r169", "r307", "r314", "r370", "r371", "r372", "r386", "r387", "r450", "r464", "r465", "r466", "r467", "r468", "r470", "r478", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r97", "r98", "r99", "r125", "r494" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r20", "r21", "r307", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r20", "r21", "r314", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "negatedTerseLabel": "Employee stock plans activity, net of shares withheld for employee taxes" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r24", "r25", "r92", "r167", "r168", "r462", "r481" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Cardinal Health, Inc. shareholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r56", "r92", "r97", "r98", "r99", "r101", "r107", "r168", "r169", "r314", "r370", "r371", "r372", "r386", "r387", "r400", "r401", "r415", "r450", "r462", "r464", "r465", "r470", "r478", "r539", "r540" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "negatedPeriodEndLabel": "Balance at end of period", "negatedPeriodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r90", "r292", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r314", "r317", "r449" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "terseLabel": "Stockholders' Equity, Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Axis]", "terseLabel": "Subsegments Consolidation Items [Axis]" } } }, "localname": "SubsegmentsConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Domain]", "terseLabel": "Subsegments Consolidation Items [Domain]" } } }, "localname": "SubsegmentsConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r471", "r482" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r471", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r471", "r482" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury shares acquired, average price per share (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r37", "r315" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r37", "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)", "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r21", "r307", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury shares acquired (using cost method), shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r37", "r315", "r316" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedPeriodEndLabel": "Treasury, balance at end of period", "negatedPeriodStartLabel": "Treasury, balance at beginning of period", "negatedTerseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r207", "r208", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r374", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r117" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r112", "r117" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares\u2013diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r111", "r117" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares\u2013basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r287": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r373": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r460": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r562": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r563": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r564": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r565": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r566": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r567": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" } }, "version": "2.1" } ZIP 77 0000721371-22-000133-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-22-000133-xbrl.zip M4$L#!!0 ( 'M)9%7J#>S.]@< #(G ; 83(S<3%?,3!Q># Y,S R M,GAE>#,Q,3,N:'1M[5I=<]LV%GW?7X'*LZDSHR_*] MWOF'%FOESE6C7F\ZG7:G.UUMQKW+3SUR->PIK:WHIBYM'1_1&_P*GA[_[>B[ M3H>=Z:0N1.E88@1W(F6UE>68?4Z%O6*=3F-UJJN9D>/P/_@SW YW'BY>=-OS(Q%& ^-M*UZ^;>VT MYA4JGJ8 W:C/HLHM^/MC3 ?5-1D?+B##0_GN3(9)A,],8SDT3N!7F]%6W_]W M2"6=C!=2S4;?GQC)%?O C='3[]L6*[)CA9%9L++ROP+P1+O^<1K0NPMYY&XL"I"A%A:5-A8^]>KZV8)O6^6!^$_M74R MF_VY'1[>[?" .GS19C]RJTOV4Y>]H_5GVBRAV]5, M=4>)S(UV[N]G>"7+%*PPZD3['C[/WO.H.^_6,S>]/$81D/:&1N""Y7PBF!$3 M*:9@?Y=+R_ZA3<&B?N>?3&?LE!O40PSO!%Y@0--FR"?N 6 MTX*E4LS85:FG2J1CT0[S9$2EC6.I%I:5&BD<37!9,E[.6%TZ4U/20U+W^1U3 MR5F!)Q]OQA.\,DP7X!VG@]V*02D282TW,S(I^)5 NPL^+=ZE" 9-*B\.T 89 M)-) #,"L1'5$@GS+IKE,S(U!B6>+P_!R(;GS5X&D8!F8HDRH]=M);@./,$>Q62B790:6X:1A M\7>BZA0^ :2%&6T#A-*H&:N X(P05NI6XPV\+!WFL8R2+TX;I-%K6 8&J@ MQS=G?3P)MSG+E)[:.6J-&$OKH*P=X_0RQ(THVPO@L_-@5J)]N?@;;AC^+I:6"4OR2MJ<:I!9 M 08E%J5G; D2I6V->L2M!B+3VU1&)R+%:\NV@954 'P!$.?72<[+L6 GH*U/ MM8)%M,,[T>ZV"%%$NVEX"H^2MBAE "WY9\1M"U@.V*)8UFXH6VHH0T/4S[L( MAP5E_B"-CZ[I\)BP'"S/D$^'58M2DW)[RVZU>A)!D+0*1I M*:1=71LX '=-I/6,""M1>C\DM&^Y=)&/C5#<8Z[)N[>X:3=<3842O(I8K%8R M]2<'MHZM3"4WDCH@@SKP&:(D3[6EC.U7J?7IW?.GM@(!.? U5:HX;6$RO360KT%Z? M=&.%;% M1*8$7-IE^M,?;@%Z$J2$9K^E&3?85I+'4DDW(R%P7[.TSCP(/;["$EDR71"T M/J5<-QVJ:E,!W]8+ER31)O4!>&D[%B7TB +,42(J6C]D MD>H(QU)BNP^@L& M<[(A8.X.O:PXGW!5>R*CR199!FDI)Y@F>X]$O%$=:Q!S>+Q?-7KXHB)(U09M M&NO:/1S!.JF#WU@+$M[9U_=.+)Y+>K\B11@)Q./11PV\3 2F&X) 3Z=A9E<1 M0KOY1NOYDGMA^ @2I;2ODZ0VA(.%''N/UT);A_=TD Y?-H&CWVJD:+C>?J!* M!D"#WNY8-X%CTR7\002=493U35RO0U0YMS>"A(C1+P"1^HSAQZ-A\QE3\DJH MYE3BCGW[R4/T9-!O]&YN]Z7LYOS!93I?->U;#B-*743N+9T1]AXA5%;D[TUT M'!+8:6-OM(%_ 9=%(9T3X@L)(]90'U2>2L3GG6P#W^!G2_R/?TF(SQ>E^*V6 M"-\OP+I,_/G%Z_]OVIZ%D4\4I!V&2 )XM&>FW7Y#DS)E[ ,[/TAA M#_J_LW G.NCVUZWG48S_7T^KX%E_K5V#EO]:_VAIBB?A?]N/) M+Q\_^*_8']^_/_FT]/'^$1<8?L=P-2@DC,(1\Z=P;-[S1XXEG'R+@;QS!> 9 M!^^O,3ZGN109.[\624W' .QC4,!/&J?U+Y,L\.&=JU>5#G?/1N&<>"(>O(S5 ML%[_M@J/@=3:K5;YRJ66YC?<)O/WVH[_!U!+ P04 " ![2615/W9)8/X' M !')P &P &$R,W$Q7S$P<7@P.3,P,C)X97@S,3(S+FAT;>U::V_C-A;] MOK^"3;#3#."7_,C#R01(D[038#J=3E,,]M."EBB;&TI42T MV3R[/&/O+W_\P+J-5L0N#<^M=%+G7#6;YQ^WV-;(N:+?;$XFD\:DT]!FV+S\ MW"17W:;2VHI&XI*MXR-Z@U_!D^-_'7U3K[,S'9>9R!V+C>!.)*RT,A^R+XFP M5ZQ>KZQ.=3$U M;64RKX\$M=_OMAM[O<(=3F3B1OVHU?KWUI*I$]>NSI4(JIH.#1C?J45C.X/]DUG 5<<-'W'3):EDG:ASL[]]9W&I$=Y;=Z[;= M:.^W_PZWW<[=Q8MNFWXDPFA@O&W!\W=;G:U9A8(G"4#7;[&H< O^_AK3=G%- MQH<+R/!0OCV381+A,]58#I43^-6FO]WR_QU223WEF533_KR3P!,_3K MT;Z'T(OW/FK,NO7"32^/410UHET:@0LVXF/!C!A+,4$&<"-IV??:9"QJU7]F M.F6GW* >8G@ON'*8J(L\;F""#E[G!+4W;(*^XQ;3HG.63=E5KB=*)$-1"_-D M1*&-8XD6EN4::1Q-<)DSGD]9F3M34N)#8O# MW8I!+F)A+3=3,LGXE4"["SXMWB4(!DTJ+Q#0!AG$TD 0P"Q'=42"G,LF(QF/ MF"WIYZ;^1!A1.:$.9-(J* <2(1/I1NB@+43L R2_!4+3Q/=@;PS*8+HX#*\7 MDIU_"B0%2\$4>4RMWTQR#7B$.8K-0KG,4[ ,)QV+OV-5)O )("W,: T@E$9- M60$<$(0)VDK=8+2"A[W5-)9!X@5RC2Q*!0, 4P,]OCGKXXFY';%4Z8F=H=:( MH;0.ZMHQ3B]#W(BRM@ ^.PMF)=K7B[_NAN'O=^Q;/Y,7C!OA,0,,2-H58&Z9L"2QH$"H!IEE8%!B47K&MB!6VI:H1]QJ M(#2]36%T+!*\MFP'6$D$P!< <7X=CW@^%.P$M/6Y5+"(.KP>]79$B"+J)>$I M/$K:IN0!M.2?$;X.;6L755"C!JXC%:B43?WI@RX&5B>1&4@=D4 <^ M0^3DJ;24L?TJM3Z]>_[45B @![ZF2@6G;5FI.-$^NN6#N,G\J!%TQ*+\P5\# M089@9M07R;.8>+,Q/=A83#^:R%:@_7@*?#3"L2K&,B'@AQU=8(DNF"X+6IY3KJD-%:0K@VWKA$L?: M)#X +VV'(H<>48 Y2D1!ZX=,(-L#E+'.9 %6?\5@CC<$S(VNEQ7G8ZY*3V0T MV2)-(2WE&--DUTC$N>IX!#&'Q_6JT<,7%4&J-FC3@2[=W1$\)G7PN;4@X9T^ MO'=B@YFD]RM2A)% /!Y]U,#K1&"R(0CT=!IF=A4AM)NOM)XO60O#)Y HI7T= MQZ4A'"SDV#5>,VT=WM-A.GS9&(Y^*Y&BX7KGCBHI UZNV5=!8Y-E_ '$71& MD9?SN-Z&J$;SF_,%E,ELUM1L.(TI=1.X-G1'VGB!45N3O/#H.">RTL7-MX%_ 999)YX2X M)V$,--0'E2<2\7DG.\ W^-D2_^-?$N*S12E^*R7"]PNPS&-_?O'V_YNV%V'D M$P5IAR&2 ![MF6GW'4L!F%1)?;YYF@A^15DZ2#V?I[U(]2>LLW.G)X&OVN>$ M$XLUM,<35+1BSGIW K62MJ@"M$&!UH)4L- )MLR %8R0[TR5;=:>T+UR&;!) MNZH39/O4@$YJ@(#P) @0^#X[&X\X9618.MFRI\ ,R6;K7* M S==JM]PQU8;6_;-A#^OE]Q=; T :QWO\BR M&\!STB5%FF1)BF*?!EJB+*ZTJ%)T'._7[TC)K>W$2]NUS3K$@ 53=[S7Y\Y' M#IX=GH^N?[\X@DQ-.5R\^>7T9 0-RW'>!B/'.;P^A./KUZ?0LET/KB7)2Z:8 MR EWG*.S!C0RI8K(<>;SN3T/;"$GSO6EHT6U'"Y$2>U$)8V#@7Z#3TJ2@Y\& MSRP+#D4\F])<02PI432!6K"4,W"J]< Q2@9CD2P.!@F[ 9:\:+"TE0:=UC@,NQYIC8.XUP[#H-,) M ]I+"/''?WAHI(/LU9Y2+3A]T9BRW,JHUA^U?+O;+E1_SA*519[K_MQ88U7T M5EF$LTD>Q6@.E4A69,SIDF$L9$*E%0O.25'2:/FCG["RX&01L9RSG%IF4W]* MY 25CX528AIIQ3=4*A837BLQ^BIR;5.O9[>\MC9+2?PF2\6UQ;:QV%')75K@ MV;TPW$IV;6\K[1_%^K8?^M]";"O83EX5ZYA(5-' >)<%R5\T@L9R0T&2!$$7 MN> 5:D7>UV'UBUO-W%]!AH'R9B:K)*+,5& YU$)0KI#1CFL^?4VQ4C)E?!$] M'TI&.)P1*<7\>;/$BK1**EE:<97L+XKP1+UF.:_0VT4A!ETUFBO\'MUF;,P4 M8$2]@:/Y5^/F&"2N5$5E(9:6)M;V7!%8RU\=\?KN'TO:+M-("4,$U'HCK8>I-6VLE;WG"Y@&"M-\5W7_S)O_YR5F*3%MT5_ZUYW7Y$2^[_9&88A]8F)77WS> NB!* M,H215G*43S@KL^96A"T!6LEI0FS@BS^*3X6>RHC:W6F'_<](1=VL+$Y3%07W M)Z=ZQ?($D1E9FNDQTK7G[2_]^LZZUX/D&_]UJBY0F$A8#)>T$!(+(8>70D[! MT((]K[T$;C>< MZNW=4.#^?<1KKZ^+Y?^)6?^_AEF6(S"GU5]BC3R$)#B_O#NM? M)2XU_#0XD1=*P5D"2R]_C*!M#'7?*% _1BRVS;.?=-1[ZDM/?>GAOG0QO+X\ M&9T,S0GG[-?3DZOCI]ZT+7#W' >?^M/=D_"_N8E:F;TV[FT+45U<1Y)RHMOA MUIO0,<)MINYN>>!&K'Y65]'F4OS@;U!+ P04 " ![26158YZ3 MF?,; !IK@ &P &$R,W$Q7S$P<7@P.3,P,C)X97@Y.3$Q+FAT;>T]:9/; M-I;?]U=@.K5Q4B7UY79B=SNNVG+8@$):0I@@%(J95?O^\ M0)"2VI[9R4I;Q:F:N,4# /'N$\__\NKM[8?_^OFU6#3+4OS\R[<_OKD5)].S MLU\?WYZ=O?KP2GS_X6\_BJO3\POQP?$*5LHS-9^DEH/K[MU_3LV>G5Q1-<5F/A_WF8V*_X ME%9\UN3;]QY?G#Y[^G3O[?/3B[WW'ASV\O3RZ>6?,>S5X_VWTV'/:"=X-V"_ M72VK;TX>GX07:IGG@'37Y^*B;I+Q_C6/7M;W^/!-@AF$RD-(,A!AS,( .?A! M8%QCKS\[I__=X)UI(9>ZW%P_>FFU+,5/TEJS?C1Q0)%3IZPN^"FG_U" GC O M_5PS]GX-@Q!V>6QF_'U]O] SW0C G(OG9_A\NF]GA(D[J&(7JO/+,WS-C_._ M>VOOO8?&_:UUC2XV_]JM?/RQK;S$K7S? !,C?O9.S:5%!!#?&;N&/Z<_&G.' MO]]4A;%+B>Q3?,HV_2F?,\2,JYV?\](!/P:FK"O1++03BC%E(C[_[.GEY?G- M6DWHKXN;<,6T=GBI=>&"K(!(-2Q26E%;4YFVI*H<]^Z&MU.>?77QU M?O/X?,)RZPM\TN\*78CC^!WZZC*$O_% M22JU1N"52CK<=$NCT=Z+-6QOHRJ\:"SLB@M4X<12YDK,-G2K$C.UD&4A3 %H MEGX24(=")':B-@ZU G@6YUPK0((&OG0I-_YQ^)$#V+.FI$%G=-U86#13V&S# M&*:J#!XM/"V6GA:3E34+B3M6E#!6;Q=76JUAVQPN$P&8PRL,\WV#"0!(H:UK MZ'._%')FVD84;=-:)=0*IYL@ ;@:YN(_?X._8+FTD050094A#=?*$J^ M9^* M#S E; SLC(-/=EGK(FDJ]\!J +0P+= /SH%PS4#P2'C/:G?'<&\K?XVH@G8B M,VT)9%,ZP(Q;J5TD?""/M6YD'^^6=/GM[L99U]G0GYMK_2F)I^>LD\+54! MC.YI7S9[;LN7-%!RU5Q/\:%#\%]B"U_%3_T_GG^P44].40B>O,C,LE:@9>L5 M@AK8<&L)-$03L-5WJJ&?ZX4&X*Z5,(#&$JFV(_#: EK0O_Y] .FS$:2' FF? MRH"I ^]$R6((I@%8P/^0)'.UQ']0\LU5!:O(1+V0P*4RU9)".P+SH,!TL$VZ M $!4*!.!YBR*:+11'! F@@TH>&GR3@5BJ=T)W4[G4^)O*D>8"J?F)-H ]FV! M L'"S"E)KT U,ZW#P6O01DC&T=]ME<.?5JZ3&0QJ2#'A-T:*P M,D7A5(.K6,((@2H_Z'4;0@#0.@H-MBJ#'WC5 M;N8$B 2C+UAEC:CD,19?0]5O\(H?R>$<?K(&0P49*1L>. M )"R!@!) BZ@2A!;,RO)(!L %1[-V\P;/JQP$J+!D_ R&0"HZ%2.[0C@8H0J M56.].@Q?A\M@%9OLJ70Q#HP;4L.!SP![DZC+H\-#@J7I#8GUPH 5*TM4L,%V M98\JL6E\8O>R>;EK0%N%8TK;!)SMK18,$&:F: 'M^WZ=*=HR!;9&0V9OLK&L MS($D:4#AQCF(46^_Q+0PDL+A2:%CC61$1N;HL0V8*6,\XL=^_!H%WV%M*Q!Y M58LP]#:PN4LJU:X-#1U=":I4M M)-AO,\5NFK4N2_@A*KDD#:PO<'/M&JMG;4 =M-HRJVO^76NC 8W0H[ D9;$9 MN- 8^WH+F6WHZBN%'(ST2ACV!T2/3'5+G*E2JQ6Y^$ ?8!<0>A2F@)' 87%V M+Y$G.^^9$B2 UP_AP4SE9*H&-]GPLX)?A)B\*4O8"?0Z-NA^&>GBH'2QGQ@J MR7%(%+1-R>XW.;>*_P($)FI9L<=N)E4X.,P)_R4+9(CMN%RV0 CWES4O3$::7:)NJ]#-%^G6^Z_S M*(3)S>8QU%CW:"=>[J$'1W8/.^R0ZEN,.8"!HRIO!J+R2VX9WCR8$\:E:8,Q MU7V#+I 8"ZE+THPL^1/Q^3GK2L1)\#;_1$4$;*P((;#YEM%YN@M*$QR>_8VP MC4"82]#&&VDWG8H.FHTLR1B 2]UG(:[X+XALC]6N@E8CY[#/ /)V)-^#DF]M M&B05F"*72]2 O89M5=TV7E[(''%8]= 2*$=F36*JJ:) ESGC98+BWON5@6J.&$9:;Q@DTH:IY@:Q#,A*KHRE M^'[=SE#<-.C2@&T$>R%P@X^=0KV,Q0S@V",.:,(\B*_B+4D(E&J(A>\4QI4$6 @.\9#<*7*) M@4&FLV:!,5/6JNI25B2-&GG'VP%F0^O#504)DIX0Q@\,Q)[WH9U;-(#V^+0K,J]*:BJ"B@U7^@UPTY>;'#5N < <*,[]NE MK,1[95BQ ;3F6U:108"Z2:=V/*"?C'AX2#P< M!@$P8M6IB$'#"%J%5T*Z<'L(H_ELCO'"./ M83\,>?7,MHGIM9+.3AX1YJ (@_!?P$,$,,>.!O3P$KR(/001?:!&MTG>":+-V[IIE^_N1Q ?&L0A*@043Y:W].Y2K]?%N,^>D)&# M>Q1*P-0=%"&$&;L!/P+[L/Y3[]SPGASFZ.000)[^>RL)#[1S+:H*ZX4B#IX$ M?CCN$>,X%/D F@\8XC""C=G<+8"-8H-FS5E;H'Q/"\W>F0T&QW&"3D&(%K"" M3[?T!CIN,\Z5P:%[D76<;^E#[[DBS289+(2N,*6JBM$?;W.BI0 "[D[.?82^ M2S=U&UC_DI?+*+[!:25'L4#S81VJ,Z]U]1MN NCMSB>G>0,>)2)PQDW/D=3C MBS[= +<=+!>PO,F$P6_BM8 ICXF%G+48 ."_3)0ZD*P')#X4[.C>+"5(7TQ0 MPR'# R,-'I(&9DRK99&+O3ETI&[BO;SL5KQ.2, M4?5EOM05*ER_,(GV8^B"]VS/Z=,:P'TC*&4]]2&CN; MPIPM@^Y1>)I_@+K7V28?LW6"@\D_@T/>ZI4NQ3O<=X&PF^$T^N&U\,_L1C:*D!@R\.3 C ML/]6H *&1&!$0J%D!OJ?=&KB+< XN<[3R5/T'FNN4YN<#5>09)2L\*XWSZASQBXHTEV#0 MI>LA4K5M'4QV/R"51X!H*4NDL/T.K\34X& %$%(9M"RJD6#E4P!3=5$QQ>L4 M:DBWRB8K&56:@Z;4+I!;^SR;)/-T\H]FNU)F+9:_ *;,L-15#7WEKJW1-=E! MGA4IF6NCG0%XCC[&P_L8*7QABHFWXB3*[!EH!H )+(B!TZ##B("I@W+(>2V@ M^X Z0@(VN1_2E&>HQ "P 07D2NH2U9H1WD>6B]REB ZRXQ^Y816C^-;*3D-T MP\K"GF.*) 2:S62T6PD*8\M."#(+,)6%;!R&KZ^G GFHJ$ RJ14;$>;X@F$< M9J(]#$;H;@3R B!;D#D;S>7=TF* 0V"P4,(<3J;N:RK"ZYR>2*BIAU!7H'Q_>1_M]\V.(4J'#N]*/\$VB2S#89 M!%,'&5MM%<L"/4N[4JM21N^UZ[A^L^D",/M".'O6="6Y35# M5/*I[R'$0RDXBBLK>KZA#+1J5ME# )S:Q)II+5R8DXRCTB%8_J2E94?+'% MU8U+B6Z4O(?$WGX$)3&A.D#GK6+6$Y%!9L-\]:V;_ 8@JA*OFP5\)*CY;^]U M#MS3.U-=2@\QS(2!FQ 8<;)0,?)$KK[$1!2=@=G%A0CU9LJ7X#.;](Y&[=(8 M52Z MTJ!WH12#<)(\!>S?4)7\ESB\]X&4>'^B+I'J33&O$ P.S0GBU="!10T MA()??/[9XZN;U\U;^O=+:MQ!04I84@R+A%!BY+>=/$Y"G4F^BAJJ#UNUM5M4 MXGID\K:C#:\I "IC()6,XS6LW-5HZ4Z\6=S/5Q]6+9.SG?3B2"FL*73%>S'= MODNWC;FUG/A+ H<4#4PMQLCF9A@@IG7?U^PK?&C9([4SJ]@[0"SM=A*R MOH:5,(7Z\6X(;FQITELS"Y0R%,N+/",;_'V!,@OD<\KTU%M5# M\3/6J4TL(<6)"!6=WA!R)%.\( M45-5C1T^9$U@044O*.K]/7&Z$0V/# V#)N_]QIT[V!<\ALRC*3X(V$=)."&Z MA/E^H;*(E-W(OSS^L/\ER1>*22>Q2\\@$R=6FP9?7QCN\=7YMR+';*FN MTYYY5':-6!&1M; M77!Z553 M#?")9/O09T+Y>3&S>JLQ#XE:8INM!8O2<5_S MU+'5/EM.V/!(#$?2&2CQSW1FK0!CJ:6+ZUT MP]K*!$MVCI6(:6R1Y?U_F%H<1EXB+:?+Y$Q7[9*ECHAVX*B+#V+8KBP<,"QP M00J-L)3U^#<1E:FF5E5JC9:+DMCE&KN$Z,J;.ASHTQ5UL(J1/\JSG7;6P8G<9DE%1O3/FVVZKB+/74<\OU= MNY=WZ_224K9IU)B]W3GTC9_+CSZBT_%D3OFX?M0;NJ*?5'VVU/:DWX@<*_M1 M?4\R.V,5%]F(5LW(M9:T^YQT$X%%H%A9A[]*ZR023Q7:X7: *^XOF)M8S1$?1 M=\9.7Y;EB,4'98J=S@380OD90>)5_4\O%&MNE,Y\$K,3F+DJNXL!:M MMP3UN](ZKG_1S#^YEBWRR\+8W3E9(Y8J0._1Q 9C%:9E3 ;= M1V(*1>R+2<#VT:\1P$<"8$Q4<64TR1-[V?,#[<_-V"D()BG-QWI^2HJLTTD%D+BZT\LUBY;CIVUF"(6',X/=9O_ M2"K]H%7K=K\RIRB1.F0BA/K\7B["R,^/A)\OC*LU*G"S=H-(.;>FK8DE#^^, MLOC88+>E0(7"AJ7)5>G5Y?V1(U*@0Z.@726 LLMTY>GP(#ON=>,SM=,5C&AQ M#&@1#\4::F#]V!DZ&D!QZW4WB@D(_8:3#YRDY9W=(>%BQ( C.9P!*XC BLK] M:2L<3^M9VYRX'[R,+.#GVA?==5GGBH-;&B.XX1)S7;!;1MIA M)YZR,996'+XX9ZOF>R^T>FG4>+:R]&XN\E5'G,(>CQ9E5I+QA,FB96G66.#% MB:,=AON4$69.,&A?$-_()!X)@L%9?_I9(7S7,5!L*(\>X H@1\&6Q 5CHB=Y5[B\TI^OC7G!#1WD M#8Q-^ZA?/.#AS]P3&NX:O0(Z^P0H@14A&KD\$)1.7H32S][&]H\XF0@'-HU: MF!(MF5B<&9O9XHDL)?-VA2 ?2>S@)+95X-A3(9)&0RS:J9:\#&J$0$3H-=4/ M1B_*@9G:RJ#&LX;IA*D@U;NC>HE#-T2EFAL;AV(;/A*$VE%0^)MZ=XZ8H<';K=S[IV%%)MTSZEI5M(.I&N7AMYQ62%:<(^/'6-VH6W.'_)O^I*F M<"_IL"9S]7M+]5#H6E_Y_A^[SZUYX!,\RF:MM8K.VJ:3&'T+B6X3PDEI_=+S M71&)4)X% NS6P(Z@)EX A."30!4'546N))YLUB0]P$>GT MPWC> ]6,Q.97L8XXL=%KDE[\HK;I0>>3?4OV,SW0VA!+\JF45853N7S7NF3X M$4V/5##B6;6P>^%P%3KICY6=@#8/GZ;+21'#D=4]M^1'2Q_39E.T9$F&=((B MMR0C),1:8-B*I%U4XKB1(7>"V\[."._A\0]T?+K/T"#K20\UUUMFZ\,;,:TN<8AW]'7M[L(+EBTQUX^ONAT,SHM:H M'+:5CJQ[/[U\DFX6T!+0?^HVV&M<*X^5*;,,ZZ&BT]"&,W!6/MXHK--0)2GN MT\A(#XG-,UG=H;Z-QZSHBHXRQQ3_B%G<+"$)"J)+>U>5%#MRUE@(CUJ[/Z&% MCJ222S041C@?G\"A* M7UN)QPC[ X!8Z $VK:A3$K$89$9^UA@9X:S*>)0F]?G;N=S$DTZ_8R\D[R1, MSFKOZ7I;GSGBXO'DY0Z;4H=*O3Y,N:M5*"V8B$;">@J,S]QG_C23&1\MQ:>G M>M>#MC&WMAI*4N\G25TGG<\DB,)*L8D#>$]^NM15/6+1\7$TA(_W.7TO/H7/20]XU*696S:CGBWQ'9 1JC4]2_+RC)(#,M]!0V6+"CYNOAG!?-"SF6";-!"JQ @]GSU Q,OGYSF,+Z M++W4DM6?@R@"+YG.X%U"-!\@ ]8&^QVYC^8O;Z3\*W^:N=U&]Y!LZG*AU?K M4E;#:S/0C=5J:P"49,-K;H$>P>'5;-?%]:Z+H /]MN,K?,7#UA)*?0=J<[Q* MI0:^73)LAU6^[[_GV)CIPSUQ-V& PMBUM/FT-.8.R9UJ,=E7$0;U21RUDG? M%5!)CWTT\M#+MGL-3$%,/ 8;E.-*8"(:;RGT'K.J\)U\0:6G&$0((&$13JMS MU.\FZ1O4.;#!A=+ I-_3F2^9;6&64_&K2LR RB1MBRC5NDZR%B>HF5:5[_!WNI'G9M;Q"\S:P<6!-<)H-V\,78_%O@LK0;?$FS;\F%;+6* M9]ZF_>LL.6L/ AQB?.MB]EI$5&H>HI8Q+&Q1K5Q+Q-RUM(DB;"617$?;9Z^Y M,I(I%K4HD;)%#6P.EAA+W]]I;*.2?ZYU1X,^J]?O?(?=]+L[!4.P^A5>7&KNE6GP]X@ MNYZ^-[=ZYRR]>%5=?.57.'I@F+?.I.R/'W R5\7@U86IF_-!/YL]M+\R=6MR M-1C?>7EYN3.>=-+K)#WK0?1JD,E>[M*L*P< 0O]XV IQ"XT'\0\ELX>!M1,8 M*Q_(GK8W+[WO9D0F7CP>'K[X-O7$)2GN1T*(5\75T:UW[IR>B+^L9#Z:R/UC M>JB.9YNG%*/X1^LK[YC8TQ9L^-0#(P#\:%L1:X6\1=!H'&.3V5"$"U- O,J3 M64N!N:%7__?@]V/=MEW9N@T%+=M33VF9F:0G.SLZ[1;#AX*$8Y3*!G=Q#[Z\ MF +JPT;W[MVH$,_&,M^Y]AS5X56SZJS?_XW_\CU\'R:!CW\ ,6Z.)_/JJ_.[75^7(*C77;WXU MR460#ZX[]I];)LG['7G]NI?V++P_N7KM;[19^6=BC.T5?\+U0^ X6:++UU\- MCJS[YU8"A,]Q\Z!E[]7_L]5:0&!C:D#^OU5YZ\3L^NC@E!T-SOG_Q];TX_]C] M][>#D_;YUW.-#KY\_GYZ_@?ZN-=.3O'7SN'>[M7A]S_/#_!I>/!^_^IW*3W<.^P>G'3:AR?_[A[L^3F8;P?=#]\/ M]@XNS/MWB7K_.3H]__/\Z\G^]<'YNV^'7]XEA^^/.C!&]W>J9/^%=K/?UI)\?]W[LWWZY<]O!^_X]>\G^X.#X_#J]Q.XMO>9'/SQ5QS&6@DK6HS&ND6C M4+5$Q*-6Q)B)$9>$$K;U)H1_,< J1K^^F@+K,J'\=IAE .)W2:YEY]3*;+]G M]D!L;0#],T!_GP%HP;BUFCI@>XR"& [CEB2&MK!SVL8TCK"16V]:K3!J>0;P M;% >Z20W8'X'W^0;(/\,R.$,(&,781<"-4>"$E"XE&V!@D5;EL/_8FHY#X&: M 0QD91#^!..G9@/CN6",9L"8$^64!!IV#E1I2FC:/ MY^34NP!>4X"X(\\V4/T95/$,J$I%,7&PO]0*D,-2R!8G\,,R(F)$0T.)V7KC M9">W=P#[:EKIRJRS(#BUS6>HBEXK?YT72BJ /B@4^M<#4!#_N94GW7[':ZS% M=^W,8\:D5KASE<,4?GTU/43Y^IMW5E/(TV%6?"KLE=<5MI6H\1AL&PUD"]5O M]"DQ_K-+;!84$[(S[8"W'_[/M IS^^$WHZ^F1^\7K&KT"13Z;.#U#\\_<0OD M9S@>ZN;:>)IFXE91B-3I*Z//HY>\FMJHF?LF8A4I,)TQ1YQ&E(J(P#J+HRWPX,>TFY_+PM :W&*^M:F0\S M^Z8"0'%Q-,3HVNBS'^/.>,,"FZV@'#(R9B01!7A$HM),PR,CKFD2!2(%GM0%3# M'8@6LP,1DE(PPF2H&15,Y4 JQ[=!M]WT][Q M(-7?RK%^?37S%>-=&\]D5:"Q2FFMHA!9(VA,0Z$8P2*2('U='#N[-J YL@.9 M]*S9EUDOZ9WE#8$/JP>T)M8H%V(1\I!&+%9&49"6@N$H J5S#8EXJ>K_ MZ@$*_)A;ISAV(:($6_95'P >6$,4TDYY;&.)0J-ESI MD!&$-5)\;>#SK/Z6!0%'2P/4PFR,D*'82$X8BH24D2.<$\S6!C@U\+9K0&7K'G4AC0PEQAH0028J&02B&*8Z8,C:RFTBG!F2%L;4#SK K# MXN 3,VX)I]1Q@$PLL, N#7R>3V%8''"4HQ'(%F$C!\03(6XX M#D-)K6"2QH2L#7!6K3 L#F1& UNSRIH8!)$B3EJ)L6"($$4%=W)M0+8"A6&! MA(68EB+2$2>6*AGQB,6<6@FJG5$ZYL\'I57M !B%UEAN0DX-)=@(ZSE*A"F2 M)%:2KB *;DT0=B61>M->48&PM0K3T!BJ(]"+L5&A<]@@I2)NUP^VJS^B6@F@ ME9(JCD,'-JD%8"LE:,2L19$,36@Q7C] /]\1U4H :@@W0A!BHEA081#PY,C% MBLN81\"LT?H!]#F/J%8"4DN1B9T50*J*QJ!AQ,A*!EQ84VHMU>L'TF<^HEH) M5#DC/K+1&"XTE0!13K7@PH&-1G'H5*5 -A^8S^AQ6I SD J_80Z%.E14A1'' M&E0AP^ 7X5R:M0'-A'>5X;8!3 X_3@D#&O.[@ $@Z,A1CPA$0 M%V)48!VQR,BU =EJ/$X+@E(D)<" :0E&.&62@B3R68A 52P,M7I&J;2J'8@) M%@AQHI@65+-(Q 29"*9*&)?P8UH1KF4,NY9M4(@RD^1[P"5RF-,PLR62SKQ4 M'\WW5FS[$S3?.)22*XF=C",:82FXL4)CB251Q,H&)(T< 7BRH08 1MYF^:# MW9Z![VQV8:<9SGZWWTFOK3VV%S;S5:(:DGY@N'$4RU@)PJF)E8PD5A%L(XN< M)M6QT7J Z)W42-"%D<"QV+,+)A)/@Z G;I)%@#L&JJ8XF,9E M8:"R,8YHC*6+7/VCP.I$IDL*U-/64@@4D0Z>(=IAJ''$6KA&(GEGF M+0A 0DN#$78(]%;0&S&WH39QQ*PF(4*.UU\I&9NIOPUAWVV>'Y=#Y#<6P*>V MS+I2V^$@T;+3$&W$&NI$1"S"C--0@&$F#7>48B5C870#U,4Y('-@38- 0I5E M$0J9=992!Y)&"NMB'7.&?"D:U2 ]H@94LWH%(@1H1KX\G*.@,U@M8R:B..)< M<2*H6D4EM2;2VNH!R9 D_M"/(1#3FBDI521(-J7F2%. M,]JD[-PCVT^S 6C;GWO)X X\_)=KPNW&)?]Z0S_Q>\HX]N'/T0!S%UZ,G,)& M2&D$ME0SP95 PE=5$]A1:67]*7056+ 4R@10:!W!S]@QRJ45&"PQ'!M#<400 M;H"U[+L)N 1VW/Z>7%CSH0=;<9:HCMW-'3T=Y) M)HWMRNQ;+GOET6]#8(8DM\1ZT480U>D-']WMF4_2MZQI"EFRF%'O M4]'.*(I]*)I L43<& RVG&A2(:":@FWU%,F( ]O<..)0!*S79W4Y3 W7+ 3" M) U0-A_%VD?6M.K&[WTDYZ=GWD.\,UA32QU5C;,"3(@0'/L7!<.^?3 M*&-'B%I[B?F,\%L]C494Q]3$D>,"?DNK(DI =E*!3:Q5V("ZV@VR0A9T,L'" M$"GNK(8? #,N'(A/&49@@H28T@84H*VS)KL.*,E_*WDK&J>4, MKH"YOV8@6Y5RNJ@*SSJ*"=4$Q891%4>RZ+$:$4FUQ9JZ-8/6RA67!8'-86*$>1D]PZ9YFR3C@A )(-2O/;LVKPH>>#4?R#-T2UBWI;);D,P!,@4]LV3HE"#[AG:V#3 VY)G@]>E M3EE9:!-6P-L_C_]E96?07D?G"<8B)A%3+M2*VI#X1"RE% JE1II04E^J\B#[ M'IMFWC_TD3U?D_7=8$F"N>&)L(3;6F?7 ?2,<@=&NM:ER2@"@I+9@'*K<_F<(#^U?P(^3 MZ_ZM9)];-SS5]/!X45+[#4N8<)NF ]FY?7G)V7 M5%X:#3!7P^DR\C%UH%#:+$L&:9;<,WAYYT?W^?CDYLYYWC6-Q6$41R0F"HPC M"CJ#BC".G:52RAC'PM97DZL?-BTL=)D# V':*%3T-HDXMQ'HU39&W'=]'D63 MQ_43$%[^L=!?VV%P E8/)!/WO]Y<_'70=0+^B0A@@96FMP"KD1(41*/H*D2;4 M]UDE3%;O7'=<8QO&$B&,*:%.4L(T MFZB F0TMF&92+>A<QTB@F88AE%)KZBI)5.IH^ M=63B)^YNWE9\G2470)>?@) 7@'3K(#S&KJ=..=69SJ;JVH/=2P0[SBS18-U& ME,1:,<Z,)KPYW_8@5=DZ_I@R0U!ZCY\3>OP6=3"=78BUER(VQ M%E'I*Y RK!V)'%*86,EN*UDU]-4]*Y/\F?O@?4,]14_0%N-''T.-.79_!+Z9 M/'M\]<%!-C$8IB9B25-#)((F.0 M,(+;V(28NY(->D1I;3!FI1CS5"Y=Q.!W9-<:^38=]I81(7R+ET[AZ(]YZ=2M M3^E=9XL.C)A98:BRD2#2:0-&.+=*4,HV?.\ALK?AO$T@1RS%U%$64]A1>4J2=_GN8);E)"E-CJ3;&\Z'BZID88"<)54AI'%D:8Q2X,L4 4 M+0+<-> #2X&U(HIPY&+B.[6K6'-@S-@K&%&D MK4&5]V@4"HQK'0J\6-5B 1)WWDA@O+!(X(A(K4D41X9AL(.U0LXBH21CG)I( MBFEG(*ECB,_"R\ ^3$<\UK8G8;]O.,CHFW=I9K5<>JOT![CNR,*Z60G#M%01 M-A)KBI"/$ );@Q-&G58*APTYJ5\.[[^IAO;89A>)MA^.CNN#,0OL!>. =\3,81.!4N\XCU!HM PCBF.FJY[K8\%1 M;TZS@G.U]VEJ+I-.YT.W+Y-L.N_Y[K7GK*\\M]1:'/?!$8T=,X[%(+-B$4H1 M8VDY,C&AG,BX60KG7/9%7?0_3K@F,0.C/)+ ^+E"!#1]%5K$;438.NKZ==EZ M1V4D51S&*E84H"#"$" A;>B $GP4=OUE[K(E8ZWH;_4RE\8TCAA3,1>:@H$F M#,%AA#%A6*'0UKC^2Q'X)J\.Y 082*^0V;VW3!O3@ <0EA'W LGCBDB6')L M:40L]B4ZE;'US9Q8.006U1(J%#:6.K)6P\['6(E8D)CX0S*%&6M"05M0ZOZ4 MG:'][7K\Y[]@1)GI]O7OOO[;[3YWU4T?>OWA("_N0(NR:28F0<)E8X0*KC!D5&8RB;T#W@VF#TK M3B^AC-Y2$(@*J23"W!&LJ)&*1UH1&C,$_X44+-\- JT&@4A3$,A$3$2@YB/" MP+Y5"F-0^@5&U#&M18U+%BU4A.'=GOD9R&J(TG7!(FL9"6/C"( 7Y!CC+%(\ M9* *Q=I@TH""@W\_F!$>.T>5D@ISRD!V2%!C098@9D$#:411XXWRNDKK!V@^ M%B[R3O:8S9/SGHS2@&,+EBSFU?WWM0E7Q2Q[]DBI3&YL#=C'R7YMQDG9C8? M',%LCB]E?YEOS]_+I.>3?WZ[KE8]V=[G'DRN[FR(X<6=L5I9B2G\"S56,E(. M#&9?EQBYN"Q<4,LBQ!O<;2;NHL6%Z&+M\2ED&I3T,$1<(BVDM1*%' G1I/;Q M\^'/6YFWWW72RZ6!:?4G^2$Q2HM8L3 "F&HDE1"QM\*0X1&EG@!UR4&A3_JG]JSX,9]>1;X$Y;EVHF>_J0#$!OA7&ABHFD!&:Q:+^ M]ETC'+F+JLRM&)+&*6(LI\1HP9&UD8MBI6*$HQJ7:VX4M!;D.Y%&*$>C6"#I M@*1"A8AP2FNG72QUU3^EWG*C;/0E,WMD^T, D^2M/X^T1/ MI$CNHM^23@<&F?WX.O)2'E(G#5-AI$)*A ;B1"*BD3':XE@T(;9[5?">FW^, M!?C^?X:P86_3;C_MV7&"X.BVDZSPN5X?#U+];1UQ37$GL0#*AI=H2'VXFG%7AN%L8;8W^V&#;>F";SP6E M\V';U*U/J6"@&8LB1T*K-/6.;JJ9E,#$K Q-*!L07S GDNUJ/>P..]ZQ43E9 MW@ZSK#@[-N?#?.!'^-#3G:%)>F>?TJQP40P&6:*& ]\*^20]3'M^Z[(44,3[ M)\I3EX981+$-C:1A1'G,J(LMM\J),%1$^E:AXYS?M8+SH1V,CJO>96EW\IS# MYNL,:Z4E;+XF5L4TYE)(H6/?A(0P9821ZP/K5"=K#,?(AJ 'J- GOU!#N4*Q M$BH*N8LYT[()5NW:,NG5VZ%< ,2I0=1P0:U@'/@YPE3'3D8&1W<*D:\5=C2 MM:\>0UQL+',T#)FS%(Q8P9#62@*>.&L(:H(7M+$"8?70MUAQ(H GA)13D!J" M14P('\["$7*JQJ5&UE9H+*=\I DC% EEJ(\3M4AQC97&FL964>H:D)BVENQ_ M.;!&7 L7:1%*"AQ=*&*QL"'UZ6S(V0;D0C>.D2\G/A9IBZS1U!A%D>!"^H0@ MAPG&)C*AK>)CU\!":R)O1HNKGB),1 1B(2<7&PYHP9IH4F &!*$8?/,L9%QA:CR+KU@74=>?/BX.A5J9 RPV%4JBR2C'#? MMCO$.D0.R?4[[6L.DU[]Z9PC(:4X0LHR3'V_(T(L%Q'B$7.*8+?6V-$ UKYZ M#,%.*2\%,,5@?PDI2%'QDR"MO3-W'?E';03"ZJ%OP3YS"H7:8$E!H9GG<0463D? $]N8<7' M44K.J"/(PB.*[V\Y\JDMLZ[4=CA81.>1J08#/W[57I*7> \/RIXY[EN=R,XS M-+]:$X"%J@,:ZP>-ZX?%J;'/!I7 Q#T-0 MR'R584)4R"0%I4S[Y/T&\.,?0O9PJ#M69I\R@*&__5\6(-FNJOLOI(OFVI!0 M(_EP)")JE<-(1Q%%ALO8$"TB; E0"7.Z 7QX@[_UP-_5\%]C:*B\&B5;-!*5"!".L''& 1C(26EI+#(LX13S"32CGL4&B M57,B@XDVD?9E%"PU"DF-&(H%8YA@,',VEOG3D6A!S4!_J#!4[S#3-DR_; &\ M_!;NJPCJCI$R& DA+:*:&*ZPX4R%H9,1H<9LN-\&<6O)<9U S$:AI<2')G(K M&/!< Y(\Q!%6N FV]P9QB_YD)NG)3FF:[0[^Y2LWI9T"@]>2X4K+"7!9B+B.&J(DLEK'V]3_^GIR@ MF73)G(LX=X*($*#JPU%<'!,4^:P#&C>A6NX\L'R;9OT4H&D/TUX%SG6D3(2Y M<%PC%V-"2":6*IC$.#: CJ#=>A MB9PR+(YT3)IR(+5:R*W&)\E,#'1F8AY9:BEH."B62I/0<(M V6D^S4W4;?^\ MENJIPR@*I>&A)93:&/BETUP*L$"4H$!_S2>^YP3A:C)B. I#+*734E"GL2+< M5QP$594X$JD:UZ>HNXMAV>?X2RE]@+F+1&BD=28$ILR4Q-A2@L%B(:#NVOH6 MI]N@PQ)JW&$9$K!98QPJ2KG#PC@NB0P9B2(LZES1I.[HL#0'Y'(JHEAI2!P1 M3E1$I:]G$T5Q)&+-F'9(T U;J#D>+*J*AN8&28)43"4E# OM:Z<(!1)"V2B2 MS>8'S^+L6 I]"J$)P2248:@IV%.<2 V\VT8@Q9U5#1?;*X#+HBH,&8HXP;[P MC*)647,C,GUWT[#9LCZX.H],":HC[\YUXRR(^. M/Z^CM8M]G4:_M4Y'-)18:NTX(Z%A1B)LFF#MUA*8JSF-B7EDC(M#3!S%C FC MP!!F5@O+I8I4\RGSD\U<"B9'3]NB8<):>J HD2;"L43.:4H($@HCQ930 $D@ M2])\FGQN,*ZF*@\&FB.^?CHVU(*)P2C8%L82'6,,4K.^^DM=..I2U!?O!%0* M(8,,*/S*<&4-7A(+QAKC4D3V]>'/E>O27\_<># MI)=TAPMKO%<3MAT^B&U'"\J'T3%CS'+AA*14A\I&BL<"@2I%I!.%1HS$"$'" M#8*L#D&0F!]!PH4AB)4BI@BIR,01!9!Q4*]!N1:^-R,QH6DH!Y%7ZX<@J^$@ MPF%NM,!,^@9G2G'MB+81QYQSK&/>4 ZRC@BR&@Z"%(PF#',:"TH 1<)(8CF L=$RICK2*)A2&&@\11@C3!D?.W M09#5N&VED1P0(F:AHR9D8,9RIXC"5#K*$&TH!UE'$;,:#B*Y51@;%3.I*;=$ M4*X9)T1K$G%4I5LUCX.L)8*LAH.@.(R0H3R,@6,PQ<'N=;%@DCI)"3&-]4X^ M _26XI=$1OC6/#%8E8:",B@5Y08L2F:8T4K4."RI;@!YC$?R57+U&J:6#C-M M\_)CVTI3S,$W#'=8?_'*9F$'[-0K#_[DU?:?,SN!FE0X&:?K95//3+]'#^Q1^_57EV_FM!.6\QK ^@=F].;J\DYQZ=7 W+U&\ XFY-[+X0ZZ]]JJAJ5S M#?NJV(ER-V##\[X$Q"=;HP?ZTO@"UJ]Q_RI L,?%II;[V['NSIZ7VUW"_WDK!VRN M[LJ3[_8UAU<7GRY'J!;^4N!"A7H>V\JY&:M]] G0[^MA#]#)WP7SD;681]#. MK/OGUG_]G-;BK3?FN!%Z\* M4AN_[0[MWZ;H2?30UE-G.3JX572X&-#HHH MJJ# 1,"BZOH@[<^X."^$'@R;>R@47OE0RD#1+=*(9Y#&UIO/AQ].]O>"XY/= MD_WC:62N_^2/]]]^/OIP\F'_.-@]W OV_^_;?^T>OM\/WGX\./AP?/SAX^$# M5E1]XP$>+7^!:*X%?I%Y&_!LD/:V__N_4!3^LK?S=B? (:-BSI6)Z96)&H . M^Y6] T4M^!64GU[:.QQV81 =5#K2D6?)"58A*1C;%A8$T@ M.K/!<]"37ADU-GF]E^JAU^J\EKA5%4XD?UZKO?3B=WQT<4H.AN9\_^+K>W'^ ML?OO;P_D ML'/ZO9]\W=NGI_B4')Z\ZQS@#^'AR1D][1YVOY[\<7EPHM'I]\/NX=YO[8,_ M^=7O^.OUZ1<='9R??C_X\N_N0???YQ]/OET>PCL.WG^X/MC3EP=?]J\_PN^/ M7SY0^'QAWO])S;_^W?F*.Q?J/+T^/#^X.NV>7I]V#]C'D]WPX_L/EZ?G'RX/ MO^]>G9Y\H/";G9Z?71XB3@]W_\+*,(ZI;6G+9(M205I*(=D2R(*];K'2!@0: M"EM_% KH#0S>!#_#*X]%K.F2A>T@%"U!YC;-WIXKO'A]S:\XQ1]/?] OY[_ M43WS)[R+];Z>I-^_[IU>G<*:3O'GZX,O?X0'YY_IQY,S>.Z4?'Q_&AZ>_]D] M.(5OPQ;C%AA&%..65$ZVL.4* M(>8H1WKKS7__EX@I^^4VSQBSC)^KM,M#Z!\+I7 N!"P<4YL-@7/SURX?P].3@^N.7P_9AH\2 MD'* ^R#^7Y?R?XE<<+\X3/.O+-_82/;V>)4,KM._I.*AC"+38L+I%E6Q;'') MXY;?2LQI3*(PW'J#6@B1F-17!\-T+L_>TI'IR)[YW@.R-SB$*W\_A+KZ2PI MJ!";5FP5;5$"ZKXR4=3B)O+G^HQ8QX'DJ[KA05DX?#OXT-,[]46O\5%>,=KK M9 !OTG/@VXO]*ZD'!9;XP[ELC!V!S(/<]X1T"=BH22](!GF@VX4%^_)Q[O-Z M6 XLBG8P*\^V9EL.4R>,TQSD;@ M.)Y_Y-DGK8C=.6I%;![MN22AVSC?38SIV%6HT$N77L"$JX(EB4J MWX(]>]G)_#>[F?Z][X:'^#/\AN_._^R"GMQ'<(J*=Y5$+BTB A1$J,"ZH;&&)A6-4 M$T;CK3?$EQQ@/(JB'Z+Y; Z/[P;3U(S#BXRP]'Q\%^M]])KVU6[-PT MD0>'Z<[+.;#M1Y%;3XVD6]-;YU;,YL*TS#_]-Q)'N\9D-L^K7[_#!-!&%/U, M%'V?H6N%3DM*8]EBTL8MBC%O<>*B%I*ACB/B0DO^V^NTF.>BQ;?PY\?L)+W<6#WS4.*'VY3H3"25@IW66(+5$V/6XMC%+<1B M3CDED8C,UIN]H0(0;XBO(8MY+N(K=.*/V:+L-,]*2-E(^U5IAIS>.B940P*<4,+SS->F7?KD-=O\4N^]X)5"H M#;)&MC#A(("T"ULB$F&+HW#93Y_A>C(;/"NA8R7+PL9+T;T);_ON_.$;Q+WDPL!W;]V@1] J\V Y ('2&GE4'$D@Y MT%-LKXGA##0<'3\_/)Q!\%$HQ((/Q8$3+&ODA\SY'MT'W]%]1*T$^9S*_#&H M-%DR2&Q>Q>W8S)J@/\SRH0_@&:0!W%&<&R#\0KWT"I$/V]S5@]?S:(B/]'VO M8)<>J.^<)(.R%(&5NAWHCLSSISDY&K#D3!8\[_BZJ]+.BP=IOXU<\&$5T%: MV%[IMJ]0%0 I7+83^.:&7N:AA+O\HJZ[M"KCOV)%UPBK@KH:J7]5>:3?OY'3 M[]_8P?F_OQU^_W?W\/UG!'J6SQV]^KKW[?OAR3X]//\<'G;OYI%^/#'^/=<' MW3_(0?.OOOV\>0 '?BG5FD._IO MA,45ERR9Y :%YT#A_3O')H0PP0EMQ3+$+4H-:LE0FU8HD1)P 1OI@ZMW_[5! MTB>RVOU*J)5A_+00CD/S<'_NX%/;S83Y(W/4J,J ^]'ROR($-U'6@ MVQ86"S/]!MJ4+:*^O%TQD3OP E4NG[;, Y=TP"R1G4Y0-A#QULI_AHFW5X@+V%0()8@'X(:F+=3G\\P2E\;M.7@]E(NY?1\_63+AZO5O-P.9,\$ M+_#$DA70'=RDSF%!_J'B?GC2SZ<:K&B+4LRDF*[,!X$(RQ&,O,YWRC_O_ESZ M"<[;89;!W,IT6R\-!W(PS!O)19[D4 O_DDAK&JFX!=H7:U%L;$L:)UNQPUQ% MSCBKZ-:;4YO?IO%6T_]P)V@75CDN./&(.B^ :]R'Q85JO+:*_/,[[V1B& M[)D2\*-N,A@ &[,=X$M9VO.J4N%.&C+/B(_LV;!31JL>MTZ"%Q[$\2^8X)WJAD$[*1+)^CZ1[%E8=CGI M,1.V^)7?:;7#';OQ]W17\QC4%,AE'+(:Y:-$2D)608MAR8O4QJV%;N M?L!='\@T3I(N: U>7SM*N[*W"+:V>K:UX>R+X^RDH9P=F*D,.K 4&TBM@;/[ M9M6FX'.9UTQG?AL .;5F7LB[(!+@+=E(_0,>V(4=N-[VVC@,!XJKW[:SX P6 M.FB/+N^ <\,B\OHE]%M/[WAWOF-[O.Z^-8] MD]SR>6%46!E8M/+(M)@V*G84<"-Z@4&-*(Z%XA['Y:@8_9%B0_?']3SYZ MU&B'4;;P89NV!QS-5W%]2:71GY,]/D\(H]=[L[? @L[2['J&9ZVXJ6!.NKJI MT4ZVPR^?Z=?W?[8/0#D[A7']?#[NG7FG&3[]\N]O7[_\$7Y]?Y0 MM.&Z'_>W]N'WS^$!S!G>:'LQ31#:S7B92/2Y6]U+G'>GOYL5+,UPW@2]=1BCW];9C#F_-\ MC6MB/H]N>I\ M[7G._K0#8,-LGL)L1IOYOMC+MR-?RH;I/(GI7,]@.HPSIJ7"+>L0;U&L=4M% MD6YQK",>2Q&+93&=Q^7YK-)+ZG[@C?1A_C.=J(F;=3)6G(>!\ME+B^.L85YZ M,F&=987^&85NTZQX5^?:O]R'X,%LKH.>O?1NTLQ>)'FAS/9D3_L5@XKKZY3Y MFWVC0R,SDP<^_S@3\#@19]!CLX=5[\IJV?.;%[FC&K#G$_:HPR] M$1_-[B;SZK&&Z4P_L3\ND12]6/QPH=6"! MV&+0OQ?GW/O&_HI"'E%#7$LZ9%HTY+HE5$A;$<*(,R.L\2TK<(2W07IMAVQ< M&7X$WS?W'_*.:C;BH@%T/RU5O]>9]7%-%_;>EM 5584WCTB5IYWAX/Y''J!= MORD* M[JF'NKD^U\G:_CK=$S[>S&,CBS+959^0UV=&"SU[)S*:_SK5?WM];Q;ITU7YXQ]U%^Q_NZU-M+8XQ?3#SQGBN9(=;I?)_( ?.X_YDBY^ M9!<]\LWH=HOLG[QYC- +E:'S@>$/%+Q+O$SP,HX$18]8WZ0T6/V_&7V^']61 M>[&JR7R]=FO0LT#ON8P!X!%_GBHY"BG1@O1$+=L[YG+J+T' <,LYGM)^G3 MO.ZFCB]NOQ8E^_TN.+><@Y9R MC,C6FP/9 \CZY*S_E0=[($Z'9=LO'U:Z"SK.=9X4=N6[L6L7Q((I?(-K/(9R5H\\")/ QM\#T@ MWG"%QG,%@K;>[%\!F'IR@LIU"M3?2:J.!B[P<4SO=W<_33"& ROS868?1OT; M J\?@7L,0-&&PM>5PFD(QK,_?TT&A8.O(''XHC/Z[/6 3EH01UHEVQHMP;P M71[M1EMO?K=GOLN-)]JB/,"&:AM/M0!5C#94N[94*[;>>-4X>"?U(,TV!-MX M@@6 XHV/:]7P71K!,KSUYG-OHHCTL>S8PHF]_Y]A,KB>K+SF->C/>7$B6LGD M#7TWG;X]_#'9T/?:TC??>G/CF"ZZDW7+4(8-X3:;< &PF&X(=UT)%^'B]*F= MJ&1#K8VGU@*:=&/XKAK 2R17"H)V''CY-DOS/#BR#G3JGK;!!QCR:D/%C:=B M #+=6,.K!O 2J3C>>G,,FRH'FT.BM2#8V#=*_1'!+B+]_1&I+<\>S+Y;1"_< MD[#QDX#V&C2[>];DG!7&N->UZ,(MQ-D&C4;O%%5F?9=MV)FL7Q%JD;E8)LHC M$8OM,J'^K).JHN1X NAS5E;\:A=#:9D!&MGLPO?F+7R,_2PU0SW(Q_GW9;F$ MHN0K[$#:A7F;H,BO*VK-^I(,[33O^Q9A^?;4L-?YP';ANWY;9EVI$Y\]*KO* MURE/L^L@'V9GO@)ZB=1P3M*L>*3?OLX3GJ(=P.4]8;]'+ M 9;J4TK;:=?N!%_LJ+S#Z*UV6.!V^1!L3?&"\2+]ESK-!RWKG"V+L-\LK2AR M;GMMZ97(?-CO=WP) PDOM'XB\'I]7;Q2I[V>;SDQFM/V:!)^57UY7?ZN=B&O M7MN5O:&3VLNZK-S&">@4&ZC3M(#[./Y1V4%1@[U\C1^A"IHN9E%^#-)A%JBJ M1%7Q5%G[J_C^IC)&5@5,^]V[3 $%S@K/U.O@T]2V%0, M 9L<%GN>^G8\K?32%X8HX=@K.$"Q@?E0Y8"ULD2A8:_C=\/C295./*I4GP>I MKT-QF>2 /1^++2IRN:XM3,KV3.Z;U_U[V+,!"7=N;(J\[$ERD_;E)W#S&1>? MX99WI]4U^ /[UJ?^RR(#^N8UN7^/IZ^T>"-,WK^O2IT.MV_&KZ8Q2J:&R?=+ MG.U2Z>IJ3^=I8!-$RK8F^N^/?+L\A*L.,N ?2MW]/T6]$[<<)MNA&8 M3Q28]T%VN9(T6B76S5L) ?C9'T/IFUP FS^J>&9O(I]SU#3H/^5=%:T>VSZ@ MYTVM@XH\@Q<%A]P:/[[U,GAQTP0YZ94E!CQGAV\K 5ZV8\I&3.9EU349N,V6 MJZBB4U%%/J:*K0# [P@]U_;*\\2RO270@H5+ +^M+#E\+Y*>!8\#WBH%R>5 MG/.\R=B^7Q2(EF'?ZQ)#+YQ\GQ(O9V'U!O[LI/WBM3O!@=<.[I]7(/M]ST1! M6-QD]XR+2BPJQR=XL76P]]^RV_]E=^OE-@B^HBT)S-JOIUAF/A978UAL5^U( MN_+:=U=)_)(3EY3;?YGZ(E%%UQ()&U_NZ/96L.4CE74"PM?Z3UY8]XS_R^+23? -^#G]- M2D>81 'A JJ%""P18W*[ 6U\/2T/A IP(QD/D#L;@EP$E-J>? (V$LP2#[EB M3+_27EZ4?,Z&H#'M!"=MF]LQFA0ZW4USK2S)OY78-(2!LP'H1<5!=8%-Q7)! MBQD6XPV&$QH'/&H2YTK\LYZ @=Y42>/*^&96HG>LL41/*RP0VW-!EY?,/A-A!HYT.MB:# M:HIF!EZ7VNWU_++NTN$!R_\.)5>5'PQ'J)2D5[N!._N)[ [ M*PF VN4WF OL:%F'I>@,X:MOC3H F50/2XUQ_TH#ZQKI(T71M<%-_QX@!*#? M#NRPEYL=>0DT8X/"#3"0WVS02X-4 3EGET=B,6"4\:+QH,?<- M,<'4X.&^S,IG??G&K)!;9:W'SSO'.\&9[8'P]T+#%S#O^X$FRCSV,V#F2=^' M4;W8\F2Y]7(LQT8K+&WK7NX-='AZJS>BX+N[L56RO-MM,+U@&%<<]*6DDE*5 M>;%UO/\6-+UL"!,HQ54&(WD]I=KP4E+]X(VEY5@\.)GLF%>,.LE* 6B 2^N! M=TAX-TU6,(M[1X3U5@J#&;E+*JGSI S+D1T_0K!Q5:\QGMT543MW:[;<8@>, MKK3ZTY3O_Z&^Y69S6>%Q$ MU1%4TW/(Y6WX+>?K,DI\S;?U_^]Q59<7L0=_H)6M>G6+GEG*[,'H_S/%^W$% M%'W%CZ=74"STB^=7#9Y=$?!V610_1@_ ="?B>.$"FX4[ BVA%Q_:06&\B.): M=PTZ2Y$C;&1LWI3O'0O@\OH"^U94)N22^,I(+Y^C9\$SKGFYPGMD("]PS?.Q MMX<'H2RM3F?A,5A2C:W%^?&>Z:#'@O$\M7@Y6OR-XT)9L&1]\(0WAVWFCY@+ M#\3(91V4MG_A@[VQN/74?F4W^Y6.]VO2V2R[WFM1!2%4_NIK?[N6>3MP,(.\ M7UI;6?=DN(_?^8%T>;/S8$Z-DIPQR M:%OK)S2X]UAK= X]_?785?Z#=TP?/%B9]7Q2>7D<->]3DQM3^=@'[5%)"N3M='_O$^;&C6*CSYY>:.@PJ* M&9K),(+B+/$^'"N/A/RQ$^@LQ9[!>L^'O=*%4KS:OV_"@W+CN/'[-'U.\'-W M2HPW[I2-.V7C3MFX4VKC3L$;=\K&G;)QIZS,4J9'B,5R7I:1_C G<@XGTC7JQ[K\D_J-B) I5T.MZQ889%ZD->%#BJNL86 M?JSI-!WO-AEDB1J.O6B%"PN4YNO;=Y;92$5J31G-V\\2P+.DB(GIY;ZDDO&D MJ3)9S/_6X^5,8$KV"FXMW''PMIX=%-UDQX/?'ZCXV(3$>E!_$=+C5SR.[ZE\ MNCX(MO+-;5A#;5A#\[Q?,=MA)%J\TKO#Q7Q>JH==8_1QHZ[+7*.=F/-%*/T_ M]<(A5JO&0_-UFCLIY.%!*0_WI^6AC^=_2$^BU6OZM]?\T-H2+Y)>T"T%>_YR M'CO@85'#UKZ-LSCUEZ;?9[M3?.'=YM]7CX^ORT.MQ_"T^[NB"[^ M/=2MT4V,Z=@5++E0@=.Q"FQOJ\#34O'>Y%B7R_J1E2 M%I.3^C_#I$P9:159)M;\[33$^$&- M-59)FHP6LV'S C_8N5Q'P&QTQ=G@_1WTP:I$Z M?SP[FE=C\Y2O=EMF9?0(3 MK+LF<(_1W)3#Y1IK($W&B@49S36&SG/KA],91OC.8>.#3R+CG9C5@J'.YB#C M:/V%A2H]?>OJ%)&QV%"F!>Q-'=C.[$VAN&$:^<)I?%(;C#74]FKH>$>2U)$JKEZQX@HUH&Q MHQSG*)[*<48D'F5"!:8,#7A@^O1-UG*5(BUA5$;+NT9#]S.?Q'E5] TH:N"= MI:GQ389\:YS*\1R43I5@=/A6%:ZKFO?!^XL.?V4Q.K\@O_JB.5-U0]4"T'?> M</_2[L)-W[(^:34TUGR@: 8SK MVOF'?Z)_+J5;,:Y+V^0?3V3^-KN<>;-P8 ,ZV6GWV4EGQ#BV_%R*Q/JWXXJ. M4]4Q;LJ+'D_T,/.%!SS/]]L ER;[HZ5E38%- M<A?V-C+Q?[9VT]F+'AA M1O4L03GYTEWK0QP?ZGXY]:LYM* M@_8SI#A5LX1P\VHG(?'7-ZE&#[7$5\U8Q5R3FLY,W]>(V]>+^X;U^ M0>Y3RN>J%_?(,EKU,/'GKQFW!#.3[> Y7C_#:^DWNX5W^%TVKV1N*SA.1&O_ MS!1=6*VUM<*%^^O:/0LNS"3<]<>%F@F'1937,\K_[]&) ON._2 &GOFQBQH M&/<+7J![4/YG4&IDT-U30VD?O/;ZAO>$.S1L2*SL0W=]V=%ZM_C4W.&L3::< MIX:K-I)R9B\ZW!%TO3%XKI#1A6!SO7CB"_: NH#/ -,:A'QN2N)M-N'94WJ7 MK,DOICC@; .QR:F<]RF*X:8$S+RO_!NE^&ZJ!*[(S_'<@%Y:E< 9^U KO+^7 M'_*&\,/9B-84RZ*V>'&?61@^TBRL(WP>.\:Z5W_95 K\ 6/$3?$HUE@+:3)> MW,<8<;@^\&F*EK@2&_II)0,;L#GXW6NZEY.)\+8%/U<*/ISL*+AW:,JS%\FJ+I/CLSK+19*[/.=0"3A$F# M\=\NSHA LS56/8X9UET#F,T,JW. AO##&BL?34:-C7+X:.6P?L?]=0HA>'3% MM:VX&.\X^-#.R#QL29_SP,..%PK].D91/C4%>[,;4 M07COU(^9YN #OXD?VB_N8D]1!? MR1+)JUZ"X<4#@K17C48UB.#>%.VM4]'>^?8 U.5QK9%QQME\S8!ORR*H/H#AYY..AZHR,LM\950/?K(J[+D[W^&LC>X*4E:7@JLL,EC,^QH=&.%?4E9RW5K_PJLWMY-9-#T??X]XR%NZL4>6)D/ M82D[6S4JCSHG?,C+8,X#__S6B?^HI*RO'CNJ _V#\L_PL*\?/:Y*?4\YZ%$1 M50_)S)>G>%3UZAU?HRYP-S7KMHL!_*S]-)7M65^B=6H.@'EW9PU?_@/A\:3] M]OC[;HKI%N/*7F\(+RJ1T9??]2_Q)7-W@MV;XKKE'&375Z,>X>]H)K[,\ .* M<\,$JL*ULM_/TJNBJG7G.E#7ODAP<=6O N;T#WQG]O:J#],LEST:J)@:C'21 MY/Y./QVXE':+I=A\$@HP-."'S["HN'NUS=? Y.;E3U%MR@/O/0:]MH,[OIR; M4L)LNA*[S]$M=KXWRP5T\]BM^NU@.$^6&W92#](LK^H^^QF/"UOU?E3@>+H& M\7;0EZ#CR Z@2NH2FS_6$&X^7 %D&4C6MH;_^D9O;/^$);^DG\XX6/97DY*4Y](<2" M!U6EL0&+;^_VIG;\:B?2O-KQ&X N"*!@V500+0#:S/G':]3(P%@PP3K/492^ M'G4@W_KN))Z<]_\S3"YDQV_*IOKC:JH_KLPFFI/2/H+%J$?X8F_P)5"RXQ/E MBH8=_R [+% CS7IPKZKNG1R@H)BRK\1.//G,OX<]>]MP>:1"ZDV;8LZ%$N]O M!=?P!:B;@TYI:5S(?!!TY7D*JMCUB+&E_20%A.K(RWR8P&Z[I%,N M(_=LK%3-.JE7W,Y\\&*OLG#@9[FP%P5W/"[>4KQS=_3VK9>EZN=O. ;D*MP( M<,.>O;"=M%^:OJ#T3A8Y]V\[R6#7\[&^-W)0;/2]18M7$5?:0;1V(O8V2+X,>*[IH]5X^^-T^JE3]SH,:H M'9NN-S7H5K-0I6WQ97\7G,PV9]^2Z2/K);[^GF;6*VJ1LND0].;_K:Y9SJ9# MT*,[!,W79F+3$6?3$>?6;#<=<38=<7ZPYCITQ)G%#A8G(/!/-Z*P<1_N_[C# MWE;@OOTPV1/W0]D3=T[W;<,;BFX\N@MP[/R@\7+/GA5N@LYU((OXC=+G.*L) M\V0KX$FO3@8SZZ?9H$JN+CVIWNN::BO+L N3=BVL7@V:R]*&($;RJ",%K>.]KR?P5*YDF=(N?F!-<76P6I^'WPW:YG=<2& MG=>I/YNOVM.7G;$[HQON:\L,;,[=8G/*7J<]4SCA"GKPP]T$2G3+O'E[$R*D M!X6/KBTO"D]YZ^B\& ,4BZF;TT*2[\-93.P'L0A'9 MT,G3P%ZDG8L"I?S9!&".S0KWH]^!K(H(@05JF^>EX[(Z!@B&>1%;%YS!J*"W M%F_Q-[N.O4I4TDD&UT6;\MQ.!!455:^*EYO$@:SPD1W%F'Y+!\5Z?+BFLN-A M!VU D0\J,&Y8BP_?Z!3/M@'#"BZ?#R:ZH+>!!W2!8HRGMW1X MUBZ//(;]?J=HD9[T=@)_(.3C N\@W3A\J@!>">D"5+8"U UTJA[J!;5G/CI6 MG1<(/AKPS/;& 2C#7H5*8^;@$3)T6\:%L.BC>483=%:-ZXVFT^WH/; M-%'R*SF&&A![N=TE\"K(>$X(;]9)WV-]$9@&;X/K'N:]=%",7$6M3A"'';/2 M$056'N_J+9=V8MCF\:03OW$=3U^C?=M^B)"X(:Y;XN*&]1?XOEW2^PWDQD+I M4UMF7:GM<#"SV_SCPB1_R&DGB:"BQI\QW1]/W MZ4[JX^?/MH-N)15'D:&CSV>9!&W@K .2#GB, Q(-\G9B.V;TJ2OS;_E$-\<^CC:(=>J8(+.0A0;2O&!PLS,(M\DB6:Z6G>XGWC M6=\;'#W)ZVJ4&3 O.L*29R@0=P/U8<^'=AF&RZ0HK6*A01OT,RV\%2-5UH]1 MH4 #M_D'INF,W5_"+H^V]A^(3\?R%.0[(JBJ2MBD2E/HR=Z4NS5]RDB9;0]7A+M] MGR%5\LZ)H)=9^05S<+[UTO)&F_6^RF#8Z'>UT^_J0=%[-\D[%1^?R$SQK-.- M8\A&1GS!&3W9%?0TF\BG;;;/M,G4O;Z?C?-]ZI*H?-OZ_E MO$CQ?BJ8TJ#(8"L\74#XP(FZ!=>%:TEW9@+/P'LX*Z8UF;ISPS=&'.:%O1J[ M2&$G;H<,R$'K7S[U[-@'8Q4.#8!ND9CVL@SR].7*\F@^ K]\O*Q MAO!)D7E:K: $2"ED;I(;9R"VY M<#7Y:GI><3 9& 6]R6Q 6=CVQ:[XS*XB;\N#]ZZ&->.)>U!CDT[5E/#:NJ13 MU36#Y5EW8;>2!A/)EM_LM><"PVZ_9'=^H4$^<5!;WEOPE5+)+4QM'Y:?=A,= M#,HX]3FT,9^RV3&C;,VD-[FA,WCZ<^0'+6ZD>H0!+V/QC5$4-X' -0C@?>9 MX#G>O0EN771PZ\K"/(--<.NC@UL7@_Y%M:I5Q-"Q&0M>V%'++$&Y"?;=!/MN M@GTWP;Y-"O9=@4]ZLNOUVXFNU^/\TDVA@TW$P>RHZAN':%5'P,?P%4Z^PM?K M8YYF8E25;#_SVM;+,N1PW_M'!X-@-\]3G7A?WW;P^\ZGG;(,1W7Q@W]967!/ M=JKK+P;IF?5!"-O!5G4?C%DXOBIGJ_>1_I:",N[=&WM)9LOJ6.6DB@M;+[=] MJ37O82["&8KP")B K\HH^_TT*2(VG1^H9R^]6\7VO8O8QSN,QML.;D)Y?86K MJEQA&>-6..NKV6V7+E[\,JCB!_%9.P=>2 $KW_M0+[^,IQAL5:1@?O?K8,@8ZTDR)>5':&-X%TX\#:<;E& MV;LNBE]XMYJO*=CME@OGTZ5$5L9D.DIO]\^OJC#KC5N@Y MD\:G(@?3\K63OL2./?/D[$\OJN"=BR8SF]&,X#!1P61$-_?";JX=+PXO M-L<+"SA>H&+KS5&2?PO>E54*5WK(<'.>]--R'-41ZT@\52SW!SC?!/?SI@K% MQOG\-W(^;ZI0S&$/1YLJ%)LJ%!M'_7*J4'C43\P_M^8H(BJVGMV;W13?M??G M1/'&=;UQ7?^]7=='-RZ$CV,70@.*5CCWN%V)Y_)P_WA7?N#5CA;<[7%.C_Q1 M&5M?5[^[$#L(L;^WVWVLFR;=LR#/-&"&;+>\(RT4)/SK#.V<]\^V M >[[DR MO2XSCP>D,FP(A06[T]9WIIGV7<_\IN_2'JC(X_\3G/!N:5--?GF((&7!XM:[:,=>37> MM=EN M@UM-FUA^+:VR(-X2%LY:Z1JHM_-3#(YD.4Z8(F<_4,ZF#]TW^=OA3O>_Q^QN)]1^MRMQIM,.T_M M)MY(VIF]:"* =O!ZX_!XC!_U]EX(/M>++R*VX8FKVOL9[<$?HG]5+ONFZ%]5 MCO^]NOJ/"&_&4AM 6V0[CINB:PTCG=B5F,9=9(.[M;5>I3$6D-5D8KM*(P:(L]J:GX\ MS0VYM@AWCY@DVR)&&\"O,>#O,4K)ALLT5#%HF%'Z-LWZ_@3R<4*^H6[E M=F-US(6,:P*8I[&'>M'*X<[!SB(MI2HX"M^1$G.+D-*"FH7,50)O;?:N-*;N M,:*>;;_J=*:TV//8!>Q-?0FO,#:;J08^'2[/:Y,\;;Z// Q>+\)>[&'QFA#V M_49]Q#<$]F@">X138$G$5B^)T5"GP4J0N09.A7MS/>X4#YBX=BOO0'52_>U. MED':K[(+*-_!Y"EYE7?F-O/]77G5J@H!%+'SO_@4SRH5H_SB[@RWYAW\QXLK MP^:?E.[U2+@C/%?ZU*TNS5]?! M/]B."%159JCJ-%%U$_"5?^"UMJC0I3)9+.36V\J)PPKL59*/BP3Y-@B^)-=X M+G6J3#4?_HX:4U2(6Z/Y/ZXGU;C'EWT:PMYI-M%)+P&W2CSPQ7>*KEYE([:R M;?($YFX''=_@XN;AB9Y2@&.^Y\G,CF G,SJPE 6DX/:TZH0%0/&]/XK><..Z M5QF\/E"C*E.71:/8W+='39W+ 4N! J9HSY?3O]VZY*?(N\(LU;>^$Z[?NM&6 MPZS-)F>U1CFK46U8P@A7QN0)*S434@$1WR5(%WV TN ?H&>$(\GP0 7[) &R M#0Y! ARE7=E[8LN1E=4AFV!2KBR+5K7R'?'-B?X?(_[J^1;P$F V)1K M=$Z!38C_%IU3'J\D;FK-;6K-;6K-/3=7JEVMN>>Q:E?H<7M?&/<'Q3S6R'S< MN 97[AK\63D[SHO?.@SUO.;F(;:U?@[@ENA)CN/TGI]5C9M//UGGN3[(C?)HE\*FPMW*U;)-A;M-A;MG0J--A;N55[C[6:1> M,_C1R&;I3MLL?^>P[4T^QOS1M=L1HIL VU5&BV\R+C89%X_9%"!=^K3J?6M/ M0INJY3MH7.1JUW MBU@Y_Y;;\@T6CT]>F[LW@' MRH0 %Y!D+HN7)0/3')LWDS2@94OE"YH"=8("DQXOUK\Z6:^#2X;@ M%;@">%FH6*[BDP+(Q/IB%ULN*#;:K=>PD=Z8PYH\HX_C%H+GH.RY;B M.M3II+=5,)35!"SWNBQ4N"175"%P(>9=7]69WBE;R7($%XLTX.GA"VN_R%ZW MI*3SE^VAD9['X3A.8]:]'-?M\.#+;SP2>W"DG(A.T3(GO0N! MIQ;>ZE\#('-MNF_FQG>L[9[Z&$UU^C76]4(Y,CRRO_#(XT'$R B)C)#("$FG M>$U&2)9(4FJL"EW45Y^SKU6&238(D^B>(\,D7?3Q/LNM*\,D&X1)=-V26V@M M74B&2=J+@J3$[]K2["E$LYN2Y@>/'+S=)APP4);4XH9[? '*I=TY7H<(6"DZ MW,8N+9\QS6%.DRR?D@K8*"' A=SW/E!(H5S3),%_,X9AE/$B%YA*.:(N00OM M=2VN&=K4+,_AHA>CTD>"P8YJ<1HT9J 56*T;_^2TK8)I65DGI!Q?P-M9W O> M2MG77X V<03[-YTJ;^D53;()7L!B0,TR4%RI\QQ&7"@% F+ TUAD+2Z4L@Q+ MB6 =468PIDB4D$Y)G"R.L7T\2VMZZ^9;:V=V Q]AKGK[/K*D?V4-$AVA Z@& M#XR.L$7-]R/4M\\K4P]>P^G.2P"))-$4;)$3I#( M"1(Y02(G] 4YX>'-U?4RP$KHYD]Y%L5W N'*/*Z]YG%UPX/Q)U7H%4EFF(%: M95@V$C!]YMP!B[Z1?@F\,U#(.$LOA"MG3$DQRQ'>%YT/=Z@DNY!];7.Y+1/E MGZ0; U$NH'=@!J0(9*Y\F<(' MS-=TL.@YBE/&6=R-M\OQT:SO0BL?(2>S56.WU MQB/S)R6\A$R>E&F ,GERG[RVP^3)?LB;Q1XX>^N1W:7TJ=UF/O8D/6I%0T[S M-D]U=[-<.I-T=<^\Q'YMG-WF'?9DXZQH>*F-GC8#;Y$5^"2R_D92'G8HJV\3 MQ>ON+O2=$INBBGVEDG[;OFN9:@^VUJ&[/NY(^V+N52 NO'(K@=CUA5F1)&^8 M&TJ?#B_/_41$MW;,V?!TN!-K=.-CPADZ=H>%YWDVG0< :48OG[D&8QG][)G= M&97XH1JX]XS;VI?<-CRYZD]XU5=!R&G;8LA)4Z5WILJ;+)]@0(H^)V/%<$?2 M7.GDD7.HZ]:36!IIJCQ$'6MG3)D520[,E F:B5.-0DB2I_"O1"S9?=SNB< > MK$ L,67U^J."+6QE33S+72W!3-8/.NJVW%U;[ZXM;/5G@7-R.'(D'OQFMOZC ME7 8:U7U5 47'1W? D#[9D5(G8/\:(>;%T&)!A[*5JCM@V7T_771\!'&HPEX MGM80[5&>C2N<]@4L=[RMF%"LVYC>+'Y90JTS7/:"*A$)IEF.0"XY;87NWP-R MS.,!^:_'W24\?7_9FM7:M:#L(S_7;2&VY.<%:*'5V/LS7$<.,"E9Q=)%D5[Q) ^S?5(#Q M7,?32[;E"WAQPA!]V.<,I)]>W'1]@RR[DV_?$W87]H3!"U)HLW%&-9$M.W*0 MG#:%>BE,8?V#65$PUF%??&0UE6^R\21+&6 3,,M*^PI1(F2<(D29@D"9/42Y@DTIQ7,#1KX.;VBZ8P.YII&\A:+RT# \YW8#$<>UC:T0<:RA;:QW!F[R6%T;.OIH+S SVX'7 MW#G8]=!K[FNX>A)FI@I38ZW42WVI^,W2#WM;-+ MV4Y0Y_8RXP?8]KW77=^/)R3.>'%R1.CWY)T!^556E'";H\25%03)Q* MZ;U@%3K+8RNJ9NR>(2=T2%E[$FRQHM[4V#@__B'$T1/ISOX!-)$+KJ,,E'GAN-7OV&KF/EMC@CGT5S2Y&3Y>1=UZ M#+)DVOW&3+L/PK1[VS#MCH5I=T9[59-TS^[:J%E>I/"J4"'*"]VV*B:9Y)B7 M\$-)@=4"4EPJ%UD67L.7+)6"$W51P"R4"K%>YG7.1C3+V?84U1L';_*85\\= M!P'8"BQIXQ._S!]0 M.8<*B1$JZ-(3LB6A%S"UD$;(14)=@N,S ^;!*UDM(5/NT@AF# ?F%4V)$I K MHAP>O/_/FX,C)8H34._*VE\EB8D?)_'T1@D2$H]EC[_=B2'/$6)HU%\Q=%N' MORW[^?5L/R]M8[!6LC$S15[HSIQV6CN\6(UO CL3=%^AYH,%D\/,E81<%[-X MRB[AM<7P>);L2<0M8S:(M8R:T0.0=KU4ZZI4]5<*I*#*>TZE<_*#RIQJF5.] M1DXU.[=@ S:5;^+#AAK42=$^9RZQ!:?(7,QNW#Y/NCM9T?>H-G:LH6OO/M-X M-+2,[8;)RH!M6C%+DNX:$MQ^A)TQ?A7N8#49(G-R#A,=%D%A>7+,U^OL5T-T2.>UFQ>:I]7=@,'8C M ZRR-4Y*6^/9I'P-,)UYSM!J(.O[-XKI8H^'@./0+S2 J-'OJV>(\#;KZ\"2 M6!DRR=^S^(HD+#>PXYQ0*B8G3#$Y65),WC85D]XQQK9Y0YBIK%7Y0JQ.MZ43 M *MX /K G2$=3WCR4 $?%4$>^_/YR#)+;Q=9>I;(TK,[D:6'6JJAO=HJ99C= MJ[^Z=^+8'<=--]H+S(&?WZ>[0/_2?61S@0XT!=AI[M[N/=!V3G =EYH.N=!SI2 M(?,ISZ[B0M0*_7+X*TTI=B1$+\_11N4R#3-&%M \YP*:-7V52DME*MY#6>-+ M+%3'BGG6^1!K:0ZUH7-4^2O9+:.A67ZP"*5P?EG[.LL:^98'KP/>4(\3]L*$ MY'6%_@1K6=4;2G(<1IR%;*#+O73A;3[?5@7WGI8C8ZZV*Y+,!.@&5@>5M"8["43>Q0BFG4U&PQ*EP[UDWL5 *?A\\ MB#^V= ^UP1EP;*V&B]"G,#U9R+LS%R&<T=(85?LPB3(D0'Z,9?KMM-E(2S>U.@[S9I$UZ@0)$WQ: &X*)M=7*[[*,9*9#+!5MOKW5&RRJT5N^6QB S,U8RM,%%:DO3DO-[<0 M/B+-ILV=MF)+7< C1*]L(0IS?&W;I.*4*Y>E/$+.$?K<_(9$0"EXR S&QUJY M5\^JF]39#S8K$ ,O#*/&K.'<7]7>X_!7[U>Q=X)*5YEK M@%94&@K#OBEGNF4G]I2U6H-%#NLN; W(?(XW=_N ?)*@@: 4EQ0O!E9:\39D M%B:HEZG'& 1;Q>7<-HIF#,102"HVTR8C[$)V[*;->F^"P++'O P#/ZLPL.PQ M+WO,R\CFP['_H_68U_66&3]8DWE\:AS^S\'=OC'#.'CP^/"F:6"/$!8Q1EOU MM\6XL&;O(R[LV+O',3+TH;EF@UL9%WZ&<>$/\=^S.$1L432^WI!)C';F9UJ M]1_0+D2(EW).EGAB._HXZ^7)KTF?OOB2_JR\<MIE],0_0HD0+1:A!869G[V MC0;S+=394Z(DNV;NRTL"@R A!:M[VO;2:09V.3SI.LN_\[OY%2FE8?&J,2&$ M\ SB">^P)RYBWH60]298>6W9I0![Q5]/13''#U@;S 5XA5Z':4Z"*?-C^8D M419!1YP)NK5B[J6!=Z!_84)NQ&^E\W.>%*Q^ -;P*@[HW.T#;*80AS!D_OSB MDKL\)T"*2PR3OF(??T^SZQ0(&F>PU9(:V+F@TRGO&5$-8:B\CY#*(0VP5000 MDZ87Y(*Y.[*4HF=NC/[?1@L ' 5E9 -J9]P)@US&7CV-Q^SC2"EFZ%G-@4P< M0K5@JSDF-VQE\$TD""B+U?*U@%WQ'5TU"Z&MB$?!THMU 54?(S?D35GE'HM>97TLS;;QW0(M_20+OB]1+IL(BEGNT-"M[?U:#RK$/\[RUJ*S MRB/*^G280UOQ2RSSE;[1N42.%];0:=[S[UE*%UVI6P8\,0S)QCS!'*N0%]W5 M!P(*D"MV:/#!@UVYZ,-N9EW4CG^,4A04/<2E/U_(/8;^;#K&?%1U(5SZI1:7 MQQ4W61$+D>#2S= 9?'K!N2.$(85O50 MJZB/(G))]O\%#3-B(B,=1,$R#CGQ$SH=UN\SRJ0IVZ!B.2]3IQ+7CEFK-)>JV MRI(Q^:$*O^G0=O3_?H7&LK"Z^ ?+TN9@W8??+JCLG@@JCMK(<=3G=;?YR%2[ M9A@03 B#)2]@&G$$Y&"*VYQF LHF<$7!51$B4K(J!26 J6=C;*4@=*$!6_64 M,5*UJP;5UR@6X.L0G\A4G88F5P:C 9A('*8C%EY>X\9-UX',V2 WV^ M*Y5@Y3C/<=O4S:7J++'W*79F&TO=\\GKGOO>S\9Z1@\WZ=]5)CUW@X#)3W/& MD)\(2.[>B:F%M@:M$HLE([0=2SQ#H?1-@.A):A_1G=(-4_V,AIH7U*2<("E1 M_%_D9(SNF. [UY()?U3S/OY)3J^RY(H-;\[UDE!)P=X?<]T,!?.4\%.:I?-R96_E9%?. M!)6Z\M:[1]I'1JRSS!N9H2F]1G_9FA,OZ5CE#B[&9=_-V%(,E \?WBB'(C?Y MS;_>B53CH^K&I91W>ZB@M;FT/O.>OY5#0XDAO%O*C*E78X)M)4&7(O/)/&@? M)JPM[ 556"(X;BU@*>:;FH(BJ9A#Q\:401U9LB4[?U"UZ6&@'>-)$G-KF(-V MQ$7I: +"8!<@^'G:KB7T2/7OQCGQ(4LOU',TKGH)'/,G%V#3#+7S!.?"#,6& MKW<@!'CI^BB]NA-LHRJ:Q8F#H38T0>7(68N; MO%"2%L#\VFBP5H<7EKEER; M#V83S787-;ORM@>\K1EOE]@M,FE/)NU)[):.8+<8CY3B)3,<)79++S,<.XG= M(G/S9&Z>S,V3N7G[S\W;=T8.I\A;%DC'H(B,BME?_35!_9B--0: M#JH@R&=8*KLZL-'(J*D 6!;3$EEDO$1%KD%0T#$K,9)WA)'L"/R342?P3PZV M0D<^P+@5)NP&4_84EMW#HD#\J65J5QEF@L?[(,4GH"J'2@;"1-'=9GUX7=K- M8 ;$4UJ3M3#K['B2QZ#RWS/3C:7 AG33S#0>)EN=E-:@#$91OE.6"L'KZ1=> M4-SQ, 7C+#?*OV?)38U_Q!S>JPG$"5K%]]B%!2WKI:L78_)O& /9R?AW[1DQ-^C?!]1RGBX[853@^;C M-R]&3IV].8=%UO%E?ENFWO=N;3]BCZF I9&>PA;4FPMU/+N @56?\<3+7S.2 MAZS30YQ3GD/'8"2N&!R1P#_ ;#M!$B:TM*'EV0Z"J_#*^+XQ\G^MTW]YQX7W L,I9A_-YT"+%&W,-L+P%250>;X3I MIS3!'!VZ7"FC'!X4;42S[ZNV?;!OA,'] MWT(U-G MQ5B[$>.7T#PRRO^LHOP2FD="\\C ]7. YC%[ LUC5SI"9\/_FS]HC:4^C\>@ ML)[1:^5S-B;I/=7@_?: M?L&(V@C]T*[,]>N RZU08DDS)VVID?P_=#SDM"A8%6^^&<0."R5U65,1<-N\#K=V$^H.7[[)8R:)E&..S8"NRD^PJ8.R8/0+3=%A M :1O7'$B@+C[Y^9F#76 WV9%48:\")A:-T6,'6]H@;J0:/'" .N+V622E!C> M>&.2%2SX)E!(@I)^I*;.I$F_HJ)?XXH2R+Q0,,011W$-V[X:)ALS.=I,D^63 M69R3#T+0N:WZ:-Y4 1.^:F6+RVR&& 3H@">A: S^;98N= :_YV98@N"?%YO] M@X1X20U!N.0^7-)MBFA113%M+)8\H M+N >,&@(QV_ EO=>54HWV;A!4^CX(?XA&;P"MZX ^>,#0JRE)DOY:6E="C( MF#*<$W$:QGDP&V-U-9:?!XPG0WH%PF8B,B]8AD>+60!$G<$FR.INC6?]8MO)",)2X^%YAL(B-PUGWX#-^]8Y_=="HC\1; M%JYMTPY27O[,[XGBA/4:J#;9EY,WP E([_E3OL/X<67/HS5S5/M=0B>S5KLO MF#]5 ?>Z4PK(7(Z?A6IUHP<+S^9(&!S#-6M=E&*?*;;M06 VKF2QZF'=X:OQ M%3X:Y4><(I@ RB$!/A<7/- _WYXE@OM80T#*DSY8J36+B\?32G6J\SMX0T"& M)<6 _I)A0!S17XD@TEV) !DG\'0/S#,\ .^6P(X[9 M+W.S)0OSQ?M9.RMV(\Y_8;8,Y)-?5[TZY$_?\.UA1GD3'_HCH")58HFT4^0! M,D\H7%Y\4T5IGD$Q=TU;?Q]^WS8\P1E@CDYWLL50.6ZA;4@C1C#"&H;5L"\% MY4_N',MB7(Q,U7]A!Z26851(*B5DRBM1E+/NTWH(3K.6#"^UU46 M#$P:G#)%?2K2N!98:3 G=6G=^16;2UU5$$SSZNZFDA6%Y<+9A-ZC-!S@W2E% M=&*2WPR:8B:N!<^RN$&%'>:$:MC\?#A.SHHIE?W0.#XA)SJ?)Y))6 VU91/P M,P I+Z@(HFDE39C%D16LLR.\$^;)D 5%\ZIJ!@,.-<)31Z[X*U-ZP<:*BU<1 MEB$67E)V-#[$R=6A?;%>GF93'"CKJO6=V]U;YFHN-AEEGMLXG7&UIVD(A[RI M6FV6EU9EHV(H3J.$;1'TKI9='YG0_W0"##DN0>8G> M5!/BMZ!SSRT;ZC5:8?>Q'M#JOPBEEB,%0:'&/D X3V_>'B/K@WMN:;T1!'C2\K& M"N6E1GG=T4!XS+ QP,*KT'EU7*6G)C>\U6V!YR0K4N#T$5"_KE:]6LB'E-=0N.\[;;&HT0Q#W< %HX M[X1=)2RKYOG,[=5F*U!2-19=;O+* ,-M:ZYC\^(:5T47I&AVS=V^YF>AW7$] M*N%0O0 A?/1+DL&^A2&A=,L*U,HCT=&3X\#748KU^XR6/3R7Z(!SJZ&46^3[ M/)_"20+,%F-E"S]*6NY8(;H6EG/USKJE6I8E],RU>"WA[)=G]6)49^\C@)Q8 MS!?ZT*W*(_"Z4MK)#/^=9?B[MDCPM_J>WU]575=1K2XIW&N6IE_&"9I-E1TE M%#N0*;/QA-O9O!2X$49A!Q">)+#CF7;!6H"CMZX]O,,%?*,,Y?4M58-LJ!F%=R'M:>\.[>HJ"V$;\Y7YJK$,$#/%'P]&,+ MC*7T"#1)\$Q)\!E8)XPAWZK@J.K9G-6!E9)O0 U=1KFD/V@P:\X*K,-IS'2L M.3T[FR#FONA8';+#GKE@&!0LW+KH)O'AJ,0C9"RDIL"\Y^_'-<2[AE6*$D, SY-2!@O/#U]0/!K86&+$@ZW\$32"S5&:TV@\BRGP M;T6?IH+5-\[29JNH56;XH&I!T."7YJ(1/YMQ@QG8@531R3$!)IC..(A]W:F< MI0SCW+,TUP"]%-,64X5Z\: M89%&6+&@25+9P[PM\:=/)Z_N]"*_PO 'G;^@+=3QJF%CXV7D!_NX4 X;MG@V MQ1@_W,B^IAC-.GK%_4K-9&?N5F!>]S0$HN8L&0\Q9[)Q'"C3''&K,&"RY+5: M=$>A[XE'&7B, 6;" AAQV@P9\2RGZ;+'6\Q7.*I8FT1,)89Q,Q]:TYDMP'OF MG.-U;"ZMT.-@?;.P@HCB.;US5FV;ED?HH F4SQ@LIIVTA;Z4 M:\9%K&J@1AXMW6OX@GFD)%.K,.Q:N\'>D5&^M4>I.[)9@NQ(_Z+T+TK_HO0O M2O^B]"]*_^+=_D6['R [IO[P(#M;'O=].MMMN-,9[=X[9PQ=9[W2P8T>B]UC M-SK;GZ_3[^0'YA34.0J?TS+%5_.S[^U$@\.@7+:@X6?<".*(\**>LE@4V73#CV4PQ Y4&KJI;1R-]^Y$.[GK!_"4IU*QY1(5DM90W.6XE57A*5H"["JSVP\ MH6G!9^$+!(1KYM6,Z16MJI?@TVJ$B'Z/D#^-'$!X9U5(RO<@*Y4JL,9OH0HK MI[Q."L%=T*,$Q*HSY+C+JC'/TC7*DU-OV%RR]"+#!2H7AP&6EX.ZF\#,*X<> M;U:57,RCSHSI-(\#=A%FT+-J,<(JTGB:&KRN2OIC?D%>UXTQ$$9CD?:V!+71 M6!F&8B'\B.A61B@F%9NRJ R4B74!X$GD:5GC*[BQ21>65D\JUS%;QVF,L0IFIWL\37EF] \)5 M83ACRCR> YZUQWSG.1M=R]/O%FS5Y%L*M>Z^6P"L-$^E!B16_<1&3G]!ISA\ MS )E$88:5B> /13-4$"4TB'ELNXW3^ET/JU ;4HA6HCR M4.!]6#9>_L<[(C!V E.%IP%S*5*U ZIV0T/PEIA9Y1G.:T@Y"@7*D^NT GNK M9)S UFD6A(DDU.IT*P,#/"V\:);3,N9[N0E["55215W]I=GN\^7AWQX_^ZCJ'L1B=4@[W#9'ZWN M @]SP,55.X_J::'?"C MF%R=+SZ91U. 8W"&KX&=D8M$;0Q5T:!4^C&.):IF&;78.4O9N5J^CN%4%,JA MB*<25(%PNZ'.Q"4L%M[.L$Z7G3L!<"^H-*@7LD"O3R_)528BH,-#A/,@A?/#>-@6N*%T%*& MX@-6L@:3)@U)PK4;H%O,"D59DGP31H2-9)8S;*SE@PY+&. "D#Q /K8*R]>P M8S(3^@J0"ET D_JD+Z71THU,BPMC?J1717@*5A;.S:YFC69]G@B-UR)R$T-$ M2JP]2:PO,R ULLD%GDRPJ(C5P*LRV F%=;./5S0FRH.*AD"XSN$05K,H$KM( M%-0@GFH8UZ)$5'?4=1]\4KQJDT%XE-H@'-Q,$T2&OL*2?ZP\@MW&ZIS*D_[? M(,JPL-_0#*VD$CRE8$7>RG%19*50*P_JX_ *'UL>YF5 _WU:3/,9,V78Y8<' MQ\>G[T'"?F" /"96K]0+PN=XE24SN!Y>#^<]*)B\,A>$(FD.!0VY"0D$D #A M5EL@H#8Y74HU!N>9$-1]>,4Q5_79S4<\=2@7K9GAIPQ$)::V?&+/%HX(5A_% MK"L&NG6-.1;O&;-PFA6KV0H4(BX!BE;BUPT9RZ5EMS'9PU(@JM-,7,4>REZ* M FU)D**9B/-N6)2LP&Z*U:ML(Z#=R^V&VH1MLP07-#(A16M!W2$Y+25K!R1K MW>L/UJSR^2BDZEW*6+<#PI5OH5*)2^@%20;,7@=F*@LAN8A@_39Y"B!C;6;F M\#P4[IMCP$+5! ]9Q>^;QN2K)JP@\5BLFST"]RBK_SS!K*5I+5!1%G\8?AH. MJF_><]\;=VKQ+^$UV04#^1DH!^(Z>'P+J%6S<)!/NIH'#"&E%QF6A/),0-Q5 MV/11U *V3*&JN&P\QK_AAB&]5GXM!<5GRKS ;[+Q. :I4Q7:+_>M;((K]X6/C_N<46PS$B%0SJ/_9EP MZ]2&#'=7-JP;_)IO85YSSJ2E@!IA D)@?Y2#9#TTQ;:=MP-;/*#ECN6NJASV M<59WA.5P;GQ5>+$ZCG1I>837NK1+>69IZQ[%;.E*>ZD;$C3S:^]T^B] WC#L M [8HQ3_ OKXN\[0/>ZL&\^^["*K,CIW:<-;AS@0[ENG'@ M!#A'QI/J4A^#(E2=QF,ZP$4 @0R3KUQ^"\KM5CNCJ?CFZ/R'X?'>#T&0S_!G M!D>[H(U,!ZP@ M>,R@BA@VFJ!2JC*T.@X6!U1=N?^[4=ZP^XKKWB1 RN*&#A0E/'!QPQ8IVX^0 MGLY!!Q_@%%J1&#YZI%1X60GR^O\>KRA"5H)L70FR7GJRK&&0-0RRAD'6,&Q= MP["6A^ Q_ '<:D4#Z IL.B8],..4 V:SD$?.&K4&-SQ.CW[F.?14CD)9QY(0 MS%.XBW <"T889E\Q#W2<-_*-5F2T;B6(;VPH-MX+\SKA9SQZ (3?, M@YS>5.T).:YKLM@KM)BSV">B85B9E98D&7?_EQBU I9X4&)1HOC&;E M:DE';!><8.\7P-X1ZQT]Z'>@O3^:+XP;0:N=4OL)WR[UUA3IC:5,:PBFLIF: MJ(G@4#O\30U@_<$*O] #"+">[3J]?[O.&KKV[;ON X=RQN5MIGOE9=[HX^ZQ M6WR^&5@D(LV%\HHO)CE8H!@CF"S]@FT^D1'#@W_P_S%FT&!WW H7:KNM.N<\ MWGA?8J^A!=AV@Y6[56DKI(I^-AWD!/9$GM(;]!A3T:;#K;ITS#<(4MB\?D&PB$Z0W'?&)! M60PNSUAR=9SPU3:#NA"ICBDWR"J>6#9FHPS0/RX8C3'SI]F6)%EGSRQZ[Y= ^@W&1 N] M#LNN@I,\BQ!D"E4DT5%M0<\U+%!C!;S)MZDA"%,2=36=Y5YIJO M13;Q!)Y%M;1#],4=@IAV/DTI$JNIRW)0.31#>=,XEF!<98^B2C%4OK#D7-$ MISKW2HRXM,HN8:R';>;@KD%#XC3F(V8 :UZP#G5(6]Y.B"NQ#''?QYQ65(,Q M,83G!S-%M3&%%4_MV4'Y)-73#T(-I:P^$ZZ#F\&"N"PE7TC]1SPGFSE+C92D MJMGN]&:"\@5+9\I#CM?*@?!)&N?:W)FV?:K@O.ACEF&;K1&VM-&.OR--?$J]Q/F@[%&7&"/ M3V_JCEC H2FYBGF\X_$VECC[*RT2F#)M $1P%4A,@4-=CD4EQJT3XO@#Y;&F MB=*TA3MX6S4LMUC][M*STAQ#I7NM>/>B*J)[S)E45]?.;S5NB9=2Y8(A7@B[ MG+(EY$4<54LU=G_==T8HUUM)(.Z(8T7Q? Y3T7B(S+L'6 8@M@RL$'GYL;]$ MB2J9NY[N?(IG99SB@O!WI%L3NKG(NL?6L^FQ"ULSP;F+>#EA6F%SE3%-E[6!/D::.)$9L' M?T-.&Y7I;$,C)S NP,*'FB/GX ^VA2SP'F!UUT,Q> NJ;LH]KQWFS/:Q_]9 M$:[LFRQ]M//I91/7N%C$-V"N_GI;^#>LL5G5?JT$*@D0MV9Z36E:.N]4D3G? M3%YC_I/%+_R;UL^[#&?4OK!5M*ZV$LMV=B\?L3_CTF#$V8$?'>I'OQR* M N^C@7)H'-U2[OG+(:\AQ@M-N'"]HCBXV#I:E6=_>YH]W&HSW]&=J=9PY>AH M/L%QC818N,LYVK)=+'<,';I'3=/[L/90'/TR[];I+VM7/.1S("+.!'A0T>+E MXZ%AW#8LR>Z[9_=U61VN](ZJ\-MM?@_^>ET[6AS#6L9=G[<4*G<5_Y9:9:E, M+A6ZOD^#X2.>)FDK:,1RKH[(G'F00=7D>\0@TSKK)B71TY=$ VZ>"302.(!6 MZ['=J(Z0S1]D?<2SJH^0S1]D\P>9\O\T=7'T.8+@1B-!9FE#?Y$ M;7 >HN+1JL-;7Z?7;>OG-+>;YF^\XR5;@B]_Q* M;))=VT@4MOLE9TSXTC+6%0@M/%+. J=\*;A8PS"\A@BASLY6L,<[]X:;KQTW./]"(O7[D#Y6%7UG2S4/FSCRA!# M[?/T%5%6^YE,Z;,B146 7WE^@VAH=([Y#<^*$)_F$H.4PU_G,H,>CBS="*>M M1[,S.ET2(+L;@STTUAA%2TX%^A!58^@N^_U\4E!^2.EKQW[D6G9^+?<05ER/ M:&VGAN0G1IJW(GGJY-.7OK&37,HGNI0=HRM/_[E=ANRN*JW;5I1AW9$4UCN% M\OPRIU0YA>LN"^4DQ9S2+V )T[$/IK"I#1@"ZYPNN7%\60BO'>O+_O;^]+^5>%Q=M#2TI_J3XJ\3? M#JWLWHL_F3XHKY29IO)*R2KRRBZRRDJ$[FUCM8^DCK=KAU_6 ^!2^AJ[7$O' MW'1!>Z!CCGIB;FRQE^YM;MQG;]]=_WX?1I-<]CA<]J 6[5-C D,R@60"2S*! M/&SV[435;D/ODERV4RY[.@F9[2OZ>0U$X"=M]+2L5P^$@.'U1 2T;X>];O2% M5VYU:$BNZ"-7/+T5[5E&LES0.[=H7\Q$*;@?5J=W)5]LPQ?;1BWZHI\?;]B' MXTGKZBUKUX/-[?3,7'\$HWP7#A[)%;WBBJ>WHGI?CG"YHFNNJ&T^[Q65DKM= M63?ZDL7<,;YX:&?ZCEOZK+=$[[?J@?<0J"JM*([;H:K4J!5W >3TU]KHIRM! M[\VAU3%/@F2+)\T63V])S;XDF\@57;LZ^)D'\*3L7E$V^[6BC+W']CCD0)%<\9:YX>BLJ%_2)+:CT_$K!W9J^\\QW^IXB MW6 M2^65#WFE9!5YY6Y894<8OL[0L3OA&UC1S44TY.ZK^;^;Q7I.2'!]@8&SC)[% MHKI1*WU_ON\6&QP:FD19E^+NR8L[T^L+/LA#B3O)ZT^5UT=]\8-(5I>L?D^Q M;O0EWU]JL?O48G5#:K%2W#UY<:?WI^I!RKM]RCO9&FW>RUP.H+S28-&M%9[G MFA+&2GS/WC=RW?U\[^JR+-\CW]/M]\@FSMUOXMRN?*S3Q%EO.Q@>K,SQH2DB MHXI=,E#:U^@I&RCM,[9TN^MVPBY3$+J[$&?#T^'3]PO(;2?Y!9VPX>D=Y3FH73C=V_ M\LJ.LLJ3:#;YW'JN]"_TW;YNNGN[*O(8&L=.>F;)!=I?0LA3H>T=:K@D[3W8 MMBNTE7)EE16J]7Z)GGI06C;*Z!'.7?L2.EM&DKJ"-B=71\)^;A5;V#*T("E[ M%V7M.PP"*5$>5ZTRM'ZOSYI9G5W7G>[7LJ!C>M$V&E3/-L[ARI*S_6V,#>23 MI.:=!VS?2*2OA.J0-!(TNEW5D!MS*[>+V26B/G47RCIHXD_HT'\J:O1=48^N M*]%R=:1QOX>(E"3LON)14J \LE:T9:%35];GB7A-/@CW""5YTVZ??S)*Q_RRGOB]K?"M6Q7>],I1?.9(/G?9_F>;NW>O:C2W5/*-NY7PWW/ MO?Z D'\[9^MN+>2A;F\+"/C :_C0E-D6'%7*P6&JY;:J92#SUT.ZD.CEV>Z%(323-].$#(7 M]"]3XB<4_@WCJ]?_A+\6 APJRJR7NCN_X-]FQ32.;OA'<1K2=/I2Q8O$I%[_ MT\]_>5V];:?/W@W![*%KWT4S0_OO5Y.,5]2^9!6U\15]A6R@FD,=;U\$[B8% MQ2> -.&B9/GOW?<5\=:8QL'KX^DTC_T96VUEFBEO2 Y+ ,_^%R7)]'*@O$^# MX3->,*-K"_8NRY7I):P5PV0?9PR3G;9CLAL#)5ZOKJE8*&Q2XC1(9B&%FY1) M3M4I^:%<9%EX'2=)XYD*SXO&FU_HMJ7 7!/,G2[+S(&A<*RG-$3B*@6]P+N& MBH*SB.("/X1QF@-V&;X77^33E$;Q=/XI<='R7OCPA6Y4K\4)XG5\[/!SRIY+ MTG0&+Z)11 -<>?:2'!X]5(YQ@CDM9LF4CX&,X11@N4O-D42;$!W?GU/@H% A MDTF>_8C'\*[D1O%O8"C\6YP$#.F%L31X^F,"H^2S+A_$W@U/NHH+O!)' U]E M8S836*.0PRCA5?!H@GLM9U. #P25;RC)][2/[Q#J8UBI."V/4+/UV3N5"+JV MUD8Z!^(4LW%))R#G)$NK?1* 0 !"LH]!.J+D*)0QN0$"1PDLD,*T!09>%>(D MV Y;3>"N$N%/BCP*O'E%\AO&0V)K %/1">4SS/@VBH'/_U$H*9G.H<;4GN9W9=PV M3AF1_"0+OB^>"G!@O.+/L-RAH5L+C]A@C=L&NC3O MEC:,2$R9WT]#]M6"125XU!@:IKGR:VVHK_SNL1YKK?78]L9G]GI]SQK&(J6& M8UA;]&5ZA.?LKG_3AEE'5=^C=H'#FR4]\.G)]L."L:3<8A,(PMY[(.U=^?YO M]];(FB10?M/U<66KID6FO=NJ*[[?=GRT[,&)_]K4#/R*^WQHIL>M.>/FXG]_) M#VU1;:Q&KR<0+&VU(=,GHVM[I\*6Y[)Q)ULRI\+O,Y).XRFSLYB? #Y(RM_? MPM&99,4LIX5R[&>SJ7)*\N]TJGR.B^^]\Y^<,X?')8&)^92F2IHIZ.QCSP\N M27I!B](+^?7_)?*=5V<;TRTLG/D'38[0J&K!? M#GT#5^0@)]DZ?,JS@(9([@ZQG[G6/$ZN2#+C<"6PY/764KH_P;7]DY3/D88# MY3H&(XOYP@G*S'A231WVAC+)80_ 9XE"?]!@QO95%D5Q@!BX0(;Z^PB,-OB1 MP;FQ[[GOOPH0I+0HRJ?6NQ%.U@91)Q51E4."WE)X*-^GGV>@P.DF477[D!XI M,^:-Q^=_@5'E\32&6TY^<.F@' \3 7"SMDX_$L!75 1(#&) 5#A86\ M@/0LG 1+!M_BER1)LFLVHN0&&#!@T2&=!E(>OU_CQ=3D8&DK0-)Z_EM-W;GC'81-[&,H6-O$CK9 MF7K0)V7 & TU8[3S4]N& 3F[5P8,;3C25M\J8S0/%:-YX'#/#L.<#^[R_4 O MX$G,%4IQ]OWSA;Y/%5PXYCH2B=63:CI*2(L@CWT:*CY-LFONT4S8I.NKBL9E M<7K7L;>+3=&:B\_H&:(+CCG"7C(_'<^W_R?IQD"4RYQ&_W/P7W*9W# M?PR_##%&,\WC8 KOF>5U8<&7;(;G1%I_#T_[>!EG"L&"C6):)Z1C4C6Z@X6# MF>;*F#GUJHC%KQF,@L>#\7@7NJZ,6F(@/W,SVZ1#HJKRE :^[P/5C MC_HW26J.<#I53 MDF0I#_6>QL$EH;#CV$CH $M.)B49V6S$V =B\+PB 4<3-/;H$% MOF7< V.Z%NQ.0+[D<%_Q#R6BM&!D?4?]O.0)O4G6BQR>P?D @XGL82 MX\9' M]:O^ 0,JCUW@[#$("CYQ_BSQD5B? &8ZYJ%*L@D[$;N9Q+8N*#J)S"IOZCVI;U$P;5IF0RDHMGWJJ5 M!UWAX^H1\)8R AK (L1,OLP=-_,; N/C28+BL][Z+W2CJLH;@#I8% LU:2], MO:I V(N["$V-*Q(2U'0L)V&"N9-@\P8O*TDQ3_P0[@V&=9#X 5M3".!^5(6 M\$6Z"C%?QJP:=6K,';*:RQ<<"S)X(8,7,G@A@Q<="5[H,G@A@Q/'HP0M/ M%GW(H@\94'B(*$ '$KJQ>$!Y1YBWJW?F\==LIA27V2P)T="CT0PSZ="7$I<6 MY%S6J'#,5A)W(,S1TG9MTJ(,!O D5,H+#"+Q'6:%S@J1-WO0O.V VZ3,/X.W M+%R+7D:&=%+7'[#K9^@]3%B* &;-_Y[%L,O-YP(8-A?*A'0 MI!@J'^%1_@P&Q\SBI,C$$'Q:)3XR%S<;'?.<7E/F*$<7P 0& 2H7#NP:/\.Q MY-55PDO;7,=X7%6&@"F,TZC'WH<,R(=2H]F6F%N:UE5!]_M57$SG_*^]=(W5 M"$+F]%I!2 _$F&%>H/H)M31#:":QS[@C.!^$. MQ!!X(LMOE%]+YOE,KV)XUYML/(ZG4TI+OQD;^T!,!L3IE!3?1:H_G^>4?.=C M0(2+64DPQ6G8!P@6C 1$]9A<\$EC]FH(:L;JGMM,"IMPLL##",)],ZWEEE7C3J.KEO'+@7U;.$<3@O M<5@5A&7$;C)VC$R(^P5!]K(?3%D &3TMV1J71BSH@L* O -+07G9!P.N@R&G M9;BU638D-#\^(/SM-CX"/@9F9;MT;D1($\'!6<[JBOB'(E0ZQL#J9.8GL#FY MP Z8H&TE.^?5@,P$L)VH?9WD,=R$P5B M"Q@VF+X/VL&T0>7'*<.K$MKI!UH&WI"P$-06. M*1;@'87RWB#^/*4C_I@FH%T/B?L.5216I8@3A']9B:, ^<3YCTE(5U.2R\$Y M&N#%7!X!!?EJ"*G*&;K51)MCT4$+]B83'7B1R/88*E]X^#\HQ2)<+3B]S)CXCU.X?8H:*0D8 M8[)8YQR )\\E*5 ]8E7(!;I?JB;*>8T"RHV:4C6F::F^ M?,PO2!K_%'HNC/<$SHQL#.O85!/QF6]QA-ED[E@ZF0%S4M@C3.MA<736MMAY M53#:%56*"K.%XH2G-/(IDSAD61['LPO8<(T, $:6B,)0X=H+/)13]E::DJ#, MHWD/AS9_\F<:SG@RUW%0G;W ;ZRDF"BZC06_ 8.=K9@)#LMX/!NS]8,;R]PE M+M$:,DRDJ2AZ]0QQ!SO@D*%F.; ?"Z^C2[I.E##U>2=)'VL/>R O*UA=#N]: M"[.&+5 [EDJ1)FR!%C=4#Q7F!=,%96::BA3/RH\'XBN?X1G"-W_+5=DDSN)0 M+5&;\5"=Q5,F51O)'07+ &+TXWEFU[2JQE]$@&:D?6$8[AQ(\@O+=>NN$FC0U2'D8]82"IT_ M:5DK/0]:4#ZV$ PBYL6?4S QR\ ::@7]'P6:ENT>\"P6:@T0E7E3,0WU!B/LC9SS-UD.9]]5G(-E=AR' Y#W M24PC'F$H+0&!?'2C'*)R;VBOWAQ_/OG"?M9?':$\ UL]*;(!0[DI';F,2^ @ MNFTDI?Z >:4X^3G-OVGQT6C&@=%>>*-121YF/2QK.W>^LY1I<1H"GX!Q5P%2 ML3S<.H(QXR97.;J$LLSE:C'8:/^5H2<,1O9Y+MA1"#NH&;I(&>)-@##Y%#+5L MU[&201IJ=8-7<-6KI-)#SJG;XN"HPY8+-@4-%\,%S %5JQ.- MQ&_\##1%UI\!E0EA^ +Y"F1M_BO+Q"ZX1EII#4(%%VGRU>X&V1K$W->!N4]+ M#A;F?%TFQ7RDI3UDLFPF]5#Z_LDKA.9E!ZA-#?=C4\0T/64#7*48=G/3+3/O M2L/%*"\J/53S#D?&_GSA+4#54T:ANS5/::[JM".!(GO@OS)-F:QDL$!0.D[H?2JO/ MHJ-(1+)/@TSG?U;I_+)/@^S3\'PRU(WGVZ?!,!ZS3X/,OI?9]S+[OCZ$$*,WJBH]]\ZZQULS>%\6,YLJG*M+?-J^[3BQ< M&;L39>.>-S1L>YOS2[>'AK4>;MQ&CW6'KK7ZZ]L>>_MWMN7M SO/498-=S]MPAQI3[I0T8W&^;6^15^Z L+=HAES^;:(;;BGGW;54PT^L*\0: MNF%_IG2>89?RLQDFI#&["IM_L,QL]EMYHHG^ H?ZT0:SOY__J6.$.A9AFD\L MB?T3B05))G#N,X)AG=)S)4Z3BY05',1^(P60+F>!WT^LF 4^^,TS3")A+4Q MNLC)N!#,9@S,9TO1XQK#B1'N+>IXN?(?DLQ0,6:?<2HKYQC?.R4W[+.O=(H! MR7FJUT!5@L*"P$!>_/H03"\1+B_F";ZQ,R!@?W9I[.^(RNW>PW_/$@8<9ZQD M,^/NR;;[[\6XFY30E!9Z,*=A9PCB./8\O,Z"HG5_(N"WC!CK$^$V)\Q='+@H M%/:[F)UB[A=[6\,-UNZA)VU;0]-XVBS\7&43RY8R7CWMQ97RZ6G+)V/@6&9' M67AC;4\$8OJB[1W/+K97]EKFV@.9:8\V/0S;UW2O(G'AE5N==_U)5& MHZ%CR07J[@*Q;30:N/J6/D6Y2@^R2@-O6XOT,8W.^?0[8RV#V.'])![_J+TE MBG8?X_0NFO33&]A.+"9[O//5_7-MA&Y]S9&CV01;'N/EO;D?D@O-JI M?;V^HW/GM.GN_F7:F]RZ7=RZ\LBYYU35EO1R#E]V%_'RC1G]Y5HF57GW"8B3=FSXRTV:\X9R%*C!^FGA*2;H+'UAS>,#O'&QV:C M!]T:K&KV@(VE YI0WH5[$254.3PX_O+YX CQ=3!5D[7?++^;9[*(=195R,4% M0F--:7T=1]I&*"1]J"E^ UJQABI*!>)-HH0T0:!Q!A2G&W!#"2TU_[I9479L M$ W!&Z]AVCS'C8/15V./"]$>)P5#<0DBV&]X[U M!96<+1M-,3G+X+% Y'FUR..P1S]94YJ\!9(YIV,2I[Q/"4^21] Q/JH[Y5F. M^&:TB2.[^#A6K?PC+AB VM+LR]&1LO7X0N=F?>A4,[F^I&DE0,/MZYOMMN+C M+:$6NH'K))LT[[K.4J(Z=1C5239I7L-)8)CS(D!"8#4'(ILT/TT(K.XU:;;= M2MUX,)BHG>D&?=($0#<>N;L'CK*UH:?O'L_#T(>ZYD@\JG4$2YLUO"]XJ@=& MNEIE=NQ&<*^)2K3""5$3FX'Y$(;;W'4?RA!Y=ZGC=T M;7T;H>?80T-;SZ#8"&9&&YJ.O1=,G.V>>N=@1[L0I7=*!*^'. KGESFERBE< M=UDH)PQG?LYYM G<03]2]F_S73>1'@8"01S;ELUY^LM>1NM@;VR2.M!A+KFU MOF'#V6[M&^@PU594WFB&OLG^:Y]//&'R;%>$![Y_\@W\0&[YF1Z- MPS=M.R11VS='5'' M"&UMI.O6Z'_?HJC1'$U7V0^>J1TH(*OC,4F*_SE01P=*2L84'ZU>$#)Y*5B. MQ[_&9 KO^#%]F<[&:I@Q*8]WP@X#,L%=<#NSRT/S/S?^V^SJ@_'YZJMY.@N_ MG5S]]9OW[>/XW]]/SR^__?4MT$___./GUV^_ZQ_?7L9?C;^2L[?'/\Y^_N?; MJ?%5._WMY,<'\RSY^G,2__7VQ/IJ?#7/SM\EI\9[[>S\POHZ/AO_=?[[]>EY MH'_]>38^>_OKY>E_7/WC&V\ ^^:_67\,3H]_VZ??3LV_CI_ M?WWZ[:MV]O;D^NO/"[CO=QAW,O[K[>7EZ=OO/_XZOXQ.8^W'A_.3Z>D7#=YS MK)_]//E?:M/0UBU7U3P_5*W -%3?ID2U/$),*QIIIJ\=O+:\ ?STSU_FV>$Q MXJG;Y")MNB'W7G$S+_O7!\+HL5"]-Q!&'X5J^Z0W$*J^;5M:Z#F!2SW+TEWB MZ/;(=4TMH)%%?8<)5;T4JKH4JH\B5'\N"M70B

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�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end

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